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ABSTRACT 
JACQULYNE PONVILLE ROBICHAUX. Mammary Glands Possess 
Intrinsic Molecular Laterality and Respond Left-Right Differently to Genetic and 
Pharmacological Manipulation. (Under the direction of Ann Ramsdell) 
 
More tumors form in the left (L) breast and tumors in the right (R) breast may be 
more aggressive. These epidemiological findings suggest L-R differences in 
overall tumor biology depending on the side of tumor origin, leading to the 
hypothesis that mammary glands are L-R different and have discordant 
responses to neoplastic risk factors. Here we show that normal mammary 
glands are molecularly L-R different, and have more mammary stem cells (MaSCs) 
in the L thoracic mammary gland (TMG). In addition, MaSCs from the L and R 
TMGs are molecularly and functionally different in vitro and in vivo. MaSCs 
respond to ErbB2 and EGFR inhibition via Lapatinib treatment asymmetrically. L-
side MaSCs are inhibited by Lapatinib whereas R-side MaSCs increase in self-
renewal with Lapatinib treatment. MMTV-NeuTg/Tg mice overexpress the oncogene 
Neu also known as ErbB2 or HER2 and model HER2+ breast cancer. MMTV-
NeuTg/Tg mouse TMGs respond L-R discordantly to oncogene overexpression 
resulting in asymmetric ductal network formation and discordant gene regulation. 
Furthermore, MaSCs are increased asymmetrically enhancing L-side enrichment 
of MaSCs, and MaSC in vitro function was asynchronously effected. Additionally, 
when gene expression is inverted in the MMTV-NeuTg/Tg model, MaSC in vitro 
growth, self-renewal, and response to Lapatinib is also inverted. Inguinal 
mammary glands (IMGs) of the MMTV-NeuTg/Tg model show delayed molecular 
laterality and are less sensitive to oncogene over-expression. When WT mice are 
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exposed to estrogen (E2) neonatally, E2 induces asymmetric ductal 
morphogenesis, asymmetrically reduces luminal cell differentiation, and induces 
an asymmetric increase in MaSCs in TMGs. IMGs of E2 treated mice have no 
detectable L-R differences in morphology, suggesting IMGs are not as sensitive to 
early E2 exposure.  Lastly, L-R differences in TMG development are shown to have 
an embryonic origin. RXRα+/- mice with altered embryonic development have 
asymmetric TMG development but not IMG development. Taken together these 
data show that L-R differences in TMGs originate embryonically, TMGs are 
lateralized organs that respond to stimulus L-R differently, and TMGs are more 
sensitive to perturbation than IMGs.  These L-R differences in MaSC populations 
during normal development allow for L-R different responses to neoplasia, as well 
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REVIEW OF LITERATURE 
 
Mammary Gland Development: Embryonic Through Lactation 
 Mammary gland development is unique because mammary glands undergo 
several phases of development throughout the lifespan of the organism, with the 
majority of development being post-natal. In addition, mammary gland 
development is not complete until pregnancy and lactation, which means that for 
some, the organ never reaches full developmental potential. Murine mammary 
gland development closely models human mammary gland development with few 
species specific differences in development (Veltmaat, Mailleux et al. 2003). The 
most obvious species specific difference between human and murine mammary 
gland development is that mice have 5 pairs of mammary glands. These glands 
are bilaterally paired and spaced along the anterior to posterior (A-P) axis (Figure 
1). This section will review in detail each of the stages of mammary gland 
development: embryonic development, pubescent development, pregnancy and 






Figure 1. Schematic of Anatomical Location of Mouse Mammary Glands.   
The 5 pairs of mammary glands are bilaterally paired and spaced along the anterior 
to posterior (A-P) axis numbered 1-10 left to right and anteriorly to posteriorly. 
Glands 1 and 6 are cervical mammary glands, glands 2/7 and 3/8 are thoracic 





  Embryonic development 
 Embryonic development of the mammary glands exists in several steps with 
slight variations across species. The first step of embryonic development of the 
mammary gland is hypothesized to be the formation of the mammary line or milk 
line (Howard and Gusterson 2000). The mammary line has been observed by 
scanning electron microscope (SEM) in rabbit, rat, pig, cat and human embryos, 
but reports have not established a clear observation of the mammary line in mouse 
embryos although reports show molecular hints of a mammary line also existing in 
mice  (Howard and Gusterson 2000, Veltmaat, Van Veelen et al. 2004, Howard 
2012). Formation of the mammary line initiates about embryonic day 10.5 (E10.5) 
– E11.0 in mice and is located between the fore and hind limbs (Veltmaat, Mailleux 
et al. 2003, Howard 2012). The bilateral structures span the location of the future 
mammary glands running along the A-P axis and appear to be a raised line of 
epidermal cells (Howard and Gusterson 2000, Veltmaat, Mailleux et al. 2003, 
Veltmaat, Van Veelen et al. 2004, Howard 2012).  
Although the mammary lines exist as the first structures in the anatomical 
location of the mammary glands and exist before further development, the 
mammary placodes, the structures from which mammary glands derive, may not 
actually be derived directly from the mammary line. Mammary placodes do not 
arise simultaneously or in order along the A-P axis, but instead glands 3 and 8 
form, then glands 4 and 9, then glands 1 and 6 as well as 5 and 10, and lastly, 
glands 2 and 7 form (Mailleux, Spencer-Dene et al. 2002, Veltmaat, Mailleux et al. 
2003, Veltmaat, Van Veelen et al. 2004, Veltmaat, Ramsdell et al. 2013). 
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Additionally, mammary placode induction appears to begin before the completion 
of the mammary line overlapping on E11.0 and continuing to E11.5, suggesting 
the mammary line may not actually be directly involved in mammary placode 
induction (Veltmaat, Van Veelen et al. 2004). The mammary placodes are oblong 
shaped layered structures consisting of epithelial cells rising above the ectoderm 
(Veltmaat, Mailleux et al. 2003, Howard 2012).Over the next 3 days (E12.5 - 
E14.5), the placode increases in size through what is hypothesized to be cell 
migration, with only limited proliferation (Balinsky 1950, Propper and Gomot 1967, 
Propper 1978, Howard 2012). Unlike human mammary gland development, at this 
time (approximately E13.0-14.5), the murine male mammary gland will undergo an 
androgen dependent breakdown of the mammary rudiment (Kratochwil 1969, 
Kratochwil 1977, Durnberger and Kratochwil 1980, Heuberger, Fitzka et al. 1982). 
At E13.5 the female mammary gland will continue development forming a partially 
committed and specified mammary mesenchyme that is derived from the dermal 
mesenchyme and surrounds the mammary placode (Kratochwil 1969, Sakakura, 
Nishizuka et al. 1976, Sakakura, Sakagami et al. 1979, Durnberger and Kratochwil 
1980, Chiquet-Ehrismann, Mackie et al. 1986, Inaguma, Kusakabe et al. 1988). At 
E13.5 - 14.5, the developing mammary placode invaginates into the surrounding 
mammary and dermal mesenchyme and is no longer a raised epithelial structure, 
but now is beginning the formation of the primary mammary rudiment (Veltmaat, 
Mailleux et al. 2003). Additionally, at E14.5, the first signs of a mammary fat pad 
arise: pre-adipocytes, vasculature, and nerve cells accumulate at the most distal 
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part of the invaginating mammary rudiment (Sakakura, Sakagami et al. 1982, 
Sakakura, Kusano et al. 1987, Sakakura 1991).  
In the next step of mammary gland development, E15.5, the fat pad 
becomes less compact due to pre-adipocyte differentiation; additionally, the 
vasculature forms small capillary networks among differentiating fat cells 
(Sakakura, Sakagami et al. 1982, Sakakura, Kusano et al. 1987, Sakakura 1991). 
At E16.5, the invaginated mammary epithelium begins the first rounds of rapid 
proliferation and ductal morphogenesis, infiltrating the developing fat pad at the 
distal end, and growing to a few bifurcated branches forming the primary mammary 
duct or rudiment (Sakakura, Kusano et al. 1987, Sakakura 1991, Veltmaat, 
Ramsdell et al. 2013). After formation of the mammary duct/rudiment, the gland 
will only grow isometrically with the organism until puberty. At the proximal end of 
the mammary rudiment, early nipple formation initiates with epidermal and 
keratinized cells migrating to form a funnel shaped depression called the nipple 
sheath (Sakakura, Kusano et al. 1987, Veltmaat, Mailleux et al. 2003). At E18.5, 
only days before birth, the epidermis from the nipple sheath will rise up from the 
proximal end of the mammary rudiment to form the nipple anlage, the last step of 
embryonic mammogenesis (Sakakura, Kusano et al. 1987). A schematic of 





Figure 2. Schematic of Embryonic Development Timeline. Placode induction 
takes place at E11.0-11.5. At E13.5 the placode invaginates into the dermal 
mesenchyme. The mammary mesenchyme can be first seen at E14.5. At E16.5 
the primary mammary rudiment forms and begins to undergo ductal elongation, 




Molecular patterning of embryonic mammogenesis  
 Throughout embryonic mammogenesis, molecular patterning is responsible 
for not only the initiation of the gland, but also for the position of each of the glands 
both left and right as well as anteriorly and posteriorly. The complete molecular 
mechanism of mammary gland induction is not entirely known but begins around 
the formation of the milk line in mice. Using wingless-type mouse mammary tumor 
virus integration site (WNT) signaling reporter mice (DasGupta and Fuchs 1999), 
the mouse mammary line can be seen to form at E10.5, and can be eliminated by 
the WNT inhibitor, Dickkopf-related protein 1 (DKK1), showing the necessity of 
WNT signaling for the formation of the mammary line (Chu, Hens et al. 2004, 
Veltmaat, Van Veelen et al. 2004, Hens and Wysolmerski 2005). Cells reporting 
WNT signaling migrate and merge at each of the anatomical locations of future 
mammary gland development forming the placodes (Veltmaat, Mailleux et al. 
2003, Hens and Wysolmerski 2005). WNT signaling (specifically Wnt2b and 
Wnt16) was shown to be necessary and sufficient for inducing placode formation 
by Chu et al. (Chu, Hens et al. 2004). Briefly, when embryos were cultured in the 
presence of WNT signaling inducers, placode induction was enhanced; in addition, 
when embryos were cultured with DKK1 or DKK1 was transgenically expressed, 
mammary gland development was completely inhibited (Chu, Hens et al. 2004).  
In addition to WNT signaling, T-Box transcription factor 3 (Tbx3) is required for 
mammary pairs 1, 3, 4, and 5, but not mammary pair 2 (Davenport, Jerome-
Majewska et al. 2003, Eblaghie, Song et al. 2004). However, other than its 
mesenchymal expression, little is known about the role of TBX2/3 during mammary 
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gland development other than it is hypothesized to be the link between retinoic 
acid and Lef1 induction (Cho, Kwon et al. 2012).  
In addition to WNT and Tbx signaling, Fibroblast Growth Factor (FGF) 
family signaling is essential in mammary placode induction for four out of five 
mammary pairs (Mailleux, Spencer-Dene et al. 2002, Veltmaat, Relaix et al. 2006). 
Knockout of Fgf10 and Fgf2b results in complete inhibition of growth for mammary 
pairs 1, 2, 3, and 5 whereas inguinal mammary pair 4 develops normally, 
suggesting a Fgf dependent mechanism of placode induction for all pairs of 
mammary glands except pair 4 (Mailleux, Spencer-Dene et al. 2002). This 
evidence suggests that the use of mammary pair number 4 for experimental 
analysis may be flawed, since human mammary glands exist in the thoracic cavity 
and would be hypothesized to have an Fgf dependent induction. In addition, 
mammary placode 3, the first pair of mammary glands to form, requires somitic 
Fgf10 signaling from the thoracic somites. At E10.5, in the thoracic cavity, somites 
17-18 which are located beneath mammary glands 3 and 8 express Fgf10; 
however, by E11.0, the time of mammary pair 3 initiation, somites 11-24 express 
Fgf10 (Veltmaat, Relaix et al. 2006).  Mammary pairs 1, 2 and 5 receive Fgf10 
signaling from older somites at E11.25 where the Fgf10 gradient extends to all 45 
somites (Veltmaat, Relaix et al. 2006). This again suggests that the mammary 
gland pair number 3 within the thoracic cavity requires accurate somitic gradients 
of Fgf signaling for proper spatial arrangement. Additionally, mammary gland pair 
3 is more sensitive to perturbations and reduction of somitic Fgf10 compared to 
pairs 1, 2, and 5 (Mailleux, Spencer-Dene et al. 2002, Veltmaat, Relaix et al. 2006). 
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Due to the anatomical location of mammary pair 3, and the strong dependence of 
mammary pair 3 on somitic signals, we hypothesize that mammary pair 3, and not 
mammary pair 4, more closely models human mammary gland development and 
therefore will be the focus of our studies.  
 In addition to A-P differences in mammary gland development, L-R 
differences are hypothesized to occur. Mammary line and placode induction 
appear to be enhanced on the left side of the embryo (Veltmaat, Ramsdell et al. 
2013), and underlying somites contributing Fgf10 for mammary induction are 
molecularly L-R different (Golding, Partridge et al. 2004, Golding, Tsoni et al. 
2004). Specifically, left side somites have elevated heparin-binding Epidermal 
Growth Factor-like growth factor (hb-EGF) (Golding, Tsoni et al. 2004), during the 
window of mammary glands 3 and 8 initiation (Veltmaat, Ramsdell et al. 2013). 
Furthermore, hb-EGF is a ligand for erythroblastic leukemia viral oncogene (ErbB) 
family members 1 and 4 (Olayioye, Neve et al. 2000). ErbB family members are 
required during distinct stages of mammary gland development (Troyer and Lee 
2001) and often overexpressed in breast cancer (Korkaya, Paulson et al. 2008, 
McDermott and Wicha 2010, Reichman, Altekruse et al. 2010, Ithimakin, Day et al. 
2013). Moreover, retinoic acid (RA) signaling is essential to proper spatial 
arrangement of the somites (Vermot, Gallego Llamas et al. 2005, Brend and Holley 
2009, Vilhais-Neto, Maruhashi et al. 2010), as well as mammary gland 
development (Cohn, Ossowski et al. 2010, Cho, Kwon et al. 2012). Under normal 
conditions, RA signaling results in bilaterally paired somite formation, however, 
altered RA signaling leads to asynchronous somite formation of the somites 
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underlying mammary placode pairs 2 and 3 (Mailleux, Spencer-Dene et al. 2002, 
Veltmaat, Mailleux et al. 2003, Kawakami, Raya et al. 2005, Vermot, Gallego 
Llamas et al. 2005, Veltmaat, Relaix et al. 2006, Vilhais-Neto, Maruhashi et al. 
2010, Cho, Kwon et al. 2012). Therefore, if mammary gland laterality originates 
from somitic signals during mammary placode formation, altered RA signaling will 
result in asymmetric somites, and therefore, asymmetric mammary gland 
morphogenesis. Thus we hypothesize that mammary glands are lateralized 
structures with L-R differences originating embryonically. This hypothesis will be 
tested in chapter 5.  
 
Pubescent Development  
 The most extensive stage of mammary gland ductal elongation occurs 
during pubescent development. Early pubescent development in mice begins at 
approximately 28 days of age (Colby and Vandenberg 1974) with the first estrous 
cycle occurring at approximately 30-35 days of age. Pubescent ductal elongation 
initiates when ovarian hormones and growth factors signal from the adipocytes, 
fibroblasts, and immune cells comprising the tissue stroma in a paracrine fashion 
to  the surrounding duct to initiate growth and differentiation of the epithelial cells 
within the primary duct (Lu and Werb 2008, Polyak and Kalluri 2010) . In addition, 
complicated paracrine cross-talk exists between mammary epithelial sub-
populations to regulate hormonally driven epithelial cell differentiation during 
mammary gland development (Joshi, Jackson et al. 2010, Lydon 2010, Aupperlee, 
Leipprandt et al. 2013). During puberty, the primary duct or rudiment undergoes 
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rapid proliferation and differentiation, and, by the end of puberty, approximately 8 
weeks of age, the ductal network branches into a web-like structure encompassing 
the entire fat pad.  
 There are two distinct epithelial cell types that exist within the mammary 
ductal network: luminal cells and basal cells. Each cell type contains 
subpopulations of cells that vary in the state of differentiation. The luminal 
compartment is comprised of cytokeratin 8/18 (K8/18) positive cells, consisting of 
estrogen receptor alpha (ERα) positive luminal progenitor cells (ER+ LPs), ERα 
negative luminal progenitor cells (ER- LPs), and differentiated luminal cells (DLCs) 
(Kouros-Mehr, Slorach et al. 2006, Asselin-Labat, Vaillant et al. 2008, Visvader 
and Smith 2011, Carr, Kiefer et al. 2012, Shehata, Teschendorff et al. 2012, Rios, 
Fu et al. 2014). The basal compartment is comprised of K14 positive cells 
consisting of mammary stem cells (MaSCs), a hypothesized myoepithelial 
progenitor cell, and differentiated myoepithelial cells (Guo, Keckesova et al. 2012, 
Zhao, Malhotra et al. 2012, Rios, Fu et al. 2014). The mammary ducts are 
organized with basal cells encapsulating a single layer of luminal cells surrounding 
the mammary lumen (Figure 3). In between the luminal and basal layers as well 
as at the end of ducts within the terminal end buds, stem and progenitor cells are 
enriched (Kenney, Smith et al. 2001, Booth, Boulanger et al. 2008, Park, Raafat et 
al. 2013, Sale, Lafkas et al. 2013, Rios, Fu et al. 2014) (Figure 3). Terminal end 
buds (TEBs) are club-shaped structures at the leading edge of the ductal network 
where there is increased proliferation and ductal elongation (Richert, Schwertfeger 
et al. 2000, Silberstein 2001).  
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Figure 3. Schematic of Cross-Section of Mammary Duct and terminal end 
bud. The mammary ducts are organized with basal cells surrounding luminal cells 
around the mammary lumen. In between the luminal and basal layers as well as 
at the end of ducts, within the terminal end buds, stem and progenitor cells are 
enriched. Figure adapted from Tiede and Kang 2011.  
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Hormones and Pubescent Mammary Ductal Mammogenesis 
 Ovarian hormones, estrogen and progesterone, as well as other hormones 
such as growth hormone (GH) and its downstream target insulin-like growth factor 
(IGF), play an essential role during pubescent ductal mammogenesis. Estrogen 
and progesterone have been shown to regulate mammary stem cell number and 
cell differentiation regulating the size of the ductal network (Asselin-Labat, Vaillant 
et al. 2010, Joshi, Jackson et al. 2010, Diaz-Guerra, Lillo et al. 2012). IGF has 
been shown to increase cell proliferation and reduce apoptosis within TEBs and 
works concurrently with estrogen and progesterone to increase the number of 
TEBs (Ruan, Newman et al. 1992, Bonnette and Hadsell 2001, Stull, Richert et al. 
2002, Lee, Zhang et al. 2003, Stull, Rowzee et al. 2004).  
 The most important hormone during pubertal mammary ductal 
morphogenesis is estrogen, whereas progesterone has been shown to effect 
ductal morphogenesis to a lesser extent (Brisken, Park et al. 1998, Asselin-Labat, 
Vaillant et al. 2010, Aupperlee, Leipprandt et al. 2013). Ovariectomy or genetic 
knockout of ERα results in ablation of pubescent ductal elongation (Feng, Manka 
et al. 2007). In addition, estrogen rescues development of the mammary glands in 
ovariectomized mice (Daniel, Silberstein et al. 1987). ERα is expressed in the 
stroma but not in all mammary epithelial cell types. ERα+ LPs, and DLCs express 
ERα, but MaSCs, ERα- LPs, and myoepithelial cells do not express ERα (Kouros-
Mehr, Slorach et al. 2006, Asselin-Labat, Vaillant et al. 2008, Visvader and Smith 
2011, Carr, Kiefer et al. 2012, Shehata, Teschendorff et al. 2012, Rios, Fu et al. 
2014). Although the major role of progesterone action occurs during pregnancy, 
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progesterone has been shown to increase TEB formation and increase 
proliferation throughout the ducts through amphiregulin signaling during puberty 
(Aupperlee, Leipprandt et al. 2013). Interestingly, progesterone receptor knockout 
mice undergo ductal morphogenesis at puberty but fail to undergo side branching 
and alveolargenesis during pregnancy (Lydon, DeMayo et al. 1995, Brisken, Park 
et al. 1998); however, both estrogen and progesterone have been shown to play 
a role in regulation of MaSC proliferation and differentiation (Asselin-Labat, Vaillant 
et al. 2010, Joshi, Jackson et al. 2010, Simoes, Piva et al. 2011). Mechanistically, 
the way in which estrogen signals to ERα- MaSCs is unclear, but estrogen has 
been shown to expand breast cancer stem-like cells that are ERα- through the 
FGF/Tbx3 pathway (Fillmore, Gupta et al. 2010). In addition, progesterone has 
been shown to signal to progesterone receptor negative (PR-) MaSCs via PR+ 
luminal cells releasing Receptor activator of nuclear factor kappa-B ligand (RANK-
L) which stimulates MaSCs (Asselin-Labat, Vaillant et al. 2010, Joshi, Jackson et 
al. 2010). 
 
Puberty as a critical time point for determining future breast cancer risks 
Both estrogen and progesterone signaling during puberty play an essential 
role in setting up the mammary gland for adulthood through mechanisms that 
closely resemble tumorigenesis (Mori, Bern et al. 1976, Warner 1976, Hilakivi-
Clarke, Cho et al. 1997, Fenton 2006, Incassati, Chandramouli et al. 2010, Biro 
and Deardorff 2013). Perinatal exposure to estrogen or estrogen mimetics like 
diethylstilbestrol (DES) or Bisphenol A (BPA) results in increased tumor formation 
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in mice (Walker 1984, Lopez, Ogren et al. 1988, Walker 1990, Hilakivi-Clarke, 
Onojafe et al. 1996, Markey, Luque et al. 2001). These changes to normal ductal 
morphogenesis induced by early estrogen exposures were observed as early as 4 
weeks of age, the beginning of puberty (Hilakivi-Clarke, Cho et al. 1997, Markey, 
Luque et al. 2001). In addition, a recent study shows that not only does early 
menarche in humans increases later breast cancer risk, but the timing of several 
pubescent developmental time points correlates with increased breast cancer risk 
(Bodicoat, Schoemaker et al. 2014). These studies and others show that breast 
cancer risks may be determined as early as puberty.  
In addition to determining future breast cancer risks, puberty may also be a 
time point of vulnerability to outside perturbations due to the rapid ductal expansion 
during puberty. Reactivation of the hypothalamic-pituitary-gonadal axis takes place 
to allow breast development as well as the initiation of fertility (Biro and Deardorff 
2013). Rapid expansion of MaSCs, progenitors, and differentiated cells leave 
glands susceptible to environmental influences (Okasha, McCarron et al. 2003). In 
addition, studies of early estrogen exposure show that mice exposed to exogenous 
estrogens in utero become more sensitive to endogenous estrogen signaling 
during puberty (Wadia, Vandenberg et al. 2007). Both the increased vulnerability, 
and early determination of future breast cancer risk make puberty a potential time 
point for early intervention and breast cancer prevention. However, very few 
preventative methods exist, and development of early intervention is not possible 




Pregnancy, Lactation, and Involution 
Lastly, a mammary gland has not fully undergone complete development 
until pregnancy and subsequent lactation. During pregnancy, mammary glands 
undergo terminal differentiation in the remaining TEBs to form secretory 
lobuloalveolar units that later fill with milk (Oakes, Hilton et al. 2006). Rapid 
proliferation and differentiation are initiated by increases in prolactin and 
progesterone levels (Brisken 2002). If levels of progesterone do not increase, side 
branching and alveolargenesis do not occur (Lydon, DeMayo et al. 1995, Brisken, 
Park et al. 1998). Alveolar sacs are surrounded by myoepithelial cells, but unlike 
the pubescent mammary gland, sections of luminal cells are not be covered by 
myoepithelial basal cells, but instead have contact with the basement membrane, 
indicating completing differentiation of the mammary gland (Fata, Werb et al. 2004, 
Oakes, Hilton et al. 2006). Before parturition, milk and colostrum proteins enter the 
alveolar lumen (Fata, Werb et al. 2004, Anderson, Rudolph et al. 2007). Milk 
production reaches maximum at 12-13 days post-partum and continues for 3 to 4 
weeks (Anderson, Rudolph et al. 2007). Upon the weaning of pups, lactation 
ceases and involution begins. Involution takes place in two steps: 1.) apoptosis of 
the secretory epithelium within alveolar sacs, and 2.) proliferation and remodeling 
of adipocytes to fill in the space left after removal of the lobulaoalveolar sacs 
(Watson 2006). The first step of involution is reversible and due to accumulation 
of milk within the ducts, not systemic hormones (Li, Liu et al. 1997, Marti, Feng et 
al. 1997) whereas the second step is not reversible until subsequent pregnancy 
17 
 
and is triggered by matrix metalloproteinases (MMPs), phagocytosis, and 
autophagy (Monks, Rosner et al. 2005, Watson 2006).  
 
Mammary Stem Cells and Cell Differentiation  
 The National Institutes of Health defines stem cells by two unique 
properties: 1.) stem cells are unspecialized cells capable of self- renewal even after 
quiescence, and 2.) stem cells have the ability to become functional and 
specialized cells within a tissue or organ (National Institutes of Health 2002). 
MaSCs exist at the top of the mammary epithelial cell hierarchy (Figure 4). The 
existence of a bona fide MaSC was found in 2006 when Shackleton and colleges 
were able to reconstruct a functional mammary gland from a single cell 
(Shackleton, Vaillant et al. 2006). This discovery not only found a single cell that 
could give rise to both lineages of mammary epithelial cells in vivo, but also gave 
us definitive cell surface markers of MaSCs. A more recent report by Rios and 
colleges in 2014 showed through lineage tracing experiments in vivo the bi-potent 
MaSC truly does exist and contributes to ductal morphogenesis at puberty and 
maintenance of the duct throughout adulthood (Rios, Fu et al. 2014). Additionally, 
a fetal MaSC, that functionally and molecularly differs from the adult MaSC has 
been identified and has been shown to be able to give rise to both lineages of 
mammary epithelial cells, have a higher regenerative potential in vitro and in vivo 
when transplanted into cleared mammary fat pads, and potentially give rise to a 
population of adult MaSCs (Spike, Engle et al. 2012, Boras-Granic, Dann et al. 
2014). It has become evident through these studies that the pool of mammary stem 
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cells is both heterogeneous and dynamic depending on the developmental needs 
of the gland.  
 The fetal MaSC taken from E18.5 rudiments has been shown to express 
high levels of heat stable antigen (CD24) and  α6 integrin (CD49f), distinct gene 
expression unique from the adult MaSC including upregulated ErbB family 
members 2, 3, and 4 (but not ErbB1/EGFR), and a strong reliance on growth 
factors EGF and FGF (Spike, Engle et al. 2012).  Fetal MaSCs stain positive for 
both the luminal and basal lineages (Spike, Engle et al. 2012, Boras-Granic, Dann 
et al. 2014).  In addition, long-label retaining experiments have shown that a 
population of fetal MaSCs persist through puberty into adulthood, are responsive 
to ovarian hormones such as estrogen and progesterone, and are active during 
times of ductal remodeling such as puberty, pregnancy, and involution (Boras-
Granic, Dann et al. 2014). These long lived fetal MaSCs, although only recently 
discovered, appear to play an essential role in the mammary epithelial cell 
hierarchy and dynamic developmental capabilities of the mammary gland; 
however, the fetal MaSC is only a small compartment of the heterogeneous stem 
cell pool.  
 The adult MaSC, although better characterized than the fetal MaSC, is not 
completely understood. Adult MaSCs express CD24med or Epithelial Cell Adhesion 
Molecule (EpCAM) med, and  CD49fhigh or integrin β1 (CD29)high (Smalley, Titley et 
al. 2005, Smalley 2010, Shehata, Teschendorff et al. 2012, Smalley, Kendrick et 
al. 2012, Nautiyal, Steel et al. 2013). Adult MaSCs are capable of growing in 
anchorage independent assays such as the mammosphere assay as well as the 
19 
 
3D matrigel assay (Stingl, Eirew et al. 2006, Shaw, Harrison et al. 2012). Similar 
to fetal MaSCs, adult MaSCs stain positive for both lineages, and give rise to both 
luminal and basal cell progenitors (Stingl, Eirew et al. 2006). MaSCs have been 
shown to respond to ovarian hormones, epidermal growth factor (EGF), FGF, as 
well as other ligands (Korkaya, Paulson et al. 2008, Asselin-Labat, Vaillant et al. 
2010, Fillmore, Gupta et al. 2010, Joshi, Jackson et al. 2010, Simoes, Piva et al. 
2011, Spike, Engle et al. 2012). Adult MaSCs have been shown to express EGFR 
(ErbB1), ErbB2 ErbB3, but not ErbB4. Lineage tracking experiments show that 
adult MaSCs play an essential role during pubescent ductal morphogenesis, 
maintenance of the adult duct, pregnancy, and remain after involution (Rios, Fu et 
al. 2014). At the top of the mammary epithelial cell hierarchy, the fetal and adult 
MaSCs are long lived and hypothesized to play a role in tumor initiation due to 
increased risk for accumulation of mutations over time; however, both cell types 
are essential to the dynamic developmental potential of the gland.  
 MaSCs give rise to both luminal progenitor cells as well as hypothesized 
basal progenitor cells (Visvader and Stingl 2014) (Figure 4). Although a basal 
progenitor cell has yet to be definitively isolated by fluorescence-activated cell 
sorting (FACS), non-MaSC basal cells have a sub-population of cells with higher 
regenerative potential in vitro and in vivo  (Shackleton, Vaillant et al. 2006). In 
addition, Zhao and colleges found an intermediate step between immortalized 
human stem cells expressing high levels of tumor protein 63 (p63), a basal linage 
marker, and differentiated myoepithelial cells (Zhao, Malhotra et al. 2012). These 
hypothesized myoepithelial progenitors express low levels of p63 and moderate 
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levels of smooth muscle actin (SMA), a marker of differentiated myoepithelial cells 
(Zhao, Malhotra et al. 2012).  The proposed myoepithelial progenitor cell gives rise 
to the differentiated myoepithelial cell which is characterized by high levels of SMA, 
K14 and K5 staining (Makarem, Spike et al. 2013). Differentiated myoepithelial 
cells have many functions including paracrine signaling to luminal cells during 
ductal morphogenesis during puberty, contraction of myoepithelial cells during 
lactation driving milk towards the nipple, and secreting proteins needed by the 
extracellular matrix (ECM) (Sopel 2010). Differentiated myoepithelial cells are not 
thought to play a major role in invasive mammary tumorigenesis (Sopel 2010, 
Visvader and Stingl 2014); however, studies show an ability of differentiated 
myoepithelial cells to convert back to MaSCs which are believed to play a critical 
role in mammary tumorigenesis (Guo, Keckesova et al. 2012).  
 The luminal lineage of mammary epithelial cells is more complex and 
consists of several different types of cells (Figure 4). The luminal lineage is K8 
positive and regulated by Notch signaling (Bouras, Pal et al. 2008, Sale, Lafkas et 
al. 2013). Cell types include the bi-potent luminal progenitor, the ER+ LP, the ER- 
LP and the differentiated ductal and alveolar cells (Figure 4) (Visvader and Stingl 
2014).  The ER+ and ER- LP cells have several cell surface markers including 
CD24high, EpCAMhigh, CD49fmed, and CD49bhigh. The major cell surface antigen 
difference besides ERα expression, is stem cell antigen-1 (Sca-1), ER+ LPs are 
Sca-1+ whereas the ER- LP cells are Sca-1- (Shehata, Teschendorff et al. 2012, 
Visvader and Stingl 2014). Both the ER+  and ER- LP cells express Forkhead box 
protein-M1 (FoxM1), aldehyde dehydrogenase-1a3 (Aldh1a3), E74-like factor-5 
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(Elf5); however, ER+ LP cells have a slightly higher in vivo regenerative potential 
than ER- LP cells (Carr, Kiefer et al. 2012, Shehata, Teschendorff et al. 2012).  
FoxM1 and Notch signaling play an essential role in lineage determination 
for luminal cells (Bouras, Pal et al. 2008, Carr, Kiefer et al. 2012, Chakrabarti, Wei 
et al. 2012, Sale, Lafkas et al. 2013). Up-regulation of Notch signaling increases 
MaSC differentiation into LP cells, whereas inhibition of Notch signaling enriches 
the MaSC pool (Bouras, Pal et al. 2008). Up-regulation of FoxM1 results in an 
increase in LP cells preventing differentiation into mature luminal cells, whereas 
inhibition of FoxM1 increases luminal cell differentiation (Carr, Kiefer et al. 2012). 
FoxM1 prevents differentiation of luminal progenitors through down-regulation of 
GATA binding protein 3 (GATA-3) (Carr, Kiefer et al. 2012). GATA-3 plays an 
essential role in the differentiation of LPs, and is most highly enriched during 
pubescent development (Kouros-Mehr, Slorach et al. 2006, Asselin-Labat, 
Sutherland et al. 2007). Inhibition of GATA-3 results in a lack of TEB formation and 
defective ductal morphogenesis during puberty, inhibition of alveolargenesis and 
lactation during pregnancy, and an increase in LPs (Kouros-Mehr, Slorach et al. 
2006, Asselin-Labat, Sutherland et al. 2007).  Elf-5 plays an essential role in 
differentiation of ER- LPs into alveolar cells during pregnancy (Chakrabarti, Wei et 
al. 2012). Up-regulation of Elf-5 in virgin mice causes an aberrant increase in 
alveolar differentiation; whereas mice with decreased Elf-5 expression fail to 
lactate and have defective alveolar differentiation (Oakes, Naylor et al. 2008). 
Differentiated alveolar cells are CD24+, EpCAMhigh, Sca-1lo, and CD49b- 
(Shehata, Teschendorff et al. 2012, Visvader and Stingl 2014). These cells are 
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responsible for milk production during lactation and are initiated during pregnancy 
by up-regulation of Elf-5 via RANK-L activation from progesterone signaling (Lee, 
Gallego-Ortega et al. 2013) and up-regulation of prolactin and Signal Transducer 





Figure 4. Schematic of Mammary Epithelial Cell Hierarchy.  Fetal MaSCs are 
thought to give rise to adult MaSCs as well as persist into adulthood. Adult MaSCs 
give rise to both a bi-potent luminal progenitor and a proposed myoepithelial 
progenitor. The myoepithelial progenitor gives rise to differentiated myoepithelial 
cells. The bi-potent luminal progenitor gives rise to both an ER+ luminal progenitor 
and an ER- luminal progenitor. The ER+ luminal progenitor gives rise to the 
differentiated luminal ductal cell that can be either ER+ or ER-. The ER- luminal 
progenitor gives rise to ER- alveolar cells during pregnancy (Visvader and Stingl 
2014). Figure adapted from Visvader and Stingl 2014.  
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 Mammary Stem Cells, Breast Cancer, and Laterality 
Originally, many believed that the heterogeneity of tumors and cancer 
originated from embryonic remnants that upon reactivation of embryonic 
processes became teratomas (Sell 2010). Later this theory was revised with the 
hypothesis that tumors arise from adult stem cells, and normal cell differentiation 
is disrupted resulting in tumor formation (Sell 2010). However in recent years, the 
cancer stem cell theory has evolved into a hypothesis separated from the tumor 
initiating cells, but into a study of the cells that propagate the tumor after the tumor 
is formed and the search for the tumor initiating cells has become the focus of 
many labs (Visvader 2011). Mammary stem and progenitor cells play a critical role 
in breast cancer initiation and progression (Prat and Perou 2009, Regan, Kendrick 
et al. 2012, Shehata, Teschendorff et al. 2012). However, there is a great debate 
whether different types of mutations of MaSCs are responsible for variability in 
mammary tumorigenesis, or if mutations of each subpopulation of stem and 
progenitor cells gives rise to the various subtypes of breast cancer. Directly testing 
these two hypotheses has proven difficult, with data suggesting that both 
hypotheses may indeed be partially correct as it pertains to breast cancer (Clarke, 
Anderson et al. 2003, Dontu, Al-Hajj et al. 2003, Dontu, El-Ashry et al. 2004, 
Bouras, Pal et al. 2008, Lim, Vaillant et al. 2009, Prat and Perou 2009, Molyneux, 
Geyer et al. 2010, Shehata, Teschendorff et al. 2012, Spike, Engle et al. 2012, 




Breast cancer like many cancers is heterogeneous in the types of tumors 
formed; breast cancers vary cellularlly and molecularly and therefore vary in 
response to treatments (Prat and Perou 2009, Eroles, Bosch et al. 2012). Breast 
cancer is broken down into six subtypes:  Luminal A, Luminal B, Her2+, basal–like, 
normal-like, and claudin-low (Eroles, Bosch et al. 2012). Researchers have found 
that certain molecular pathways enriched in each of these breast cancer subtypes 
are also enriched in subtypes of mammary epithelium (Bouras, Pal et al. 2008, 
Lim, Vaillant et al. 2009, Prat and Perou 2009, Molyneux, Geyer et al. 2010, 
Shehata, Teschendorff et al. 2012, Sale, Lafkas et al. 2013, Zvelebil, Oliemuller et 
al. 2013), supporting the cell of origin hypothesis in breast cancer. However, others 
believe that adult stem and/or fetal stem cells are responsible for breast tumors 
through various acquired mutations accumulated over time, and the heterogeneity 
of breast cancer is due to heterogeneity of mutations of the adult and/or fetal stem 
cells (Dontu, Al-Hajj et al. 2003, Dontu, El-Ashry et al. 2004, Spike, Engle et al. 
2012, Makarem, Kannan et al. 2013). In support of the MaSC being the tumor 
initiating cell, discovery of ERα+  stem like cells have been identified and were 
hypothesized to be the cells that become mutated in steroid hormone positive 
breast cancers (Zeps, Dawkins et al. 1996, Zeps, Bentel et al. 1999, Alvi, Clayton 
et al. 2003, Clarke, Anderson et al. 2003, Dontu, El-Ashry et al. 2004). Although 
these two hypotheses seem to differ greatly, it appears that both hypotheses could 
contribute to the vast differences seen in patients especially when stem cell 
heterogeneity is taken into consideration. But only, further investigation into 
mammary stem cell differentiation throughout development can give us important 
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insights to the cells responsible for tumor initiation opening a novel window of 
breast cancer prevention.  
In addition to breast cancer heterogeneity within each breast, breast cancer 
also appears to be lateralized. More tumors form in the left breast (55% L vs. 45% 
R) (Perkins, Hotes et al. 2004, Roychoudhuri, Putcha et al. 2006, Saleh and 
Abdeen 2007, Arkoob, Al-Nsour et al. 2010, Wilting and Hagedorn 2011, Fatima, 
Zaman et al. 2013, Veltmaat, Ramsdell et al. 2013, Zeeneldin, Ramadan et al. 
2013). In addition, epidemiological studies have shown that aggressive breast 
cancer subtypes occur more often in the right breast and right sided tumors 
metastasize quicker and more frequently (Saleh and Abdeen 2007, Fatima, Zaman 
et al. 2013, Zeeneldin, Ramadan et al. 2013). Furthermore, these L-R differences 
may affect overall patient survival; however, due to deficient data sets this 
relationship requires additional investigation (Hartveit, Tangen et al. 1984, 
Borisenkov 2001, Roychoudhuri, Putcha et al. 2006, Zeeneldin, Ramadan et al. 
2013). These epidemiological findings indicate L-R differences in overall tumor 
biology depending on the side of origin, suggesting L-R differences in mammary 
glands from which those tumors arise; however, no previous studies exist to 
determine the molecular cause of these left-right (L-R) differences in tumor biology 
or normal development.    






We have developed four specific aims to characterize mammary gland 
development and laterality under both normal conditions and pre-neoplastic 
conditions. Our aims are: 1.) Determine if fractal dimension analysis is a sensitive 
and quantitative approach to  determine differences in thoracic mammary glands; 
2.) Determine if WT mammary glands are symmetric and the effect of ErbB2 
signaling on mammary gland ductal morphogenesis, cell populations, and stem 
cell self-renewal; 3.) Determine if mammary glands are differentially susceptible to 
neonatal estrogen exposure; and 4.) Determine if mammary gland laterality 
originates during embryonic development.  
Currently, no standardized method of quantifying ductal morphogenesis 
exists in the field of mammary gland biology; therefore, specific aim one will test 
the hypothesis that fractal dimension analysis is an objective and sensitive method 
to quantify ductal morphogenesis. To this end, fractal dimension analysis, in 
combination with conventional morphometric analysis, will be used to quantify 
pubescent thoracic mammary glands of WT and MMTV-NeuTg/+ mice.  
Specific aim two will test the hypothesis that WT mammary glands are 
lateralized and due to intrinsic L-R differences will have an asymmetric response 
to changes in ErbB2 signaling. To test this hypothesis morphology, cell signaling, 
and mammary stem cell populations and self-renewal will be examined in both WT 
and MMTV-NeuTg/Tg mammary glands. Fractal dimension and conventional 
morphometrics will be used to examine L vs. R morphology, microarray and/or  RT-
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PCR will be used to examine L-R differences in cell signaling, FACS will be used 
to examine L-R differences in epithelial cell populations, and the mammosphere 
assay will be used to detect L-R differences in stem-cell self-renewal.  
Specific aim three will test the hypothesis that mammary glands respond L-
R differently to early neonatal estrogen exposure. To test this hypothesis, a murine 
model of high dose, neonatal estrogen exposure was generated. Briefly, mice were 
injected with high dose estrogen for five days after birth, then allowed to reach 
puberty. At 28 days of age, mice were euthanized, and mammary glands were 
extracted. To determine if high dose estrogen results in L-R differences, glands 
will be examined by fractal dimension and conventional morphometrics to survey 
for L-R changes in morphology, glands will be studied for L-R changes in cell 
signaling by RT-PCR, and lastly, glands will be examined by long label retaining 
experiments, FACS, and mammosphere assays to survey for L-R differences in 
mammary cell populations.   
Lastly, specific aim four will test the hypothesis that mammary gland 
laterality originates embryonically. To test this hypothesis, the Retinoid X Receptor 
alpha (RXRα) knockout mouse was used. The RXRα mouse has altered RA 
signaling which may lead to asynchronous somite formation of the somites prior to 
thoracic mammary gland initiation (Mailleux, Spencer-Dene et al. 2002, Veltmaat, 
Mailleux et al. 2003, Kawakami, Raya et al. 2005, Vermot, Gallego Llamas et al. 
2005, Veltmaat, Relaix et al. 2006, Vilhais-Neto, Maruhashi et al. 2010, Cho, Kwon 
et al. 2012). Therefore, mammary glands will be examined by fractal dimension 





Currently, no standardized method of quantifying ductal morphogenesis 
exists in the field of mammary gland biology; therefore, the second chapter will 
determine an objective and sensitive method to quantify ductal morphogenesis. 
Fractal dimension analysis is a technique which allows for quantification of 
differences in complex and irregular shapes, such as the ductal epithelium of a 
mammary gland. Thus, chapter two will determine if fractal dimension analysis in 
conjunction with traditional morphogenesis can detect quantifiable differences 
between normal mammary gland development and the development of mammary 
glands from a murine model of breast cancer. If sensitive enough, this technique 
may not only be useful in the field of mammary gland biology, but may also lead to 
a more sensitive technique for examining mammography increasing early 
detection and possibly prevention of invasive breast cancer in women.  
Higher tumor incidence in the left breast, more aggressive tumors in the 
right breast and possible L-R differences in survival are virtually unstudied features 
of breast cancer (Perkins, Hotes et al. 2004, Roychoudhuri, Putcha et al. 2006, 
Saleh and Abdeen 2007, Arkoob, Al-Nsour et al. 2010, Wilting and Hagedorn 2011, 
Fatima, Zaman et al. 2013, Veltmaat, Ramsdell et al. 2013, Zeeneldin, Ramadan 
et al. 2013).  These epidemiological findings suggest L-R differences in overall 
tumor biology depending on the side of origin, suggesting L-R differences in 
mammary glands from which those tumors arise; however, no previous studies 
have addressed the question of baseline L-R differences during normal 
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development. Puberty is a good developmental time-point to probe for L-R 
differences during development, because the rapid ductal expansion leaves the 
glands vulnerable to outside perturbations (Warner 1976, Hilakivi-Clarke, Cho et 
al. 1997, Fenton 2006), as well as mimics the signaling pathways that often 
become reactivated during early neoplasia (Incassati, Chandramouli et al. 2010). 
Chapter three will demonstrate that there are L-R differences during normal 
pubescent development.   
HER2/ErbB2/Neu is amplified in 20-30% of breast cancers and is 
associated with aggressive tumor phenotype and early drug resistance (Korkaya, 
Paulson et al. 2008, McDermott and Wicha 2010, Reichman, Altekruse et al. 2010, 
Ithimakin, Day et al. 2013); additionally, a recent study reports HER2 is amplified 
in the right breast more often (Fatima, Zaman et al. 2013). Furthermore, studies 
suggest that HER2 increases stem/progenitor cell populations (Ithimakin, Day et 
al. 2013, Korkaya and Wicha 2013). MMTV-NeuTg/Tg mice are a well-accepted 
model of HER2+ breast cancer (Guy, Webster et al. 1992, Muller, Arteaga et al. 
1996). Preliminary data reveal that the L and R TMGs from MMTV-NeuTg/Tg mice, 
have asymmetric ductal morphogenesis at puberty and that the asymmetry is 
sustained after puberty is complete. These data suggest that HER2/ErbB2/Neu 
affect the L and R mammary glands differently resulting L-R different morphology, 
gene expression, and cell populations. Chapter 3 will demonstrate that ErbB2 
signaling effects the L and R mammary glands discordantly both on a 
morphological and cellular level. Understanding the normally occurring L-R 
differences and the asymmetric response to the HER2 oncogene will be important 
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in understanding L-R differences in tumor biology and stem/progenitor cell 
regulation during breast cancer which is essential to better clinical treatment of 
breast cancer patients. Additionally, these studies are the first to demonstrate a 
differential response to a drug used clinically for patients with HER2 positive breast 
tumors on normal mammary stem cells. Understanding how drugs used in the 
clinic effect normal mammary tissue is critical in the long-term care of a breast 
cancer patient. Additionally, an L-R difference in normal tissue to a drug used 
clinically would suggest that tumor cells may also have an L-R difference in 
response to therapy.  
At puberty, ovarian hormones and growth factors signal from the tissue 
stroma in a paracrine fashion; signaling occurs from the stroma surrounding the 
duct to initiate growth and differentiation of the epithelial cells. Within the duct early 
estrogen (E2) exposure has been correlated to increased risk of gynecological 
cancers later in life (Warner 1976, Hilakivi-Clarke, Cho et al. 1997, Fenton 2006). 
In addition, early E2 exposure has also been designated a risk factor for breast 
cancer by the National Cancer Institute (NCI) (Warner 1976, Hilakivi-Clarke, Cho 
et al. 1997, Fenton 2006). However; studies examining the effects of postnatal E2 
exposure have not examined the long term effects of estrogen exposure during 
pubescent ductal morphogenesis nor the distribution of cell populations that leave 
the mammary glands more vulnerable for breast cancer later in life. Chapter 4 
demonstrates that the mammary glands respond L-R differently to neonatal 
estrogen which suggests patients receiving endocrine therapy, may have a 
differential response to therapy depending on the side of origin, and increased 
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estrogen exposure may elevate the risk for breast cancer asymmetrically.  
The origin of mammary gland laterality is unknown; however, laterality of 
other well characterized organs begins embryonically with L-R patterning 
(Stalsberg 1969, Patterson, Drysdale et al. 2000, Levin 2005, Raya and Izpisua 
Belmonte 2006, Shiratori and Hamada 2006). As discussed earlier, thoracic 
mammary glands 3 and 8 require somitic FGF signaling for placode initiation 
(Mailleux, Spencer-Dene et al. 2002, Veltmaat, Relaix et al. 2006, Veltmaat, 
Ramsdell et al. 2013). Retinoic acid (RA) signaling plays an essential role in somite 
formation [30-32] and mammary gland development (Wang, Shen et al. 2005, 
Cohn, Ossowski et al. 2010, Cho, Kwon et al. 2012). Altered RA signaling leads to 
asynchronous somite formation during the time window of mammary placode 
initiation (Mailleux, Spencer-Dene et al. 2002, Veltmaat, Mailleux et al. 2003, 
Kawakami, Raya et al. 2005, Vermot, Gallego Llamas et al. 2005, Veltmaat, Relaix 
et al. 2006, Vilhais-Neto, Maruhashi et al. 2010, Cho, Kwon et al. 2012). Therefore 
if mammary gland laterality originates from somitic signals during mammary 
placode formation, altered RA signaling will result in asymmetric somites and 
therefore asymmetric mammary gland morphogenesis. Therefore to determine the 
origin of mammary gland laterality, the Retinoid X Receptor alpha (RXRα) 
knockout mouse model was used. The homozygous RXRα knockout mouse is 
embryonic lethal (Sucov, Dyson et al. 1994), subsequently RXRα mice 
heterozygous for RXRα knockout (RXRα+/-) was employed. Chapter 5 
demonstrates that RXRα+/- mice display asymmetric ductal morphogenesis in 
thoracic mammary glands but not inguinal mammary glands. In addition left 
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thoracic mammary glands are more sensitive to RXRα+/- knockout. These data 
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Breast cancer is the most common type of cancer that occurs in women and 
is the second leading cause of women’s cancer-related deaths (Group 2013). 
Diagnosis, prognostication, and therapeutic decisions in the management of 
breast cancer are guided by disease staging and other criteria, including hormone 
receptor expression, Her-2/Neu amplification, and histological tumor type (Saez, 
McGuire et al. 1989, Lonning 2007). While incorporation of these parameters has 
been useful in identifying patients who stand to benefit from targeted biological and 
endocrine therapies, the utility of histological tumor grading in assessing 
chemotherapeutic benefit has been shown to be relatively less predictive, in part 
due to its semi-quantitative nature (Tambasco, Eliasziw et al. 2010). In an attempt 
to overcome this limitation, fractal dimension analysis has emerged as an 
alternative approach to assess tumor morphology for breast and other cancer 
types (Losa and Nonnenmacher 1996, Cross 1997).  
Fractal dimension is a quantitative tool for objective measurement of 
complex structures that cannot be readily described and quantified by application 
of Euclidian geometry.  The ductal epithelial network of the mammary gland, the 
site where breast tumors originate, can be considered a fractal object and its 
topological dimension, or fractal dimension (D), is expressed by a non-integer 
number lying between the Euclidian integers 1 and 2 for a two-dimensional object. 
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Computation of the fractal dimension allows for quantification of the complexity, or 
chaos, and space-filling properties associated with the structure of interest, i.e. the 
ductal epithelium. The greater the value of the fractal dimension of the object, the 
greater is its irregularity and complexity (chaos). 
Fractal analysis has been applied to delineating the growth and complex 
architecture associated with a variety of tumors (Bizzarri, Giuliani et al. 2011), 
including breast ductal carcinomas in images generated by optical coherence 
tomography (Sullivan, Hunt et al. 2011), mammography (Raguso, Ancona et al. 
2010, Rashidnasab, Elangovan et al. 2013), magnetic resonance (Kontos, 
Ikejimba et al. 2011, Di Giovanni, Ahearn et al. 2012), needle biopsy smears 
(Cross, Bury et al. 1997, Dey and Mohanty 2003) and histological methods 
(Tambasco and Magliocco 2008, Tambasco, Eliasziw et al. 2010). It moreover has 
been used to distinguish benign from malignant tissues in resected specimens 
from breast conserving surgeries (Nyirenda, Farkas et al. 2011, Laughney, 
Krishnaswamy et al. 2012). Increased fractal dimension is significantly associated 
with higher tumor grade (i.e. loss of differentiated structure), larger tumor size, and 
positive lymph node status, all of which are indicators of more aggressive disease 
(Tambasco and Magliocco 2008, Braverman and Tambasco 2013). Consistent 
with this, increased fractal dimension also has been shown to be significantly 
associated with lower disease-specific and overall survival of breast cancer 
patients (Tambasco, Eliasziw et al. 2010).  
Given the clinical utility of fractal dimension, we have investigated whether 
fractal analysis can be applied in morphological assessments in pre-clinical breast 
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cancer mouse models. For the present study we conducted fractal and 
conventional morphometric analysis in a widely used breast cancer mouse model, 
MMTV-cNeu. MMTV-cNeuTg/+ mice overexpress the ErbB2/Neu oncogene, which 
models Her-2+ breast cancer, and develop mammary tumors relatively rapidly, i.e. 
by approximately four months of age (Guy, Webster et al. 1992, Hutchinson and 
Muller 2000). Using combined fractal dimension and morphometric analyses, we 
found that this approach detected quantitative changes in mammary ductal 
epithelial growth and complexity that preceded overt tumor formation. Moreover, 
when analyzed independently, our results showed that left-side mammary glands 
were more labile to oncogene-driven changes in ductal morphology compared to 
right-side glands, a difference that is consistent with elevated left-side tumor 
incidence that occurs in breast cancer patients (Veltmaat, Ramsdell et al. 2013). 
Together, these results indicate that fractal dimension analysis can be applied in 
conjunction with conventional morphometric measurements in a murine breast 
cancer model to quantify changes in the ductal epithelium that occur during early 
neoplasia. This combined methodological approach is highly sensitive and has 
provided the first documentation that lateralized morphological alterations initiate 




MATERIALS AND METHODS 
 
Mice 
All experiments were performed in accordance with the regulations of the Medical 
University of South Carolina Institutional Animal Care and Use Committee. FVB/N 
wild-type and FVB/N-TgN (MMTVNeu) 202Mul) mice were obtained from Taconic 
(Germantown, NY, USA) and JAX® Mice and Services (Bar Harbor, ME, USA).  
Wild-type and single-copy MMTV-cNeuTg/+ mice were used for all experiments and 
fed Harlan Teklad rodent diet 2918 and provided water ad libitum.  
 
Histology and image collection 
Carmine red stained whole mounts (de Assis, Warri et al. 2010) prepared from #3 
and #8 thoracic mammary glands of day-28 mice (Veltmaat, Ramsdell et al. 2013) 
were imaged on an Olympus SZX12 stereomicroscope equipped with a Spot 
camera. Overlapping images of each whole mount were processed into a single 
composite image with Adobe Photoshop®.  
 
Image analysis.  
The color images of the mammary glands were converted to 8-bit monochrome 
images for image and fractal analysis. The mammary gland within an image was 
outlined and isolated from the background tissue and defined as a Region of 
Interest (ROI) (Figure 5). The isolated image of the mammary gland was 
thresholded using the set threshold subroutine of MetaMorph Image analysis 
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software (ver. 6.1). The area (A) and integrated optical density (IOD) of the ductal 
epithelial networks were measured using the integrated morphometry analysis 
sub-routine of MetaMorph. The fractal dimension (D), was determined by the box 
counting method using HarFA software (Nezadal, Zemeskal et al. 2001) 
[http://www.fch.vutbr.cz/lectures/imagesci]) applied to the isolated image of the 






Figure 5. Stepwise example of 8 bit monochrome image conversion.  (A) A 
composite image of a carmine red stained whole mount prepared from wild type 
(WT) mouse TMG. (B) 8-bit gray scale image of TMG. (C) Manually traced and 
isolated TMG used for analysis with MetaMorph® image analysis software. (scale 




Integrated optical density (IOD).   
The IOD of the mammary gland ROI delineated by the thresholded boundaries is 
considered to be the “mass” of the ROI and a measurement of the total amount of 
labeled material in the region (Walter and Berns 1986, Fuseler, Merrill et al. 2006, 
Fuseler, Millette et al. 2007, Rogers and Fuseler 2007, Fuseler and Valarmathi 
2012).  The IOD of a selected region can be expressed as the weighted sum of the 
image histogram in which each term in the histogram is multiplied by the gray value 
it represents. When applied to thresholded boundaries the IOD is defined by the 
following expression: 
                           T2 
IOD (T1, T2) =  ∑ H (GV) x GV 
                           GV = T1 
Where the upper and lower thresholds defining the ROI in the histogram are 
given by T1 and  T2.  GV is the gray value of each pixel and H (GV) is the gray 
level histogram.  
 
Application of the fractal dimension (D) 
 The thoracic mammary glands in the wild type and MMTV-cNeu mice appear as 
irregular and complex objects composed of parts at different levels of resolution 
(ducts of different bore sizes) which are functionally and physiologically similar 
(self-similar) to the whole object. Under the conditions of these properties, the 
thoracic mammary glands can be considered fractal objects and their topological 
dimension, the fractal dimension (D), be expressed by a non-integer number lying 
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between two Euclidian integer topological dimensions (Grizzi, Russo et al. 2005). 
The values of D characterizing the thoracic mammary glands are therefore 
fractional. Since the thoracic mammary gland is essentially a 2-dimensional object, 
the D values will lie between 1 and 2. As the mammary gland becomes more 
complex and irregular, its D value becomes greater approaching 2.  In applying 
fractal analysis, the D value of the mammary gland is determined by applying the 
box-counting method (Fernandez and Jelinek 2001, Grizzi, Russo et al. 2005).  
The box-counting method has been the most widely used and general model for 
applying fractal analysis to biological and non-biological systems. The box-
counting method consists of a grid of boxes of size e superimposed over the image 
of the structure, and the number of boxes containing any part of the structure 
recorded as N(e). A fractal object expresses a straight line when Log[N(e)] is 
plotted against Log(1/e). The box fractal dimension D can be determined from the 
slope of the regression line. That is: D= Log[N(e)] / Log(1/e). The D values of the 
thoracic mammary glands were determined using HarFA software (Nezadal, 
Zemeskal et al. 2001) [http://www.fch.vutbr.cz/lectures/imagesci]. The HarFA 
software assigned mesh sizes of boxes with e values ranging from 2 to 207 pixels 
and 30 steps within this range were calculated to generate the Log[N(e)] versus 
Log(1/e) lines to determined .  
 
Branch points and terminal end buds (TEBs) 






Whereas the mammary gland begins its development during embryonic 
mid-gestation stages, the majority of its growth and development takes place post-
natally, with the first substantial expansion of the ductal epithelial network 
occurring during puberty. Genetic, hormonal, and environmental factors that 
perturb the ductal architecture during puberty or other periods of growth and 
morphogenesis also increase risk of developing breast cancer later in life (Fenton 
2006, Fenton, Reed et al. 2012, Biro and Deardorff 2013).  Mammary ductal 
epithelial branching and elongation are driven by bifurcation of specialized invasive 
structures located at the ends of the rudimentary ducts, termed terminal end buds 
(TEBs) (Sternlicht 2006).  Shorter (secondary) side branches also arise as lateral 
sprouts from trailing ducts, increasing the area of the ductal tree with each 
successive ovarian cycle (Sternlicht, Kouros-Mehr et al. 2006). The pattern of 
mammary branching morphogenesis is non-stereotypical (i.e. it varies from 
individual to individual), and is controlled by paracrine-derived signals within the 
local microenvironment (Lu, Sternlicht et al. 2006, Sternlicht, Kouros-Mehr et al. 
2006). 
In order to determine if changes in ductal epithelial growth and complexity 
can be identified during early neoplasia, several morphological and fractal 
parameters of ductal epithelial networks were quantified and compared between 
thoracic mammary glands (TMG) of pubertal stage wild type and MMTV-cNeu mice 
(Figure 6). We chose to focus specifically on TMGs for two reasons. Firstly, the 
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vast majority of tumors in MMTV-cNeu mice develop in the thoracic glands 
compared to the cervical or inguinal glands; and second, based on differences 
amongst signaling pathways that regulate induction of the five pairs of mouse 
mammary glands, as well as their anterior-posterior anatomical locations, it 
appears that TMGs most closely model human breast development (Veltmaat, 
Ramsdell et al. 2013). Thus, we reasoned that if early neoplastic changes were 
present, they would be detectable in the TMGs.  
Consistent with a previous report (Mukherjee, Louie et al. 2000), we found 
that the area occupied by the ductal epithelial network in TMGs in wild-type mice 
is significantly greater than the area of the ductal epithelial network in TMGs in the 
MMTV-cNeu mice (Figure 6). This indicates that the ductal epithelial networks in 
TMGs in the MMTV-cNeu mice are smaller, but not necessarily morphologically 
different from the TMGs present in the controls. To assess potential morphological 
differences, fractal dimension, branch points, TEBs, and IOD were quantified. 
Application of the fractal dimension (D) is a measure of disorder, or chaos, of the 
epithelial network. The D for MMTV-cNeu TMGs is significantly greater than D for 
the wild type TMGs (Figure 6). This indicates that the ductal epithelial networks of 
MMTV-cNeu TMGs are more complex and more space-filling despite smaller size 
(Area) than those in wild-type mice. Interestingly, the increase in D for MMTV-cNeu 
TMGs does not appear to be the result of an increase in branch points or TEBs, 
which are the same or decreased, respectively (Fig. 2). This indicates that the 
increase in D of the MMTV-cNeu TMGs results from an overall lack of order of the 
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entire network structure, suggesting that the ErbB2/Neu oncogene promotes 
disorganized pattern during epithelial network development.  
Although determination of D can quantify an object, a value of D does not 
uniquely specify a particular morphology. In other words, objects of vastly different 
morphology can have the same or similar fractal dimensions. To adequately 
describe the morphology of an object, an additional measurement in conjunction 
with D is required to provide a unique identifier, which quantifies the object. Ideally, 
such an additional measurement would be determinant of the structure or 
distribution of material within the thresholded boundary of the region of interest. In 
this study, we apply the concept that the IOD is a measure of the mass of the ductal 
network within the ROI (Walter and Berns 1986, Fuseler, Merrill et al. 2006, 
Fuseler, Millette et al. 2007, Rogers and Fuseler 2007, Fuseler and Valarmathi 
2012). Mass measurement deals with this distribution of material within the ROI 
and leads to the concept of relative density, here defined as IOD/Area. Thus, 
application of the term IOD/A provides additional information on the concept of 
mass density or relative density of the mammary ductal network (Smith, Lange et 
al. 1996). Taken together, these two measurements, D and IOD/A, improve the 
quantitative description and provide unique characterization and quantitation of the 
epithelial network morphology of MMTV-cNeu TMGs compared to WT TMGs.   
As shown in Figure 6, the relative density of the TMG epithelial network, 
measured as the IOD/A, is significantly greater in the MMTV-cNeu mice compared 
to wild type mice. This indicates that there is more physical material content 
(Carmine alum-stained epithelium) in the TMGs of MMTV-cNeu mice. Since the 
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MMTV-cNeu TMG networks have smaller area with a larger D, the expression of 
the greater IOD/A suggests that the ductal walls may be thicker and contain 
smaller lumens than the ducts in the wild type controls. Taken together, these 
results indicate that the overexpression of the ErbB2/Neu oncogene results in 
delayed epithelial growth with an overall concomitant increase in chaos that is 







Figure 6. Morphometric and fractal analysis of ductal networks of wild type 
versus MMTV-cNeu mice.  (A) Representative images of carmine red stained 
TMGs from wild type (WT) and MMTV-cNeuTg/+ mice.  (B) Morphometric analysis 
of #3/8 TMGs of WT versus MMTV-cNeuTg/+ mice. Bars are representative of mean 




Because epidemiological studies of breast cancer patients indicate that 
significantly more tumors arise in the left breast compared to the right (Veltmaat, 
Ramsdell et al. 2013), we next investigated whether the morphological defects in 
MMTV-cNeu mice were present to the same extent in both the left and right TMGs. 
Comparing the left TMG ductal networks in the MMTV-cNeu mice to those in the 
left TMGs of wild type mice indicated significant differences in all measurable 
parameters except branch points (Figure 7D). By contrast, the right-side ductal 
epithelial networks of MMTV-cNeu mice expressed a more normal morphometric 
pattern (Figure 7E). Whereas right side MMTV-cNeu networks had decreased area 
and number of terminal end buds, there was no difference in the D values of the 
right TMGs of the MMTV-cNeu mice compared to the right TMGs of controls. This 
indicates that although the right side TMGs of MMTV-cNeu mice are smaller, they 
nevertheless exhibit a normal degree of tissue organization and space-filling 
properties that are the same as wild-type controls. Additionally no difference was 
detected in the IOD of the right networks of the MMTV-cNeu mice relative to the 
right-side wild-type TMGs. However, the relative density (IOD/A) of the right side 
MMTV-cNeu TMGs was greater than relative density of wild type right side TMGs. 
Together, this suggests that ductal epithelium on the left side is more susceptible 
to ErbB2/Neu-mediated effects on ductal morphology than is the right side 
epithelium. Thus, fractal image analysis may be useful in defining tissue of risk 
(pre-neoplastic tissue or tissue initially undergoing neoplastic transformation) to 





Figure 7. Independent left and right side analysis of ductal networks in wild 
type versus MMTV-cNeu mice. (A) Representative images of a carmine red 
stained pair of TMGs of wild type (WT) mice. (B,C) Representative images of two 
different pairs of carmine red stained TMGs of MMTV-cNeuTg/+ mice. (D) 
Morphometric analysis of #3 left TMGs of WT versus MMTV-cNeuTg/+ mice. (E) 
Morphometric analysis of #8 right TMGs of WT versus MMTV-cNeuTg/+ mice. Bars 
are representative of mean ± SEM (WT N = 8 MMTV-cNeuTg/+ N= 13). Unpaired 





Our results demonstrate that when combined with conventional 
morphometric analysis, fractal dimension is a highly sensitive and quantitative tool 
by which one is able to evaluate and compare murine ductal epithelial growth and 
morphology. This combined approach facilitates precise morphological description 
which is independent of landmarks such as the lymph node (typically used in semi-
quantitative inguinal gland analysis) and permits for inclusion of regions of 
epithelium that may otherwise be obscured by contaminating muscle tissue (which 
frequently occurs with cervical and thoracic gland dissections). Similar to its clinical 
utility, application of fractal dimension to the Her-2+ breast cancer mouse model 
demonstrates that fractal dimension can identify aberrations in tissue architecture 
that are not necessarily obvious nor easily appreciated by conventional, semi-
quantitative image inspection. The objective nature of fractal analysis and the ease 
of use of this method position it as a tool that can be used to standardize 
morphological assessment of mammary epithelial growth and differentiation in 
both normal and neoplastic development. Because the combined image and fractal 
analysis used in this study utilizes commercially available software and can be 
applied to archived specimens (i.e. coverslipped mammary whole mounts), this 
approach offers a means by which results may be reproducibly and quantitatively 
compared across existing mouse mammary models, as well as in breast cancer 
mouse models that may be developed in the future.  
51 
 
In addition to its diagnostic and therapeutic decision making utility for breast 
cancer patients, fractal dimension may also be useful to identify women at 
heightened risk for developing breast cancer. Fractal dimension analysis of 
mammographic images has been used for retrospective identification of hormone-
associated changes in breast tissue linked with women who were later diagnosed 
with breast cancer (Daye, Keller et al. 2013).  In another retrospective study, fractal 
dimension analysis detected architectural distortions that were present in 
screening mammograms taken on average 15 months prior to clinical breast 
cancer diagnosis (Rangayyan, Banik et al. 2010, Rangayyan, Banik et al. 2013). 
In our study we found that fractal dimension can also be effectively used in a pre-
clinical breast cancer mouse model to similarly detect changes in tissue 
organization that arise during early oncogenesis. By applying combined 
fractal/morphometric analysis to MMTV-cNeu mice, we found that numerous 
aberrances develop in the growth and branching pattern of ductal epithelium during 
early neoplasia, well in advance of appreciable tumor formation. A particularly 
intriguing finding was that in addition to overall decreased ductal network area and 
alterations in other morphologic parameters, the epithelial networks of MMTV-
cNeu mice showed more pronounced abnormalities in ductal epithelial network 
organization and complexity in the left side glands than did the right side glands. 
This finding suggests that MMTV-cNeu mice may be an appropriate model to 
investigate left-right differences in neoplastic development, an area that has yet to 
be addressed at the cellular or molecular level, despite the fact that 
epidemiological studies consistently find increased tumor incidence on the left side 
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in breast cancer patients (Wilting and Hagedorn 2011, Veltmaat, Ramsdell et al. 
2013).  
In summary, the results of our study demonstrate that combined fractal and 
conventional morphometric analysis is an objective, quantitative method to 
document early neoplastic changes in ductal epithelial morphology occurring prior 
to mammary carcinoma development. The sensitivity of this approach in a pre-
clinical breast cancer mouse model yields results comparable to those in clinical 
studies of human breast cancer patients and offers opportunity for investigators to 
standardize analyses made across the many murine models that are currently in 
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Cancers that initiate in paired organs and other bilaterally symmetric tissues 
exhibit an unusual feature, which is that tumors occur with non-equivalent 
incidence on the left versus right sides (Delahunt, Bethwaite et al. 1994, 
Roychoudhuri, Putcha et al. 2006, Yoruk, Karasen et al. 2009, Wilting and 
Hagedorn 2011, Veltmaat, Ramsdell et al. 2013). The basis for this laterality has 
not been addressed at the cellular or molecular level, an oversight that may be 
significant because patient survival is reported to differ according to primary tumor 
situs (Delahunt, Bethwaite et al. 1994, Roychoudhuri, Putcha et al. 2006). The side 
with elevated tumor incidence is organ-dependent and not necessarily the same 
side that is associated with poorer disease outcome. For breast cancer, the 
majority of occurrences are unilateral, with higher tumor incidence on the left 
(Veltmaat, Ramsdell et al. 2013). Left-side predominance also occurs in bilateral 
cases, in which more tumors develop first in the left breast or are larger than those 
on the right (Veltmaat, Ramsdell et al. 2013). Yet, despite the increased incidence 
and larger average tumor size of left-sided breast cancer, right-sided breast cancer 
may be associated with worse prognosis. Right-sided breast tumors are prone to 
earlier onset of bone metastasis and give rise to higher numbers of sites with 
metastatic involvement (Fatima, Zaman et al. 2013). This suggests that disease 
progression is related to the side of tumor formation, which could result in 
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differential patient survival. Although studies directly addressing breast cancer 
patient survival relative to tumor laterality are limited and have generated 
contradictory findings (Veltmaat, Ramsdell et al. 2013), there is some indication 
that lower survival rates occur in patients with right-sided disease (Hartveit, 
Tangen et al. 1984).
The left-sided excess of breast cancer and potential relationship between 
tumor laterality and patient prognosis suggests that mammary tissues harbor L-R 
differences that are relevant to oncogenesis. To address this we have used normal 
and neoplastic MMTV-cNeuTg/Tg mice to probe for L-R differences at the beginning 
and end of puberty--a period when the rapidly growing ductal epithelium (Watson 
and Khaled 2008) is vulnerable to genetic, hormonal, and other environmental 
perturbations that heighten risk for developing breast cancer later in life (Fenton 
2006, Fenton, Reed et al. 2012, Biro and Deardorff 2013). Here we provide 
evidence that mouse mammary glands have baseline L-R differences in gene 
expression that are L-R discordantly altered by HER2/Neu and that are 
accompanied by asymmetric ductal epithelial growth and patterning. Furthermore, 
we used comparative genomic analysis to show that the L-R differences in gene 
expression that we identified in mouse mammary glands are predictive of breast 
cancer patient outcome, with right-side expression profiles associated with 
significantly poorer long-term patient survival. 
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MATERIALS AND METHODS 
 
Mice 
All experiments were performed in accordance with the regulations of the Medical 
University of South Carolina Institutional Animal Care and Use Committee. FVB/N 
wild-type and FVB/N-TgN (MMTVNeu) 202Mul) mice were obtained from Taconic 
(Germantown, NY, USA) and JAX® Mice and Services (Bar Harbor, ME, USA).  
Wild-type and MMTV-cNeuTg/Tg mice were used for all experiments and fed Harlan 
Teklad rodent diet 2918 and provided water ad libitum.  
 
Histology and image collection 
 Carmine red stained whole mounts (de Assis, Warri et al. 2010) prepared from #3 
and #8 thoracic mammary glands of day-28 mice (Veltmaat, Ramsdell et al. 2013) 
were imaged on an Olympus SZX12 stereomicroscope equipped with a Spot 
camera. Overlapping images of each whole mount were processed into a single 
composite image with Adobe Photoshop®.  
 
Image analysis.  
The color images of the mammary glands were converted to 8-bit monochrome 
images for image and fractal analysis. The mammary gland within an image was 
outlined and isolated from the background tissue and defined as a Region of 
Interest (ROI) (Figure 5). The isolated image of the mammary gland was 
thresholded using the set threshold subroutine of MetaMorph Image analysis 
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software (ver. 6.1). The area (A) and integrated optical density (IOD) of the ductal 
epithelial networks were measured using the integrated morphometry analysis 
sub-routine of MetaMorph. The fractal dimension (D), was determined by the box 
counting method using HarFA software (Nezadal, Zemeskal et al. 2001) 
[http://www.fch.vutbr.cz/lectures/imagesci]) applied to the isolated image of the 
mammary gland using the same threshold values. 
 
Integrated optical density (IOD).   
The IOD of the mammary gland ROI delineated by the thresholded boundaries is 
considered to be the “mass” of the ROI and a measurement of the total amount of 
labeled material in the region (Walter and Berns 1986, Fuseler, Merrill et al. 2006, 
Fuseler, Millette et al. 2007, Rogers and Fuseler 2007, Fuseler and Valarmathi 
2012).  The IOD of a selected region can be expressed as the weighted sum of the 
image histogram in which each term in the histogram is multiplied by the gray value 
it represents. When applied to thresholded boundaries the IOD is defined by the 
following expression: 
                           T2 
IOD (T1, T2) =  ∑ H (GV) x GV 
                           GV = T1 
Where the upper and lower thresholds defining the ROI in the histogram are 
given by T1 and  T2.  GV is the gray value of each pixel and H (GV) is the gray 





Application of the fractal dimension (D) 
 The thoracic mammary glands in the wild type and MMTV-cNeu mice appear as 
irregular and complex objects composed of parts at different levels of resolution 
(ducts of different bore sizes) which are functionally and physiologically similar 
(self-similar) to the whole object. Under the conditions of these properties, the 
thoracic mammary glands can be considered fractal objects and their topological 
dimension, the fractal dimension (D), be expressed by a non-integer number lying 
between two Euclidian integer topological dimensions (Grizzi, Russo et al. 2005). 
The values of D characterizing the thoracic mammary glands are therefore 
fractional. Since the thoracic mammary gland is essentially a 2-dimensional object, 
the D values will lie between 1 and 2. As the mammary gland becomes more 
complex and irregular, its D value becomes greater approaching 2.  In applying 
fractal analysis, the D value of the mammary gland is determined by applying the 
box-counting method (Fernandez and Jelinek 2001, Grizzi, Russo et al. 2005).  
The box-counting method has been the most widely used and general model for 
applying fractal analysis to biological and non-biological systems. The box-
counting method consists of a grid of boxes of size e superimposed over the image 
of the structure, and the number of boxes containing any part of the structure 
recorded as N(e). A fractal object expresses a straight line when Log[N(e)] is 
plotted against Log(1/e). The box fractal dimension D can be determined from the 
slope of the regression line. That is: D= Log[N(e)] / Log(1/e). The D values of the 
thoracic mammary glands were determined using HarFA software (Nezadal, 
Zemeskal et al. 2001) [http://www.fch.vutbr.cz/lectures/imagesci]. The HarFA 
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software assigned mesh sizes of boxes with e values ranging from 2 to 207 pixels 
and 30 steps within this range were calculated to generate the Log[N(e)] versus 
Log(1/e) lines to determined .  
 
Branch points and terminal end buds (TEBs) 
 Branch points and TEBs were quantified by manual counting from the images.  
 
Microarray Analysis 
Microarray analysis of left versus right TMGs using left as the baseline reference 
was performed using RNA pooled from 3-4 intact 4-week TMGs [#3 and #8 glands 
as diagrammed in Veltmaat et al (Veltmaat, Relaix et al. 2006)] for cDNA synthesis 
and hybridization to Affymetrix GeneChip Mouse Genome 430 2.0 Arrays. The 
arrays were preprocessed and normalized using RMA (Irizarry, Hobbs et al. 2003).  
Each array experiment was completed in biological and technical triplicate.  
Differentially expressed probesets were identified based on a fold-change 
(increase or decrease in right side compared to left) of at least 1.2, and a q-value 
of less than 0.05. Pathway analysis was carried out for each set of laterality 
associated genes (left or right) by probing the NCI Pathway interaction database 
(Schaefer, Anthony et al. 2009). 
 
RT-PCR  
SYBR Green-based RT-PCR of select array candidates was performed with 
primers listed in Table 2. Real-time PCR miner was used to calculate Ct values 
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and replication efficiency(Zhao and Fernald 2005) and fold changes relative to 
GAPDH mRNA were determined by delta-delta Ct. 
 
Immunoprecipitation  
Total ErbB2/Neu protein was immunoprecipitated from left or right TMGs (Antibody 
#4290, Cell Signaling), immunoblotted, and probed with anti-phospho-ErbB2/Neu 
(Antibody #2243, Cell Signaling).  Densitometry of triplicate results was performed 
using NIH ImageJ software. 
 
Comparative genomic analysis  
Compilation of a large cohort of breast cancer patients from multiple studies 
available through the Gene Expression Omnibus 
(http://www.ncbi.nlm.nih.gov/geo/) was compared to the microarray in - to test the 
association between laterality associated genes and patient survival. Our 
combined cohort comprised patients from the GSE2034 (Wang, Klijn et al. 2005), 
GSE7390 (Desmedt, Piette et al. 2007), GSE4922(Ivshina, George et al. 2006), 
GSE25055 (Hatzis, Pusztai et al.), and GSE3494 (Miller, Smeds et al. 2005) 
cohorts (n=1334). For all patients, clinical outcome data as well as the gene 
expression profile of their respective tumors was available. Whenever possible we 
used 10-yr disease free survival as the clinical endpoint in our study; however, 
when disease free survival was not available we alternatively used either distant 
metastasis free or overall survival as the clinical endpoint. The arrays for each 
separate cohort were preprocessed and normalized using RMA(Irizarry, Hobbs et 
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al. 2003). ER status was assigned based on the clinical annotation files, and HER2 
status was assigned based on the mean ERBB2 transcript levels (probe set ID 
216836_s_at) within each study cohort independently. Affymetrix GeneChip 
Mouse Genome 430 2.0 Arrays probe sets were mapped to their human 
counterpart genes by Unigene IDs. When multiple probe sets recognized the same 
gene transcripts, only the probe with the highest mean intensity was used. To 
assign signature scores to patients, the expression values for each gene were 
standardized such that the mean and standard deviation were set to 0 and 1 in 
each individual patient cohort, respectively. Subsequently, we calculated signature 
scores for each patient as previously described (Hallett, Dvorkin-Gheva et al. 2012, 
Hallett, Pond et al. 2012), where positive scores were considered to indicate that 
a tumor had ‘right-sided’ gene expression and negative scores were considered to 
indicate that a tumor had ‘left-sided’ gene expression. Survival curves were 





Thoracic mammary glands are molecularly L-R asymmetric  
Ductal epithelial networks in thoracic mammary glands (TMGs) of early pubertal 
(4-week) and post-pubertal (10-week) wild type (WT) mice (Figure 8A, B) were 
quantified by image and fractal analysis as described previously (Fuseler, 
Robichaux et al. 2014).  Despite increases in network area and number of branch 
points between weeks 4 and 10, as well as changes in TEBs, which decrease in 
number and initiate regression by week 10 (Richert, Schwertfeger et al. 2000), all 
of these morphological parameters were statistically equivalent for left and right 
TMGs at both timepoints, indicative of L-R symmetry (Figure 8C). By contrast, 
microarray analysis yielded approximately 161 transcripts that were L-R 
differentially expressed (i.e., up-regulated or down-regulated) with >1.2 fold 
change (q-value<0.05, Figure 8D), including genes and pathways that have 
established roles in oncogenesis and/or therapeutic sensitivity (Table 1). Several 
of the transcripts identified in the array were examined by RT-PCR (Figure 8E), 
which confirmed that relative to left-side expression, some genes were increased 
and others were decreased in expression levels on the right side. For example, 
Gata-3 and FoxM1, which regulate luminal progenitor cell differentiation and 
renewal (Asselin-Labat, Sutherland et al. 2007, Carr, Kiefer et al. 2012), and which 
also have opposing protective and causative roles in tumorigenesis in the breast 
and other organs (Chou, Provot et al. 2010, Teh 2012), were more highly 
expressed on the left side (Figure 8E). By the end of puberty, both genes were 
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down-regulated; however, the fold decrease was significantly greater for left-side 
glands which resulted in net symmetric expression (Figure 8E). Asymmetric 
expression also was found for notch-1, another regulator of mammary luminal 
progenitor cell commitment (Bouras, Pal et al. 2008) that is involved in breast 
tumorigenesis (Farnie and Clarke 2007) (Figure 8E). Notch-1 was right-side 
elevated, and by 10-weeks it showed slightly higher fold decrease in right-side 
glands compared to left (Figure 8E). To determine if asymmetric expression of 
genes with dual roles in ductal growth and tumorigenesis is a general property of 
TMGs, we examined estrogen receptor alpha (ERα). ERα was L-R equivalently 
expressed at both the start and end of puberty, consistent with it not being 
identified as a candidate by microarray (Figure 8E). We also examined CD24, a 
pan-epithelial marker in mouse mammary glands (Visvader 2009), which showed 
modest left-side elevation in 4-week TMGs, but not in 10-week TMGs (Figure 8E), 
raising the possibility that subtle differences in epithelial cell number could be 
present during early puberty, despite equivalent ductal network growth and 
morphology. 
Genes involved in therapeutic sensitivity also were represented in the 
microarray. Elevated right-side expression was detected for retinoic acid-inducible 
G-protein coupled receptor 5D (GPRC5D), a gene that enhances sensitivity to an 
estrogen receptor antagonist, tamoxifen, in MCF7 breast cancer cells (Mendes-
Pereira, Sims et al. 2012) and that was decreased by the end of puberty (Figure 
8E). In addition, stathmin-1 (Stmn-1), a microtubule destabilizing protein that 
confers chemoresistance in breast and other tumor types (Su, Smith et al. 2009, 
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Baquero, Hanna et al. 2012, Meng, Su et al. 2012, Han, Wang et al. 2013, Miceli, 
Tejada et al. 2013), was modestly left-side elevated in 4-week TMGs, followed by 
inversion to modest right-side elevated expression in 10-week TMGs  (Figure 8E). 
Given the many L-R differences in gene expression in TMGs, it was surprising that 
microarray analysis did not uncover connections to any known laterality genes 
(Table 1), including nodal and Pitx2, regulators of embryonic L-R patterning that 
also are expressed in breast cancer and other tumor types (Wilting and Hagedorn 
2011). Thus, we assessed these genes by RT-PCR, which confirmed symmetric 
expression (Figure 8E). Together, these findings demonstrate that despite 
symmetric nodal and Pitx2 expression, the left and right TMGs of WT mice are 
molecularly lateralized with asymmetric expression of other genes that may impart 






Figure 8. Morphological and molecular analysis of TMGs. Wild type mouse 
TMGs such as the representative L-R matched pairs are shown at 4-weeks (A) 
and 10-weeks (B) (scale bar = 1mm). Branch points and terminal end buds (TEBs), 
are shown in higher magnification insets for 10-week glands (arrowheads indicate 
TEBs; scale bar = 5 µm. Color-coding can be used to follow matched L-R pairs 
harvested from the same mouse in all graphs. No significant L-R differences (C) 
were found in ductal network area, fractal dimension, relative density, branch 
points or TEBs at 4 or 10 weeks as determined by one-tailed paired student’s t-
test. Microarray analysis of left versus right TMGs using left as the baseline 
reference (D). SYBR Green-based RT-PCR of select array candidates was 
performed with primers listed in Table 2 (E). Fold changes across groups were 
determined using the lower level of 4-week expression as baseline as indicated by 
the horizontal grey line. Bars represent mean ± SEM of >5 mice; *p<0.05, **p<0.01; 
*** p<0.001 (two-tailed paired student’s t-tests).
67 
 
Table 1: Microarray analysis. Transcripts identified in the L-R mouse TMG 
microarray are listed and the side with elevated expression is indicated (A). Results 
from pathway analysis of microarray data also are indicated (B). 






































































































B. Pathway analysis of microarray  
 
Right side pathways Adjusted P 
FOXM1 transcription factor network 0.005208 
CXCR3-mediated signaling events 0.007896 
Direct p53 effectors 0.007896 




Table 2. RT-PCR primers  
Primer sets used for RT-PCR are listed. For experiments that were confirmed by 
alternate primer sets, the primers used to generate the results presented in the 
Figures are indicated (*). 
Gene Forward Reverse 
GPRC5D ATTCAGCTGCAGAGTGCTGAT TCTTGCTGTGGGCTTAGTGT 
GATA3 TCCTTGCTACTCAGGTGATCG TGACCACACTGCACACTGAT 
FOXM1 CCTGTGAGGGTCAAAGCTTGC CCGTCTTTTGAGAATCAGTGGC 
STMN1 CCAGGTCTGTTGGTGCTCAGA TACACAATCCACTGGCAAGGAAA 
GAPDH CAGCAAGGACACTGAGCAAGA TATGGGGGTCTGGGATGGAAA 
Nodal GCGCAAGATGTGGACGTGAC CTCCGCCCATACCAGATCCT 
Pitx2 GAGGTGCATACAATCTCCGATA TGCCGCTTCTTCTTGGAC 
ERα CTGGCTACGTCAAGTCGGTT AGGTGCTGGACAGAAACGTG 
Notch-1 AATGGAGGGAGGTGCGAAGT GGTGTGCTGAGGCAAGGATT 
CD24 TTCTGGCACTGCTCCTACCC CTGGTTACCGGGAAACGGT 
Numb CTCGGCCACGTAGAAGTTGA CCCGTTTTTCCAAAGAAGCCT 
ErbB2 (1)* AACAGCTCGGAGACCTGCTA GTAGTGGGCACAAGCCTCA 
ErbB2 (2) CTGACTGCCCTGACAGACTG ATATTCACCTGGGGCCTCCT 
Neu (1)* ATTGGCTCTGATTCACCGCA CAAGCCCTCGAGACCACAAT 
Neu (2) GCTCAGAGACCTGCTTTGGA AGGAGGACGAGTCCTTGTAGTG 
EGFR ACCTGTGTGAAGAAGTGCCC TCGTAGTAGTCAGGCCCACA 
PR CCAGCATGTCGTCTGAGAAA GCCTGGCTCTCGTTAGGAA 
ELF5 TGCCTTTGAGCATCAGACAG TACTGGTCGCAGCAGAATTG 
b-casein GGTGAATCTCATGGGACAGC AGATGGTTTGAGCCTGAGCA 
Sox9 AACTTCTGTGGGAGCGACAA CACTTGCACCTCGTCTCTCTT 
SMA ATCATTGCCCCTCCAGAACG GAAGGTAGACAGCGAAGCCA 
p63 AGCCTCCTGGCTACATACCT CACGAGAAATGAGCTGGGGT 
Cd1d CCAGAGCCTTTGTGTACCAGT CAGGCAGCGGAAGGTGTAAT 
RXRα CATCTTTGACAGGGTGCTAACA GGGTTTGAGAGCCCCTTAGAG 
FGF8 GCAGAAGACGGAGACCCCTT GCCTTTGCCGTTGCTCTTGG 
Wnt10b ATCCTGCACCTGAACCGCTG TGCTTAGAGCCCGACTGAACA 
Hes1 CGGACAAACCAAAGACGGC GAATGCCGGGAGCTATCTTTCT 




HER2/Neu causes L-R asymmetric ductal growth and alters L-R gene 
expression in TMGs  
To address the possibility that mammary ductal epithelium might be primed for 
differential growth during neoplasia, we quantified ductal networks in MMTV-
cNeuTg/Tg mice, which are a commonly used model of HER2+ breast cancer 
(Hutchinson and Muller 2000). Compared to WT, the ductal network area was 
smaller in 4-week MMTV-cNeuTg/Tg TMGs and in particular, left-sided MMTV-
cNeuTg/Tg networks were significantly smaller than their right-sided counterparts 
(Figure 9A, C). Left-sided networks also contained fewer branch points, and had 
higher fractal dimension, relative density, and number of TEBs (Figure 9A, C).  
Morphological asymmetry persisted through the end of pubertal development, with 
left-sided networks maintaining decreased area and higher numbers of branch 
points and TEBs (Figure 9B, C). Given the L-R differences in MMTV-cNeuTg/Tg 
ductal network growth and pattern, we evaluated whether MMTV-cNeuTg/Tg TMGs 
have asymmetric ErbB2/Neu expression or activity. Although RT-PCR showed that 
Neu expression was elevated in right-side TMGs, endogenous ErbB2 expression 
was L-R equivalent, as was Numb, a notch inhibitor whose expression is regulated 
by ErbB2 (Lindsay, Jiao et al. 2008) (Figure 9D). Moreover, phospho-ErbB2/Neu 
immunoprecipitation showed equivalent levels in left and right side TMGs, 
suggesting similar activation of ErbB2/Neu signaling on both sides (Figure 9D).  
Further analysis of MMTV-cNeuTg/Tg TMGs indicated that molecular 
laterality was amplified, sustained, or inverted in a gene-specific manner by 
comparison to WT. 
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Notch-1 expression was approximately 3-fold higher in right-sided 4-week MMTV-
cNeuTg/Tg TMGs (Figure 9E), which is an amplification of the modest Notch-1 
asymmetry that was present in WT TMGs (Figure 8E and Figure 10). In 10-week 
MMTV-cNeuTg/Tg TMGs, asymmetric Notch-1 expression was inverted, with 
approximately 2-fold higher expression in left-side glands (Figure 9E). Because 
Notch influences breast cancer cell sensitivity to several therapeutic agents, 
including trastuzumab, gefitinib, docetaxel, and tamoxifen (Wang, Li et al. 2010), 
the L-R uncoupled regulation of Notch-1 expression in MMTV-cNeuTg/Tg TMGs 
may be important in the context of differential disease progression. In addition, 
FoxM1 and Gata-3, which were left-side elevated in 4-week WT TMGs (Figure 8E), 
were decreased on both sides in MMTV-cNeuTg/Tg TMGs; however, the fold 
decrease for FoxM1 was greater on the left side (Figure 10) resulting in net L-R 
symmetric expression (Figure 9E). Analysis of 10-week MMTV-cNeuTg/Tg TMGs 
showed that FoxM1 expression was further decreased, albeit the fold decrease 
was greater for right-side glands (Figure 9E and Figure 10). Given the additional 
role of FoxM1 in modulating endocrine and chemotherapeutic resistance in breast 
cancer cells (Carr, Park et al. 2010, Kwok, Peck et al. 2010, Millour, Constantinidou 
et al. 2010), the L-R uncoupled regulation of FoxM1 expression in MMTV-cNeuTg/Tg 
TMGs was notable. We also found similar L-R asymmetric regulation of Gata-3 in 
MMTV-cNeuTg/Tg TMGs, which resulted in modestly higher left-sided expression by 
10-weeks (Figure 9E and Figure 10). 
Genes with symmetric expression in 4-week MMTV-cNeuTg/Tg TMGs 
included ERα, CD24, nodal, and Pitx2 (Figure 9E). However, by 10 weeks their 
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expression was elevated in left-sided glands, with the exception of nodal, which 
was elevated on both sides (Figure 9E). GPRC5D, which was right-side elevated 
in 4-week WT TMGs (Figure 8E), also was right-side elevated in 4-week MMTV-
cNeuTg/Tg TMGs (Figure 9E), despite an overall marked reduction in expression on 
both sides (Figure 10). Stmn-1 was asymmetric in 4-week MMTV-cNeuTg/Tg TMGs 
(Figure 9D, Figure 10) but by week-10 was increased only on the left-side, resulting 






Figure 9. Morphological and molecular analysis of MMTV-cNeuTg/Tg  TMGs. 
TMGs from MMTV-cNeuTg/Tg mice such as the representative L-R matched pairs 
shown at 4-weeks (A) and 10-weeks (B) were processed for morphometric 
analysis and data for matched L-R pairs in individual mice were color coded as 
described in Figure 8 and tested by Grubb’s Outlier test, which indicated an 
absence of outliers. Ductal network area, fractal dimension, relative density, 
branch points, and TEBs exhibited significant L-R differences at 4 weeks (C) as 
determined by one-tailed paired student’s t-test (*p<0.05; **p<0.01). Ductal 
network area, branch points, and TEBs remained significantly L-R different at 10 
weeks (C). SYBR Green-based RT-PCR showed asymmetric expression of Neu, 
but symmetric mRNA expression of ErbB2 and Numb (D). Bars represent mean ± 
SEM. N ≥ 5, *p = 0.003. Results were confirmed with a second primer set listed in 
Table 1. Total ErbB2/Neu protein was immunoprecipitated from left or right TMGs 
immunoblotted, and probed with anti-phospho-ErbB2/Neu. Densitometry of 
triplicate results indicated no significant L-R differences (D). SYBR Green-based 
RT-PCR analysis of gene expression in left vs. right TMGs of MMTV-cNeuTg/Tg  
mice was performed as described in Figure 8 E. Bars represent mean ± SEM of 5 





Figure 10.  RT-PCR analysis of mammary gene expression in wild type 
versus MMTV-cNeuTg/Tg mice. RT-PCR was used to assess gene expression in 
L-R paired 4-week TMGs (A), 10-week TMGs (B), 4-week IMGs (C), 10-week 
IMGs (D). For 4-week TMGs, data were normalized relative to WT right-sided 
glands for all genes except Notch-1, ERα, and GPRC5D , which were normalized 
relative to WT left-sided glands. Comparison of fold differences between WT and 
MMTV-cNeuTg/Tg glands indicated that FoxM1, Gata-3, Notch-1, CD24, GPRC5D, 
and Stmn-1 were independently up or down-regulated in left versus right-sided 
glands. For 10-week TMGs, data were normalized relative to WT left-sided glands 
for all genes except FoxM1, Gata-3, Nodal, and Pitx2, which were normalized 
relative to WT right-sided glands. Comparison of fold differences between WT and 
MMTV-cNeuTg/Tg glands indicated that FoxM1, Gata-3, Notch-1, CD24, GPRC5D, 
and Pitx2 were independently up or down-regulated in left versus right-sided 
glands. For 4-week IMGs, data were normalized relative to WT right-sided glands, 
except for Notch-1, ERα, and Stmn-1, which were normalized to WT left-sided 
glands. Comparison of fold differences between WT and MMTV-cNeuTg/Tg glands 
indicated that all genes examined were similarly up or down-regulated in left versus 
right-sided glands except Notch-1, which was slightly more elevated in MMTV-
cNeuTg/Tg right-sided glands compared to WT. RT-PCR showed gene expression 
in 10-week left vs. right IMGs (D). For 10-week IMGs, data were normalized 
relative to WT right-sided glands for all genes.  Comparison of fold differences 
between WT and MMTV-cNeuTg/Tg glands indicated that FoxM1, Gata-3, Notch-1, 
ERα, and CD24 were independently up or down-regulated in left versus right-sided 
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glands.  Bars represent mean ± SEM of ≥ 3 mice, *p<0.05; **p<0.01; *** p<0.001, 
two-tailed paired student’s t-tests. 
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IMGs are refractory to HER2/Neu-induced asymmetric growth and show 
delayed L-R asymmetric gene expression  
Although mouse TMGs share more similarity with human mammary glands than 
inguinal mammary glands (IMGs) (Veltmaat, Ramsdell et al. 2013), IMGs are more 
commonly used in experimentation because of their larger size and easier 
accessibility (Cardiff and Wellings 1999, Brill, Boecher et al. 2008). Therefore, we 
also examined IMGs. Like TMGs, IMGs showed no significant L-R differences in 
morphology at either 4-weeks or 10-weeks (Figure 11A-C). Unlike TMGs, early 
pubertal IMGs showed an absence of significant molecular asymmetry except for 
Stmn-1, which was modestly right-side increased (Figure 11D). However, by the 
end of puberty, 10-week IMGs had developed molecular L-R asymmetry similar to 
that observed in 4-week WT TMGs, with left-side elevated expression of FoxM1, 
Gata-3, Notch-1, ERα, and CD24 (Figure 11D).  
 As previously reported (Mukherjee, Louie et al. 2000), ductal networks in 
MMTV-cNeuTg/Tg IMGs were smaller compared to WT, and we found symmetric 
morphology at both 4 and 10-weeks (Figure 11A-C). Although there were overall 
changes in gene expression relative to WT (Figure 10), 4-week MMTV-cNeuTg/Tg 
IMGs did not exhibit molecular L-R asymmetry, with the exception of modest right-
side elevation of Notch-1 and a more robust 3.5-fold left-side elevation of Pitx2 
(Figure 11H). Although Pitx2 was not associated with asymmetric ductal growth 
per se in either TMGs or IMGs, given that altered Pitx2 methylation occurs in breast 
and other cancer types (Wilting and Hagedorn 2011) the overall changes in Pitx2 
expression nevertheless suggest a potential role in HER2/Neu-induced neoplasia. 
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By the end of puberty, MMTV-cNeuTg/Tg IMGs showed pronounced molecular 
asymmetry, as exemplified by right-side elevated FoxM1 and Gata-3 expression 
and left-side elevated ERα and Notch-1 (Figure 11H). Thus by comparison to 
TMGs, both WT and MMTV-cNeuTg/Tg IMGs were temporally delayed in developing 
molecular asymmetry, which may account for their remaining refractory to 





Figure 11. Morphological and molecular analysis of IMGs.  L-R pairs of IMGs 
from 4-week (A) and 10-week (B) wild type and 4-week (E) and 10-week (F) old 
MMTV-cNeuTg/Tg  mice were processed and analyzed as described in Figure 8 A-
C. Ductal network area, fractal dimension, relative density, branch points, and 
TEBs did not exhibit significant L-R differences (C, G) as determined by one-tailed 
paired student’s t-test. SYBR Green-based qRT-PCR analysis of gene expression 
of left vs. right IMGs of wild type (D) and MMTV-cNeuTg/Tg  (H) mice was performed 
as described in Figure 8 E. Pitx2 was not detectable in wild type IMGs at either 
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age nor in MMTV-cNeuTg/Tg  IMGs at 4 weeks. Bars represent mean ± SEM of ≥3 





TMG molecular laterality is associated with differential breast cancer patient 
survival 
To determine if L-R differences detected in mouse mammary glands are 
clinically relevant, the genes identified in our microarray experiment (Figure 8D) 
were evaluated in a large number of breast tumor gene expression data sets for 
which corresponding patient outcome is also known (n=1334). Of the 161 
transcripts identified in the microarray, we were able to map 96 of them by Unigene 
ID to their human transcript counterpart for each patient. 
Because the sidedness of tumor location was not available in the clinical 
annotation files, patients were assigned to left (n=642) or right-side (n=692) groups 
based on whether their tumor gene expression profiles more closely matched with 
the left or right profiles identified in the mouse microarray. Notably, right-side gene 
expression was linked to poorer patient survival (Figure 12A). We next analyzed 
subsets of patients with HER2+ and HER2- tumors. Whereas the relationship 
between L-R gene expression and outcome fell just short of significance in the 
HER2 over-expressing subset (Figure 12B), the relationship was significant in the 
HER2- subset (Figure 12C). It should be noted that because HER2 status was not 
available in the clinical annotation files, we assigned patients to the HER2+ and 
HER2- subsets based on mean ERBB2 transcript levels. For this reason, and also 
because of statistical power limitations due to the HER2+ subset containing far 
fewer patients (n=276) than the HER2- subset (n=1058), the relationship between 
HER2+ patient survival and L-R gene expression may be unclear and require 
additional investigation with a larger HER2+ test cohort.  
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Since ER status also is tightly linked to breast cancer patient outcome 
(Sotiriou and Pusztai 2009), we evaluated L-R gene expression patterns in ER+ 
and ER- patient subsets. In both subsets, right-side gene expression was 
associated with decreased survival (Figure 12D, E). Lastly, we performed 
univariate Cox-regression survival analyses with each of the L-R transcripts, which 
identified a 20-gene subset that likely drove the predictive capacity of the complete 
96-gene set (*p<0.05, Cox-regression) (Figure 12F).  Indeed, the evaluation of 
these 20 genes among the 1334 patient cohort outperformed the original 96 L-R 
gene set (Figure 12G). Thus, the L-R gene expression profiles identified in mouse 
mammary glands are significantly linked to breast cancer patient survival rates, 





Figure 12. Comparative genomic analysis of mouse L-R mammary gene 
expression profiles with human breast tumors and the relationship to breast 
cancer patient survival. Compilation of a large cohort of breast cancer patients 
from multiple studies available through the Gene Expression Omnibus 
(http://www.ncbi.nlm.nih.gov/geo/) was compared to the microarray in Figure 8 to 
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test the association between laterality associated genes and patient survival. 
Hazard ratios (HR) are indicated for all patients (A), and HER2+ (B), HER2- (C), 
ER+ (D), ER- (E) subsets. A 20-gene subset of the 96 L-R TMG gene expression 
set (F) is a robust predictor of outcome among all breast cancer patients (G). 
References are provided for genes previously implicated in oncogenesis; those 
with none available (N/A) are indicated. Survival curves were graphed using 





Our results indicate that despite their morphological symmetry, mammary 
glands are molecularly lateralized. Although left and right glands express the same 
genes, the relative levels of gene expression significantly differ and are subject to 
L-R uncoupled regulation during pubertal development. Our results also 
demonstrate that many of the genes associated with the left side are down-
regulated, yet remain elevated or amplified on the right-side in TMGs of MMTV-
cNeuTg/Tg mice, consistent with more aggressive disease progression reported for 
right-sided breast tumors (Fatima, Zaman et al. 2013).  Moreover, the L-R 
uncoupled gene expression is accompanied by asymmetric growth and 
morphogenesis of the ductal epithelium. The molecular laterality of mammary 
glands at the start of puberty appears to be important in potentiating HER2/Neu 
oncogene-mediated asymmetric growth since IMGs, which exhibit L-R differences 
in gene expression at the end of puberty, but not at the start, fail to undergo L-R 
asymmetric growth in MMTV-cNeuTg/Tg mice. From the perspective of modeling 
human breast development and cancer, these results confirm there are significant 
differences between thoracic and inguinal glands and provide the first evidence 
that each mammary pair is independently L-R regulated regardless of its anterior 
or posterior location. By analogy to anterior-posterior differences that underlie 
differential development and neoplastic susceptibility of mouse TMGs versus IMGs 
(Veltmaat, Ramsdell et al. 2013), as well as the processes that establish molecular 
L-R differences in other bilaterally symmetric tissues (Golding, Partridge et al. 
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2004, Golding, Tsoni et al. 2004, Chintapalli, Terhzaz et al. 2012), we hypothesize 
that mammary laterality may be rooted in embryonic patterning. Therefore, future 
investigation to determine the connections between positional differences in gene 
expression, axial patterning, and the relationship to mammary development and 
tumorigenesis will be revealing. Furthermore, given the roles of ErbB2/HER2 in 
normal and neoplastic mammary development (Eccles 2011), as well as the 
significant link we found between L-R gene expression and breast cancer patient 
survival, our findings highlight laterality as a parameter that warrants greater 
consideration in experimental design in mouse mammary models as well as clinical 




 CHAPTER 3.2: MAMMARY STEM CELLS EXHIBIT LEFT-RIGHT 
DIFFERENCES IN SELF-RENEWAL CAPACITY AND LAPATINIB SENSITIVITY 






Breast cancer laterality is an understudied aspect of breast cancer 
tumorigenesis and biology. Epidemiological reports demonstrate that more tumors 
form in the left breast (Perkins, Hotes et al. 2004, Roychoudhuri, Putcha et al. 
2006, Saleh and Abdeen 2007, Arkoob, Al-Nsour et al. 2010, Wilting and Hagedorn 
2011, Fatima, Zaman et al. 2013, Veltmaat, Ramsdell et al. 2013, Zeeneldin, 
Ramadan et al. 2013), and that tumors that develop in the right breast are more 
aggressive metastasize more frequently than tumors that form in the left breast 
(Saleh and Abdeen 2007, Fatima, Zaman et al. 2013, Zeeneldin, Ramadan et al. 
2013). These L-R differences in tumor incidence and breast cancer progression 
indicate that there may be L-R differences in mammary gland biology. Previously, 
our lab has demonstrated that in wild-type (WT) mice the left (L) and right (R) 
thoracic mammary glands (TMGs) are indeed lateralized in gene expression and 
in response to oncogene overexpression (Fuseler, Robichaux et al. 2014, 
Robichaux, Hallett et al. 2014). Pathway analysis of microarray data from L and R 
TMGs converge on pathways that regulate mammary stem cell (MaSC) 
differentiation and self-renewal (Smalley and Ashworth 2003, Cicalese, Bonizzi et 
al. 2009, Carr, Kiefer et al. 2012, Robichaux, Hallett et al. 2014), suggesting L-R 
differences in MaSCs.  
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 MaSCs are a focus of both breast cancer biology as well as mammary gland 
biology because not only do MaSCs give rise to the entire ductal network, but these 
long lived cells are hypothesized to be tumor initiating cells when mutations are 
acquired over time (Dontu, Al-Hajj et al. 2003, Dontu, El-Ashry et al. 2004, Spike, 
Engle et al. 2012, Makarem, Kannan et al. 2013). MaSC self-renewal and 
differentiation regulation vary throughout the life-span of the organism. During 
embryogenesis, puberty, pregnancy, and lactation MaSCs undergo rapid 
proliferation, differentiation, and self-renewal to meet the developmental needs of 
the organism. However, outside of these distinct developmental windows, MaSCs 
remain quiescent and turn over very slowly (Hens and Wysolmerski 2005, Oakes, 
Hilton et al. 2006, Anderson, Rudolph et al. 2007, Watson and Khaled 2008, 
Cicalese, Bonizzi et al. 2009, Asselin-Labat, Vaillant et al. 2010, Diaz-Guerra, Lillo 
et al. 2012, Howard 2012, Makarem, Kannan et al. 2013, Makarem, Spike et al. 
2013, Boras-Granic, Dann et al. 2014, Rios, Fu et al. 2014). These periods of rapid 
growth and proliferation of MaSCs closely mirrors the proliferation during 
tumorigenesis (Dontu, Al-Hajj et al. 2003, Hens and Wysolmerski 2005, Prat and 
Perou 2009). In addition, recent studies show the longest lived MaSCs arise 
embryonically and persist through adulthood (Boras-Granic, Dann et al. 2014). 
These long lived MaSCs express higher levels of ErbB2 than adult MaSC (Spike, 
Engle et al. 2012). HER2/ErbB2/Neu is amplified in 20-30% of breast cancers and 
is associated with aggressive tumor phenotype and early drug resistance 
(Korkaya, Paulson et al. 2008, McDermott and Wicha 2010, Reichman, Altekruse 
et al. 2010, Ithimakin, Day et al. 2013). Additionally, a recent study reports that 
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HER2 amplification in metastatic tumors occurs more frequently in the right breast 
(Fatima, Zaman et al. 2013). Furthermore, studies demonstrate that ErbB2/HER2 
increases MaSC populations and mammosphere formation in vitro (Korkaya, 
Paulson et al. 2008, McDermott and Wicha 2010, Ithimakin, Day et al. 2013, 
Korkaya and Wicha 2013), suggesting ErbB2 regulates MaSC self-renewal and 
proliferation. Our previous findings demonstrate that the L and R mammary glands 
are differentially susceptible to ErbB2/Neu overexpression and L-R different in 
asymmetric enrichment in pathways that regulate MaSC differentiation and self-
renewal (Robichaux, Hallett et al. 2014). Studies by others demonstrate the 
importance of ErbB2/Neu signaling in MaSC differentiation and self-renewal. 
Therefore we hypothesize that MaSCs are lateralized in quantity and function and 
are regulated by ErbB2 signaling L-R differently.  
Here, we demonstrate for the first time that WT MaSCs are indeed L-R 
different in number, ErbB2 and EGFR expression, in vitro growth and self-renewal. 
In addition WT MaSCs respond L-R different to treatment with Lapatinib, a small 
molecule inhibitor that binds to both ErbB2 and EGFR. ErbB2/Neu overexpression 
results in a molecular inversion of upregulation of ErbB2 and EGFR expression as 
well as an inversion in vitro growth and self-renewal, and response to Lapatinib. 
Suggesting that ErbB2 and EGFR expression regulates response to Lapatinib 
treatment, and that normal MaSCs are altered L-R differently by Lapatinib.  
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MATERIALS AND METHODS 
 
Mice 
All experiments were performed in accordance with the regulations of the Medical 
University of South Carolina Institutional Animal Care and Use Committee. FVB/N 
wild-type and FVB/N-TgN (MMTVNeu) 202Mul mice were obtained from Taconic 
(Germantown, NY, USA) and JAX® Mice and Services (Bar Harbor, ME, USA).  
Wild-type and MMTV-cNeuTg/Tg mice were fed Harlan Teklad rodent diet 2918 and 
provided water ad libitum.  
 
RT-PCR  
SYBR Green-based real time RT-PCR was performed with primers listed in Table 
2. Real-time PCR miner was used to calculate Ct values and replication efficiency 
(Zhao and Fernald 2005). Fold changes relative to RPL7 mRNA were determined 
by delta-delta Ct.  
 
Immunofluorescence  
Secondary mammospheres were placed in 1.5ml tubes, briefly trypsinized, 
washed, then fixed in 4% paraformaldehyde for 15 minutes at room temperature. 
Cells were washed with PBS 2 times, then re-suspended in 2% FBS L15 media, 
and spun onto glass slides using a cytospin. Cells were permeabilized in 0.1% 
Tween-20 in PBS for 10 minutes, then blocked in 10% Normal Goat Serum (NGS) 
for 1 hour. Primary antibodies Anti-Chicken K8 (Novus Biologicals), and Anti-
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mouse K14 (Santa Cruz) diluted at 1:50 in 0.1% Tween-20-5% NGS-PBS were 
incubated on slides overnight at 4ºC. Primary Antibody was removed and slides 
were washed with PBS 3 times. Secondary antibodies, Goat anti-chicken 
Alexafluor 596, and Goat anti-mouse Alexafluor 488 (Jackson Immunoreseach) 
were incubated on slides for 1 hour in the dark. Secondary antibody was removed 
and slides were washed 3 times with PBS and 2 drops of SlowFade Gold with 
DAPI mounting media (Invitrogen) was added to each slide. Slides were 
coverslipped, sealed, and then stored covered at 4ºC. 
 
Confocal Images 
Slides were imaged on a Leica Sp5 confocal imaging microscope. Images were 
then compiled using a xyz stack within the Leica-AF Lite software, and snapshots 
were converted to TIFF files and exported.  
 
Dissociation of Thoracic Mammary Glands (TMGs) 
TMGs were harvested from 4 week old euthanized virgin females. Glands were 
manually dissociated using a McIlwain tissue chopper then enzymatically 
dissociated in Leibovitz’s L-15 medium without phenol red (Invitrogen), 1.5mg/ml 
trypsin (Sigma), and 3mg/ml collagenase I (Invitrogen) for 1 hour at 37ºC. Glands 






Fluorescence-activated cell sorting (FACS) 
Single cell suspension of mammary epithelial cells was blocked with 5% fetal 
bovine serum (FBS, Invitrogen) in L15 media and incubated with the following 
antibodies: Anti-Mouse CD24 FITC (eBiosciences), Mouse Hematopoietic Lineage 
eFluor 450 Cocktail (eBiosciences), PerCP/Cy5.5 anti-human/mouse CD49f 
(BioLegend), and Live/Dead Stain-APC-Cy7 (Invitrogen). Cells were gated as 





Figure 13: Mammary Stem Cell Isolation Approach. MaSCs are isolated by first 
removing dead cells using Live/Dead Stain APC-Cy7 conjugated (A), and selecting 
for cells that are lineage negative (Lin-) using lineage cocktail (B). Next, luminal 
and basal cells are separated by CD24-FITC conjugated antibodies and CD49f-
PercP-Cy5.5 conjugated antibodies (Smalley, Titley et al. 2005, Smalley 2010, 
Shehata, Teschendorff et al. 2012, Smalley, Kendrick et al. 2012, Nautiyal, Steel 
et al. 2013) (C). MaSCs are selected by taking the top 5% CD49f staining basal 
cells of the LTMG (Smalley, Titley et al. 2005, Shackleton, Vaillant et al. 2006, 
Stingl, Eirew et al. 2006, Smalley 2010, Shehata, Teschendorff et al. 2012, 
96 
 
Smalley, Kendrick et al. 2012, Nautiyal, Steel et al. 2013) (D). CD24- and CD49f- 
cells located at the bottom left hand corner represent mammary stroma such as 
fibroblast and adipocytes.  
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Mammosphere Culture and Lapatinib Treatment 
Freshly sorted TMG MaSCs were plated on ultra-low-adherence 96 well plates 
(Corning) at 400 cells/well for WT MaSCs and 100 cells/well for MMTV-NeuTg/Tg 
MaSCs in 100µL of MEBM media (Lonza) supplemented with B-27 (Invitrogen), 
Pen/Strep (Invitrogen), 20ng/ml basic fibroblast growth factor (bFGF, Invitrogen), 
20ng/ml EGF (Invitrogen), and 4µg/ml heparin sodium salt (Sigma). Cells were fed 
100µL every 2-3 days. Primary spheres were counted 7 days after plating. Sphere 
forming efficiency (SFE) was calculated by number of spheres counted divided by 
number of spheres plated times 100. Secondary spheres were derived by 
collecting primary spheres in 1.5ml tubes, spinning down at 300 x g, and 
trypsinizing cells for 2 minutes at 37ºC. Trypsin was inhibited by 5% FBS L15 
media then removed. Cells were washed twice in Hanks Balanced Salt Solution 
(Invitrogen), then re-suspended in mammosphere media and visually checked for 
complete sphere dissociation. Secondary spheres were collected after 14 days.  
Mammosphere size was determined using ImageJ by outlining mammospheres 
using the freehand tool, then measurement tool. Self-renewal was calculated as 
described by (Shaw, Harrison et al. 2012). For Lapatinib treatment, Lapatinib 
(Santa Cruz) was diluted in DMSO and added to media at 1:1000 dilutions to make 
stock Lapatinib containing media. DMSO controls were 0.1% DMSO in 
mammosphere media. Cells were maintained in Laptainib or DMSO during the 
entirety of the mammosphere experiments. All experiments were run in technical 






WT MaSCs are quantitatively and functionally L-R different 
Previous studies by our lab show that although WT mammary glands 
appear identical in morphology, the L and R TMGs are molecularly different, and 
respond to Neu oncogene overexpression differently (Fuseler, Robichaux et al. 
2014, Robichaux, Hallett et al. 2014). Molecular L-R differences of the TMGs 
converge on several pathways including pathways that regulate MaSC 
differentiation (Robichaux, Hallett et al. 2014). Therefore, we hypothesized that 
MaSCs are L-R different in number and function. Using FACS analysis, we isolated 
L and R MaSCs TMGs of WT mice as described in figure 13, and validated via RT-
PCR that cells isolated were bona fide MaSCs (Figure 14) based off of both fetal 
and adult MaSC markers previously described by others (Spike, Engle et al. 2012). 
Interestingly, fetal and adult MaSC markers were lateralized in expression 
demonstrating that MaSCs are heterogenous within a single side as well as L-R 
different in gene expression (Figure 14). In addition, the expression of both fetal 
and adult stem cell markers suggest that MaSCs at puberty are at a transition state 
between the fetal and adult states. Using FACS analysis we found that there are 
approximately 2.5 times more MaSCs in the LTMG compared to the RTMG (1.6 
vs. 0.6) at 4 weeks of age (Figure 15A). Moreover, at 10 weeks, there was no 
change in the number of MaSCs in the LTMG, but a greater than two-fold increase 
in MaSCs in the RTMG, suggesting that pubescent MaSCs in vivo have L-R 
differences in growth properties.  Because L and R TMGs show a differential 
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response to Neu overexpression (Fuseler, Robichaux et al. 2014, Robichaux, 
Hallett et al. 2014), and L-R differences in growth properties which are regulated 
by EGF family of receptor signaling, RT-PCR was used to determine if L and R 
MaSCs express ErbB family members L-R differently. ErbB2 was found to be L-
side elevated by 40-fold as compared R-sided MaSCs (Figure 15B). In addition, 
EGFR was found to be upregulated in R-sided MaSCs by a remarkable 70-fold 
difference as compared to L-sided MaSCs (Figure 15B). 
  To test the functional capabilities of isolated MaSCs, FACS sorted and 
counted L and R MaSCs were plated at identical cell numbers and allowed to form 
secondary mammospheres (Figure 15C). L MaSCs formed more secondary 
mammospheres than R MaSCs, but R MaSCs formed larger mammospheres 
(Figure 15D) demonstrating that MaSCs are functionally different depending on 
the side of origin. To ensure that mammospheres forming were indeed composed 
of MaSCs, secondary mammospheres were stained using luminal marker, K8, and 
basal marker, K14, to determine if cells stain positive for both luminal and basal 
lineages, a trait of MaSCs (Shackleton, Vaillant et al. 2006, Asselin-Labat, Vaillant 
et al. 2008, Visvader and Smith 2011, Rios, Fu et al. 2014, Visvader and Stingl 
2014). Confcoal Z-stacked images of secondary mammospheres from both L and 
R MaSCs stained positive for both K8 and K14 indicative of MaSCs (Figure 15E). 
Taken together, these data demonstrate that MaSCs from WT mice are lateralized 




Figure 14: FACS isolated MaSCs express both fetal and adult MaSC markers 
and are L-R different. RT PCR demonstrates that isolated cells isolated by FACS 






Figure 15: WT MaSCs are quantitatively and functionally L-R different. FACS 
analysis shows there are more MaSCs in WT LTMGs than RTMGs (N=6 at 4 
weeks and N= 3 at 10 weeks; mice per N = 3-6 mice) (A). RT-PCR shows that WT 
MaSCs have L-R different expression of EGFR and ErbB2 (N=3) (B). 
Representative images of MaSCs from LTMGs and RTMGs are functionally 
different as demonstrated by the mammosphere assay (scale 50µm, N=3) (C). 
MaSCs from LTMGs form more mammospheres, but MaSCs from RTMGs form 
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larger mammospheres (D). Confocal images of L and R TMG MaSC derived 
mammospheres show that spheres co-express K14 and K8 indicative of MaSCs 
(scale 20 µm) (E). Students’ t-test was used to determine statistical significance  *, 





Neu overexpression in MMTV-NeuTg/Tg mice affects MaSCs L-R differently 
Since both EGFR and ErbB2 were asymmetrically expressed in WT MaSCs and 
MMTV-NeuTg/Tg mice have asymmetric ductal network formation as well as 
discordant gene regulation (Robichaux, Hallett et al. 2014), we sought to 
characterize the effect of Neu/ErbB2 overexpression on MaSC laterality. Using 
FACS analysis, we isolated MaSCs from MMTV-NeuTg/Tg TMGs and verified that 
isolated cells were indeed MaSCs (Figure 16). Again in MaSCs isolated from 
MMTV-NeuTg/Tg TMGs, MaSCs express L-R different levels of fetal and adult MaSC 
markers suggesting that the populations in the L and R TMGs are heterogeneous 
in MaSC populations (Figure 16). Interestingly, Neu transgene expression was L-
side elevated (Figure 16). Neu overexpression in MMTV-NeuTg/Tg mice resulted in 
approximately doubling the number of L-sided MaSCs but no significant increase 
in the number of R-sided MaSCs resulting in MMTV-NeuTg/Tg mice having amplified 
L-R asymmetry in MaSC numbers (Figure 17A). To determine the effect of Neu 
overexpression on EGFR and ErbB2 signaling, RT-PCR was used to determine if 
L-R differences in EGFR and ErbB2 expression were altered in MMTV-NeuTg/Tg 
MaSCs. ErbB2 was found to be R-side elevated by approximately 6-fold as 
compared L-sided MaSCs (Figure 17B), whereas in WT animals ErbB2 was L-side 
elevated. In addition, EGFR was found to be upregulated in L-sided MaSCs by 15-
fold difference as compared to R-sided MaSCs (Figure 17B), whereas in WT 
animals, EGFR was R-side elevated. 
  To determine if over-expression of Neu and inverted EGFR/ErbB2 gene 
expression would affect the growth properties of MaSCs, MaSCs from L and R 
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TMGs if MMTV-NeuTg/Tg mice were plated as previously described to form 
secondary mammospheres (Figure 17C). In contrast to WT, MMTV-NeuTg/Tg R-
sided  MaSCs formed more secondary mammospheres; however, MMTV-NeuTg/Tg 
L and R-sided MaSC derived mammospheres were similar in size (Figure 17D). 
These results indicate that Neu over-expression inverts MaSCs growth properties 
in vitro. In addition, the data demonstrates a correlation between ErbB2 and 
increased mammosphere formation. To determine that MMTV-NeuTg/Tg MaSC 
derived mammospheres were indeed composed of MaSCs, secondary 
mammospheres were again stained using K8 and K14. Confcoal Z-stacked images 
of secondary mammospheres from MMTV-NeuTg/Tg L and R MaSCs stained 
positive for both K8 and K14 indicative of MaSCs (Figure 17E). Taken together, 
these data demonstrate that Neu overexpression affects MaSCs  L-R differently, 
increasing L-sided MaSCs, and inverting EGFR and ErbB2 expression as well as 
MaSC in vitro growth properties suggesting a relationship between EGFR, ErbB2, 





Figure 16: FACS isolated MaSCs from MMTV-NeuTg/Tg TMGs have L-R 
differently expressed fetal and adult MaSC markers. RT PCR demonstrates 
that isolated cells isolated by FACS are MaSCs. MaSCs from MMTV-NeuTg/Tg L 






Figure 17. Neu overexpression in MMTV-NeuTg/Tg mice affects MaSCs L-R 
differently. FACS analysis shows that MMTV-Neu overexpression causes an 
increase in L MaSCs but not R MaSCs (N=6) (A). RT-PCR shows that MMTV-
NeuTg/Tg MaSCs have inverted and L-R different expression of EGFR and ErbB2 
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(N=3) (B). MaSCs from LTMGs and RTMGs of MMTV-NeuTg/Tg mice are 
functionally different as shown by the mammosphere assay (scale 50µm, N=3) (C). 
MaSCs from MMTV-NeuTg/Tg RTMGs form more mammospheres than LTMGs, 
while mammosphere size is symmetric in MMTV-NeuTg/Tg mice (D). Confocal 
images of L and R MMTV-NeuTg/Tg TMG MaSC derived mammospheres show that 
spheres co-express K14 and K8 indicative of MaSCs (scale 20 µm) (E). Students’ 




MaSC L-R differences in EGFR/ErbB2 expression correlate with L-R 
differential response to Lapatinib treatment  
 To further understand the relationship between EGFR, ErbB2, and MaSC 
function, Lapatinib treatment of MaSC derived mammospheres of both WT and 
MMTV-NeuTg/Tg mice was utilized. Currently, Lapatinib is FDA approved for 
patients with metastatic HER2+ (hormone positive or negative) breast tumors after 
trastuzmab treatment has failed (U.S. Food and Drug Administration 2012). 
Lapatinib is a small molecule inhibitor targeted to the tyrosine kinase ErbB2 
receptor, that inhibits both ErbB2 and EGFR in vitro (Baselga, Rischin et al. 2002, 
Wood, Truesdale et al. 2004, Baselga 2006, Scaltriti, Verma et al. 2009). Lapatinib 
works by inhibition of receptor phosphorylation, resulting in receptor accumulation 
and cell toxicity (Scaltriti, Verma et al. 2009). Lapatinib has been shown to have a 
higher affinity to ErbB2 than EGFR (Scaltriti, Verma et al. 2009); yet, the ability to 
affect EGFR+ cancer stem cells remains unclear (Zhang, Pal et al. 2008).  Since 
WT MaSCs have L-R different expression of ErbB2 and EGFR, we hypothesized 
that L and R MaSCs would have a L-R differential response to Lapatinib treatment.  
 To test this hypothesis, L and R WT MaSC derived mammospheres were 
treated with 10nM, 100nM, and 1µM Lapatinib throughout primary and secondary 
mammosphere formation. Left-side derived mammospheres had a dose 
dependent reduction in sphere formation with a reduction in self-renewal properties 
at the highest dose of Lapatinib treatment (Figure 18 A, B). Right-side derived 
mammospheres had no inhibition in sphere formation. Additionally, increasing 
doses of Lapatinib increase secondary sphere formation and stem-cell self-
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renewal (Figure 18 A, B). Only at 1µM did self-renewal decrease for both L and R, 
however, 1µM Lapatinib is not considered physiologically relevant (Burris, Hurwitz 
et al. 2005, Chatsiproios 2010). However, this data does show that at a very high 
dose cell toxicity could be achieved.   
 To determine the effect of Lapatinib on MaSC differentiation secondary 
mammospheres treated with Lapatinib were stained with K8 and K14, Confocal Z-
stacked images of secondary mammospheres from L-sided MaSCs show 
differentiated basal cells staining positive for K14, but not K8 (Figure 18C). 
Confocal imaging of secondary mammospheres from R-sided MaSCs stain 
positive for both K8, and K14, indicative of a lack of cell differentiation within MaSC 
pool (Figure 18C). These data suggest that higher levels of ErbB2 increase 
Lapatinib sensitivity whereas higher levels of EGFR protect MaSCs from Lapatinib.  
 Since L-R inversion of EGFR and ErbB2 in the MMTV-NeuTg/Tg model as 
compared to WT resulted in an inversion of in vitro mammosphere growth, we 
hypothesized that the L-R inversion in EGFR and ErbB2 expression would also 
result in an inversion of L-R response to Lapatinib treatment as compared to WT. 
To test this hypothesis mammospheres derived from L and R-sided MMTV- 
NeuTg/Tg MaSCs were treated with 10nM, 100nM, and 1µM Lapatinib throughout 
primary and secondary mammosphere formation (Figure 18D). L-sided MaSCs 
had a slight increase in mammosphere SFE with low dose Lapatinib, but then a 
slight decrease with higher doses; however, self-renewal remained unchanged 
until the highest dose of Lapatinib (Figure 18E). R-sided MaSCs had a dose-
dependent reduction in SFE and self-renewal, with 1µM Lapatinib completely 
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killing all MMTV-NeuTg/Tg MaSCs (Figure 18E). Overall increased sensitivity to 
Lapatinib was expected and observed since all MMTV-NeuTg/Tg mammary 
epithelial cells overexpress Neu/ErbB2.  
To determine the effect of Lapatinib on MMTV-NeuTg/Tg MaSC differentiation 
secondary mammospheres treated with Lapatinib were stained with K8 and K14, 
Confocal Z-stacked images of secondary mammospheres from L-sided MMTV-
NeuTg/Tg MaSCs stain positive for both K8 and K14 suggesting Lapatinib does not 
induce cell differentiation of L-sided MMTV-NeuTg/Tg MaSCs (Figure 18F). Confocal 
imaging of secondary mammospheres from R-sided MMTV-NeuTg/Tg MaSCs stain 
positive for both K8, but not K14, indicating cell differentiation into mammary basal 
cells (Figure 18E). These data support the hypothesis that higher levels of ErbB2 
increase Lapatinib sensitivity whereas higher levels of EGFR protect MaSCs from 










Figure 18. MaSC Left-Right differences in EGFR/ErbB2 expression correlate 
with L-R differential response to Lapatinib treatment.  L and R WT MaSC 
derived mammospheres have a differential response to Lapatinib treatment (A). 
WT LTMG MaSC derived mammospheres show a steady decrease in primary SFE 
with increasing concentrations of Lapatinib and no changes in self-renewal until 
the highest dose of Lapatinib (B, left). However, WT RTMG MaSC derived 
mammospheres show no change in SFE, and an increase in self-renewal with 
physiologically relevant doses of Lapatinib (B, right). ANOVA analysis followed by 
post-test analyses were used to determine statistical significance between 
indicated bars *, p <0.001. Confocal images of WT LTMG MaSC derived 
mammospheres show differentiated cells in response to 100nM Lapatinib 
treatment, whereas confocal images of WT RTMG MaSC derived mammospheres 
show dual staining for K8 and K14 indicative of MaSCs (scale 20 µm) (C). L and 
R MMTV-NeuTg/Tg TMG MaSC derived mammospheres have a differential 
response to Lapatinib (D). MMTV-NeuTg/Tg LTMG MaSC derived mammospheres 
show a slight increase in primary SFE with low dose Lapatinib treatment, and only 
a slight decrease in SFE with high dose Lapatinib treatment. In addition, no 
changes in self-renewal are seen until the highest dose of Lapatinib (E). However, 
MMTV-NeuTg/Tg RTMG MaSC derived mammospheres show a steady decrease in 
primary SFE and self-renewal with increasing concentrations of Lapatinib ANOVA 
analysis was used to determine statistical significance *, p <0.001; #, both DMSO 
and 10nM doses are statistically significant (p<0.01) than 100nM and 1um which 
are not statistically different (E). Confocal images of MMTV-NeuTg/Tg  LTMG MaSC 
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derived mammospheres show dual staining for K8 and K14 indicative of MaSCs 
even in the presence of 100nM Lapatinib, whereas confocal images of WT RTMG 
MaSC derived mammospheres show differentiated cells in response to 100nM 





Although our previous worked established that L and R mammary glands 
are molecularly distinct and could respond to elevated oncogene L-R discordantly, 
little functional data in L-R differences existed. The data presented here are the 
first to show quantitative and functional L-R differences in MaSCs. In addition, the 
data shown are the first to show a L-R differential response to a drug being used 
clinically.  
Our data demonstrates an over 2-fold increase in MaSCs in the LTMG as 
compared to the RTMG which correlates with increase tumor formation in the left 
breast in humans (Perkins, Hotes et al. 2004, Roychoudhuri, Putcha et al. 2006, 
Saleh and Abdeen 2007, Arkoob, Al-Nsour et al. 2010, Wilting and Hagedorn 2011, 
Fatima, Zaman et al. 2013, Veltmaat, Ramsdell et al. 2013, Zeeneldin, Ramadan 
et al. 2013). Preliminary experiments show that there is a possible R-sided 
increase in MaSCs in WT mice suggesting that L and R MaSCs have differences 
in growth in vivo. In addition, this data demonstrates that R-sided MaSCs form 
larger mammospheres with a slightly higher self-renewal capacity which indicates 
a more “stem-like” or aggressive phenotype which correlates with more aggressive 
tumors forming in the right breast in humans  (Saleh and Abdeen 2007, Fatima, 
Zaman et al. 2013, Zeeneldin, Ramadan et al. 2013). Interestingly, our data also 
shows that over-expression of the Neu oncogene only increases MaSCs 
unilaterally enhancing the L-R difference in MaSC number.  
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In addition to L-R differences in WT MaSCs numbers, this data suggests a 
role of EGFR and ErbB2 expression patterns controlling MaSC growth properties 
and response to Lapatinib treatment. When ErbB2 was upregulated, more 
mammospheres formed and mammospheres were sensitive to Lapatinib 
treatment; however, when EGFR was upregulated fewer mammospheres formed, 
but mammospheres were refractory to Lapatinib treatment. 
In addition to detecting a L-R differential response to therapy in both WT 
and MMTV-NeuTg/Tg MaSCs, a peculiar response to Lapatinib was seen in the R-
side WT MaSC derived mammosphere: an increase in self-renewal. This increase 
in self-renewal is significant because women undergoing Lapatinib treatment also 
have normal tissue, and this data suggests Lapatinib treatment increases the 
“stem-like” potential of MaSCs in the “normal” tissue. This increased self-renewal 
could heighten that patient’s chances of a secondary reoccurrence of a more 
aggressive tumor type. However, few studies exist examining the long term effects 
of common clinical therapies on long term cancer risks. Although the benefits of 
ErbB family inhibitors often out-weigh the potential risks, further studies of how 





CHAPTER 4: WILD TYPE MICE EXHIBIT A LEFT-RIGHT DIFFERENTIAL 
RESPONSE TO NEONATAL ESTROGEN EXPOSURE RESULTING IN 





 Since the early 1940s the role of estrogens and mammary gland 
development has been the focus of many studies (Greene RR 1940). In the 1970s, 
several reports established that neonatal exposure to 17β-estradiol (E2) increased 
carcinogenesis in mice exposed to the carcinogen 7,12-Dimethylbenz-
[a]anthracene (DMBA) at later time demonstrating that early E2 exposure has long 
term and lasting effects on the mammary gland (Warner and Warner 1975, Mori, 
Bern et al. 1976). Additionally, studies showed that neonatal E2 exposure effected 
late but not early pubescent development of each mammary pair in a dose 
dependent manner increasing ductal network area at the highest doses (Jean 
1971, Jean 1971, Mori, Bern et al. 1976, Warner 1976, Bern, Mills et al. 1983). 
Later studies designed to understand the mechanism of E2 long term effects, 
showed down regulation of the estrogen receptor alpha (ERα) (DiPaolo and Jones 
2000), but an increase in endogenous E2 sensitivity at puberty (Warner, Yau et al. 
1980, Wadia, Vandenberg et al. 2007). Although these studies gave insight as to 
why there was increased ductal network area with E2 exposure in late but not early 
pubescent development; these studies failed to demonstrate how glands with 
decreased estrogen receptor had an increased response to E2. Later studies 
demonstrated that estrogen mimetics such as diethylstilbestrol (DES) or Bisphenol 
A (BPA) result in increased tumor formation in mice (Walker 1984, Lopez, Ogren 
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et al. 1988, Walker 1990, Hilakivi-Clarke, Onojafe et al. 1996, Markey, Luque et al. 
2001) similar to neonatal E2 exposure, and these changes to normal ductal 
morphogenesis induced by early estrogen exposures were observed as early as 4 
weeks, the beginning of puberty (Hilakivi-Clarke, Cho et al. 1997, Markey, Luque 
et al. 2001). However, no studies exist to explain how early E2 exposure and down-
regulated ERα receptor results in increased mammary gland estrogen sensitivity 
at puberty.  
 E2 is an essential regulator of pubescent mammary ductal morphogenesis; 
ovariectomy or genetic knockout of ERα results in ablation of pubescent ductal 
elongation (Feng, Manka et al. 2007). In addition, E2 rescued development of the 
mammary glands in ovariectomized mice (Daniel, Silberstein et al. 1987). 
However, ERα is not expressed in all mammary epithelial cell types. Some luminal 
progenitors and differentiated luminal cells express ERα, but MaSCs and basal 
cells do not express ERα (Clarke, Anderson et al. 2003, Kouros-Mehr, Slorach et 
al. 2006, Asselin-Labat, Vaillant et al. 2008, Visvader and Smith 2011, Carr, Kiefer 
et al. 2012, Shehata, Teschendorff et al. 2012, Rios, Fu et al. 2014). More recently, 
through lineage tracing experiments in vivo, MaSCs were shown to be the major 
contributor to ductal morphogenesis at puberty through both self-renewal and 
differentiation (Rios, Fu et al. 2014). Previously, E2 has been shown to play a role 
in regulation of MaSC proliferation and differentiation (Asselin-Labat, Vaillant et al. 
2010, Joshi, Jackson et al. 2010, Simoes, Piva et al. 2011); however, the 
mechanism of how E2 signals to ERα- MaSCs is unclear. A pro-proliferative effect 
of  E2 on ERα- breast cancer stem-like cells has been shown to involve the 
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FGF/Tbx3 pathway (Fillmore, Gupta et al. 2010), a pathway activated during 
embryonic mammary gland development (Davenport, Jerome-Majewska et al. 
2003, Eblaghie, Song et al. 2004).  
In addition to the role of MaSCs during pubescent development, long-lived 
MaSCs are hypothesized to be tumor-initiating cells due to opportunity of 
mutations to accumulate over time (Dontu, Al-Hajj et al. 2003, Dontu, El-Ashry et 
al. 2004, Spike, Engle et al. 2012, Makarem, Kannan et al. 2013). Approximately 
60 – 75% of all diagnosed breast cancers are ERα+ (Carey, Perou et al. 2006, 
Bao, Yu et al. 2014), and estrogen inhibiting drugs such as tamoxifen and other 
aromatase inhibitors are often use to treat ERα+ breast cancers (Fisher, 
Costantino et al. 1998). However, breast cancer does not occur at equal rates in 
both breasts; more tumors form in the left breast, but right-sided tumors are more 
aggressive (Perkins, Hotes et al. 2004, Roychoudhuri, Putcha et al. 2006, Saleh 
and Abdeen 2007, Arkoob, Al-Nsour et al. 2010, Wilting and Hagedorn 2011, 
Fatima, Zaman et al. 2013, Veltmaat, Ramsdell et al. 2013, Zeeneldin, Ramadan 
et al. 2013). Previous work in our lab has demonstrated that in wild-type (WT) mice 
the left (L) and right (R) thoracic mammary glands (TMGs) are lateralized in gene 
expression pathways that regulate MaSC differentiation and self-renewal (Smalley 
and Ashworth 2003, Cicalese, Bonizzi et al. 2009, Carr, Kiefer et al. 2012, 
Robichaux, Hallett et al. 2014). In addition our data indicate that MaSCs are L-R 
asymmetric in number, and L and R MaSCs are molecularly and functionally 
different (Chapter 3). Therefore we hypothesize that early E2 exposure will also 
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have L-R different effects on pubescent development due to asymmetric changes 
in MaSC numbers and/or MaSC differentiation.  
Here we show that early E2 exposure results in asymmetric ductal 
morphogenesis at puberty in TMGs but not inguinal mammary glands (IMGs). In 
addition TMGs demonstrate a L-R asymmetric down-regulation of ERα and other 
markers of MaSC differentiation, as well as an increase in basal cell markers and 
markers of MaSCs. Lastly, we show that neonatal E2 exposure results in an overall 
and asymmetric decrease in the luminal cell lineage and cell differentiation, as well 
as an overall and asymmetric increase in MaSCs and basal cell lineage. Although 
MaSCs are ERα-, paracrine signaling to an increased number of MaSCs may 
explain the increased sensitivity to endogenous E2 later in puberty as well as 
increased tumorigenesis when exposed to carcinogen.  
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MATERIALS AND METHODS 
 
Mice 
All experiments were performed in accordance with the regulations of the Medical 
University of South Carolina Institutional Animal Care and Use Committee. FVB/N 
wild-type mice were obtained from Taconic (Germantown, NY, USA). To generate 
E2 treated mice, WT mice were injected interscapularly along the midline with 1µl 
of 20µg/µl 17-β estradiol (Sigma) in ultra-pure DMSO (Fisher Scientific) for five 
days beginning one day after birth. Cages were covered and otherwise 
undisturbed for 7 days; in addition, as soon as sex was reliability determined, 
males were removed from cages to increase female pup viability. 1µl DMSO 
injected mice were used as vehicle control. Mice were fed Harlan Teklad rodent 
diet 2918 and provided water ad libitum. Mice were euthanized at 28 days of age 
and thoracic and inguinal mammary glands were harvested.  
 
Histology and image collection 
Carmine red stained whole mounts were prepared as previously described (de 
Assis, Warri et al. 2010)  from #3 and #8 thoracic mammary glands (TMGs) and 
#4 and #9 inguinal mammary glands (IMGs) of day-28 mice and were imaged on 
an Olympus SZX12 stereomicroscope equipped with a Spot camera. Overlapping 
images of each whole mount were processed into a single composite image with 




Image analysis.  
The color images of the mammary glands were converted to 8-bit monochrome 
images for image and fractal analysis. The mammary gland within an image was 
outlined and isolated from the background tissue and defined as a Region of 
Interest (ROI) (Figure 5). The isolated image of the mammary gland was 
thresholded using the set threshold subroutine of MetaMorph Image analysis 
software (ver. 6.1). The area (A) and integrated optical density (IOD) of the ductal 
epithelial networks were measured using the integrated morphometry analysis 
sub-routine of MetaMorph. The fractal dimension (D), was determined by the box 
counting method using HarFA software (Nezadal, Zemeskal et al. 2001) 
[http://www.fch.vutbr.cz/lectures/imagesci]) applied to the isolated image of the 
mammary gland using the same threshold values. 
 
Integrated optical density (IOD).   
The IOD of the mammary gland ROI delineated by the thresholded boundaries is 
considered to be the “mass” of the ROI and a measurement of the total amount of 
labeled material in the region (Walter and Berns 1986, Fuseler, Merrill et al. 2006, 
Fuseler, Millette et al. 2007, Rogers and Fuseler 2007, Fuseler and Valarmathi 
2012). The IOD of a selected region can be expressed as the weighted sum of the 
image histogram in which each term in the histogram is multiplied by the gray value 






                           T2 
IOD (T1, T2) =  ∑ H (GV) x GV 
                           GV = T1 
Where the upper and lower thresholds defining the ROI in the histogram are 
given by T1 and  T2.  GV is the gray value of each pixel and H (GV) is the gray 
level histogram.  
 
Application of the fractal dimension (D) 
The thoracic mammary glands in the wild type and E2 treated mice mice appear 
as irregular and complex objects composed of parts at different levels of resolution 
(ducts of different bore sizes) which are functionally and physiologically similar 
(self-similar) to the whole object. Under the conditions of these properties, the 
thoracic mammary glands can be considered fractal objects and their topological 
dimension, the fractal dimension (D), be expressed by a non-integer number lying 
between two Euclidian integer topological dimensions (Grizzi, Russo et al. 2005). 
The values of D characterizing the thoracic mammary glands are therefore 
fractional. Since the thoracic mammary gland is essentially a 2-dimensional object, 
the D values will lie between 1 and 2. As the mammary gland becomes more 
complex and irregular, its D value becomes greater approaching 2.  In applying 
fractal analysis, the D value of the mammary gland is determined by applying the 
box-counting method (Fernandez and Jelinek 2001, Grizzi, Russo et al. 2005).  
The box-counting method has been the most widely used and general model for 
applying fractal analysis to biological and non-biological systems. The box-
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counting method consists of a grid of boxes of size e superimposed over the image 
of the structure, and the number of boxes containing any part of the structure 
recorded as N(e). A fractal object expresses a straight line when Log[N(e)] is 
plotted against Log(1/e). The box fractal dimension D can be determined from the 
slope of the regression line. That is: D= Log[N(e)] / Log(1/e). The D values of the 
thoracic mammary glands were determined using HarFA software (Nezadal, 
Zemeskal et al. 2001) [http://www.fch.vutbr.cz/lectures/imagesci]. The HarFA 
software assigned mesh sizes of boxes with e values ranging from 2 to 207 pixels 
and 30 steps within this range were calculated to generate the Log[N(e)] versus 
Log(1/e) lines to determined .  
 
Branch points and terminal end buds (TEBs) 
Branch points and TEBs were quantified by manual counting from the images.  
 
RT-PCR  
mRNA was isolated using Qiagen lipid RNA mini kits, and converted to cDNA using 
BioRad iScript kit. SYBR Green-based (BioRad) RT-PCR was performed with 
primers listed in Table 2. Real-time PCR miner was used to calculate Ct values 
and replication efficiency (Zhao and Fernald 2005) and fold changes relative to 
GAPDH mRNA were determined by delta-delta Ct. 
 
Dissociation of Thoracic Mammary Glands (TMGs) 
TMGs were harvested from 4 week old euthanized virgin females. Glands were 
manually dissociated using a McIlwain tissue chopper then enzymatically 
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dissociated in Leibovitz’s L-15 medium without phenol red (Invitrogen), 1.5mg/ml 
trypsin (Sigma), and 3mg/ml collagenase I (Invitrogen) for 1 hour at 37ºC. Glands 
were then processed to single cells as previously described by Smalley et al 
(Smalley 2010). 
 
Fluorescence-activated cell sorting (FACS) 
Single cell suspension of mammary epithelial cells was blocked with 5% fetal 
bovine serum (FBS, Invitrogen) in L15 media and incubated with the following 
antibodies: Anti-Mouse CD24 FITC (eBiosciences), Mouse Hematopoietic Lineage 
eFluor 450 Cocktail (eBiosciences), PerCP/Cy5.5 anti-human/mouse CD49f 
(BioLegend), and Live/Dead Stain-APC-Cy7 (Invitrogen). Cells were gated as 
shown in Figure 13, and the population labeled MaSC was collected. Briefly, 
MaSCs are isolated by first removing dead cells using Live/Dead Stain APC-Cy7 
conjugated, Lin- cells were selected by selecting cells that did not stain positive for 
the lineage cocktail antibodies that e450 conjugated. Luminal and basal cells are 
separated by CD24-FITC conjugated antibodies and CD49f-PercP-Cy5.5 
conjugated antibodies, respectively (Smalley, Titley et al. 2005, Smalley 2010, 
Shehata, Teschendorff et al. 2012, Smalley, Kendrick et al. 2012, Nautiyal, Steel 
et al. 2013). MaSCs are selected by taking the top 5% CD49f staining basal cells 
of the WT LTMG (Smalley, Titley et al. 2005, Shackleton, Vaillant et al. 2006, 
Stingl, Eirew et al. 2006, Smalley 2010, Shehata, Teschendorff et al. 2012, 






Estrogen treated TMGs undergo L-R asymmetric ductal morphogenesis at 
puberty 
 To determine if neonatal E2 exposure effects the L and R glands equally, 
TMGs were harvested at 28 days before first estrous from E2 treated mice. L and 
R TMGs stained with carmine red from E2 treated mice show L-R asymmetric 
ductal morphogenesis at puberty (Figure 19A) as compared to symmetric ductal 
morphogenesis of WT mice (Figure 19B). Ductal network area, branch points, 
terminal end buds, and fractal dimension were plotted L vs R (Figure 19C). Linear 
regression modeling demonstrates that L and R TMGs from E2 treated mice are 
L-R asymmetric in ductal network area, branch points, and terminal end buds 
(TEBs); however, E2 does not affect fractal dimension L-R differently (Figure 19C). 
Overall, L-sided networks were dramatically smaller, had fewer branches, and 
fewer TEBs.  L-R differences in fractal dimension were not expected because 
increases in fractal dimension can indicate early signs of neoplasia (Rangayyan, 
Banik et al. 2010, Daye, Keller et al. 2013, Rangayyan, Banik et al. 2013, Fuseler, 
Robichaux et al. 2014) and ER+ breast cancer occurs at a similar rate in each 
breast (Weiss, Devesa et al. 1996, Fatima, Zaman et al. 2013, Zeeneldin, 
Ramadan et al. 2013). DMSO treated mice show no L-R differences in morphology 
as compared to WT (data not shown).  
 Hormone receptors ERα and progesterone receptor (PR) were examined 
by RT-PCR (Figure 19D). ERα was down-regulated in the LTMG consistent with 
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previous reports (DiPaolo and Jones 2000); however, ERα was unchanged in the 
RTMG demonstrating an L-R asymmetric response to early exposure to systemic 
E2. By contrast, PR was down-regulated equally on both sides. Classical laterality 
genes Nodal and Pitx2 were also examined by RT-PCR (Figure 19D). Nodal 
remained unchanged with early E2 exposure; however, Pitx2 was similarly down-
regulated on the L-side as was ERα, and upregulated on the R-side possibly 
maintaining ERα expression on the right as previously reported in chick ovarian 
development (Ishimaru, Komatsu et al. 2008).  
To determine if mammary epithelial cell differentiation was effected by early 
E2 exposure,  markers of luminal cell lineage determination (Figure 19D, middle 
row) and markers of basal cell lineage including MaSCs (Figure 19D, bottom row) 
were examined via RT-PCR. Markers of luminal cell differentiation, FoxM1 (Carr, 
Kiefer et al. 2012), Gata3 (Kouros-Mehr, Slorach et al. 2006, Asselin-Labat, 
Sutherland et al. 2007), Elf-5 (Oakes, Naylor et al. 2008, Chakrabarti, Wei et al. 
2012), and β-casein (Liu, Robinson et al. 1997, Anderson, Rudolph et al. 2007) 
were significantly reduced in both the L and R TMGs in response to E2 treatment, 
but more so in the LTMG, suggesting a lack of cell differentiation especially in the 
LTMG. Additionally, markers of basal cell lineage determination and differentiation 
Sox9 and SMA (Guo, Keckesova et al. 2012, Zhao, Malhotra et al. 2012) , were 
also down-regulated in both LTMGs and RTMGs of E2 treated mice, further 
suggesting a lack of MaSC differentiation. In addition, markers of MaSCs, p63 and 
Cd1d (Zhao, Malhotra et al. 2012, dos Santos, Rebbeck et al. 2013) were both 
upregulated suggesting an increase in MaSCs. Taken together this data suggests 
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that early E2 exposure increases MaSCs and prevents MaSC differentiation, 
especially in the LTMG. DMSO treated mice show no differences (L or R) from WT 





Figure 19. Estrogen treated TMGs undergo L-R asymmetric ductal 
morphogenesis at puberty. L and R E2 treated TMGs (A) show L-R asymmetric 
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ductal morphogenesis, whereas L and R WT TMGs (B) are morphometrically 
symmetric. Linear regression modeling of E2 treated TMGs (blue, N=19) 
demonstrate that E2 treated TMGs are asymmetric in most morphological 
parameters compared to WT TMGs (black, N=10) (C). Slopes were tested using 
an ANCOVA. RT-PCR of WT vs. E2 treated TMGs show an asymmetric response 
to E2 treatment and L-R different gene expression for genes known to regulate 
ductal morphogenesis and MaSC differentiation (D). Bars are representative of 
means ± SEM of N= 5. Paired Student’s t-test was used to determine statistical 
differences, *p<0.05; **p<0.01; *** p<0.001; NS= not statistically different. 
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Estrogen treated IMGs are resistant to E2 induced asymmetric ductal 
morphogenesis at puberty 
 Although mouse TMGs more similarity to human mammary glands in 
anatomical position and early embryonic signaling than IMGs (Veltmaat, Ramsdell 
et al. 2013), IMGs are more commonly used in studies of mammary gland 
development because of their larger size and easier accessibility (Cardiff and 
Wellings 1999, Brill, Boecher et al. 2008). Therefore, we also examined IMGs. 
IMGs of E2 treated mice are not L-R asymmetric in ductal morphogenesis as 
compared to WT IMGs (Figure 20A, B) or DMSO treated IMGs (data not shown). 
Linear regression modeling of L vs. R ductal network areas, branch points, TEBs, 
and fractal dimension analyses show that IMGs of E2 treated mice are L-R 
symmetric and do not significantly differ from WT IMGs (Figure 20C). RT-PCR of 
ERα shows L-R symmetric expression. In addition, markers of luminal cell 
differentiation FoxM1 and Gata3 (Kouros-Mehr, Slorach et al. 2006, Asselin-Labat, 
Sutherland et al. 2007, Carr, Kiefer et al. 2012) were also L-R symmetric (Figure 
20D). Interestingly, traditional laterality genes Nodal and Pitx2 were L-R different 
and asymmetrically altered by early E2 exposure (Figure 20D) but did not result in 
asymmetric ductal morphogenesis therefore are unlikely to contribute to the 
asymmetric ductal morphogenesis observed in TMGs. 




Figure 20. Estrogen treated IMGs are resistant to E2 induced asymmetric 
ductal morphogenesis at puberty. Both L and R E2 treated IMGs (A) as well as 
L and R WT IMGs (B) are morphometrically symmetric. Linear regression modeling 
of E2 treated IMGs (blue, N=19) demonstrate that E2 IMGs and WT IMGs (black, 
N=10) are symmetric in morphological parameters (C). Slopes were tested using 
an ANCOVA. RT-PCR of WT vs. E2 treated IMGs show symmetric gene 
expression in genes known to regulate ductal morphogenesis and MaSC 
differentiation (D). Bars are representative of means ± SEM of N= 5. Paired 
Student’s t-test was used to determine statistical differences, *p<0.05; **p<0.01; 
*** p<0.001; NS= not statistically different; ND= not detected. 
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Estrogen treated TMGs have increased MaSCs and decreased cell 
differentiation at puberty 
Although studies over several decades have demonstrated that neonatal 
E2 exposure has long term effects on mammary gland development resulting in 
an increased risk for mammary gland tumorigenesis (Warner and Warner 1975, 
Mori, Bern et al. 1976, Warner 1976, Warner, Yau et al. 1980, Bern, Mills et al. 
1983), no studies have examined the effects of neonatal E2 exposure on 
pubescent MaSCs and cell differentiation. L-R differences in markers of MaSCs 
and MaSC differentiation (Figure 1D) suggests that early E2 exposure may 
increase MaSCs and/or prevent MaSC differentiation. To test this hypothesis, label 
retaining experiments, using 5-ethyl-2’-deoxyuridine (EdU) pulse-chase labeling 
were performed (outlined in Figure 21A) were used to determine if E2 treated mice 
have increased or L-R different numbers of stem and progenitor cells. Label 
retaining experiments show that WT mice have more label retaining cells (LRCs) 
in the LTMG than RTMG, and that E2 treated mice have no change in L-side LRCs, 
but a decrease in R-side LRCs exaggerating the L-R in MaSCs as compared to 
WT (Figure 21B).  
Previous studies have shown that LRCs are a heterogeneous population of 
stem and progenitor cells (Booth, Boulanger et al. 2008, Park, Raafat et al. 2013); 
therefore FACS is necessary to determine if decreases in LRCs in the RTMG are 
due to decreases in MaSCs or progenitor cell populations. FACS analysis of WT 
TMGs vs. E2 treated TMGs (Figure 21C) show decreases in the luminal cell 
compartment and increases in the basal cell compartment containing the MaSCs. 
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Quantification of FACS analysis (Figure 21D) shows a significant decrease in 
luminal cell commitment, particularly on the left side consistent with the RT-PCR 
data in Figure 1. Conversely, FACS data show an asymmetric increase in the basal 
cell compartment resulting in more basal cells in the LTMG. Lastly, FACS data 
exhibit an increase in both L and R MaSCs compared to WT (Figure 21D). While 
the L-side prevalence of MaSCs was maintained, RTMGs showed a significant 8-
fold increase in MaSCs (0.5 vs. 4.1%) compared to LTMGs which increase 5-fold 
(1.2 vs. 5.9) over WT. These data show the ability of individual mammary epithelial 





Figure 21. Estrogen treated TMGs have increased MaSCs and decreased cell 
differentiation at puberty. Long label retaining experiments (A) demonstrate that 
both WT and E2 treated TMGs have asymmetric stem/progenitor populations (B). 
Bars are representative of average ± SEM, N= 8 WT and N=5 E2. FACS analysis 
(C) of WT (left) and E2 treated (right) show L-R differences in luminal lineages, 
Basal lineages, and MaSCs (N=6 for WT with 3-6 glands/N, N=2 for E2 with 15-20 
136 
 
glands/N). Quantification of FACS analysis demonstrates discordant L-R 
regulation of MaSCs (right), and mammary epithelial cell lineage determination 
(left, D). Bars are representative of mean ± SEM, N= 6 WT and N=2 E2. Student’s 
t-test was used to determine statistical differences, *p<0.05; **p<0.01; *** p<0.001; 





Previous work examining the effects of neonatal estrogen exposure 
consistently show that E2 induces long-term effects on mammary gland 
development and increases risk for later tumor formation when exposed to 
carcinogen (Warner and Warner 1975, Mori, Bern et al. 1976, Warner 1976, 
Warner, Yau et al. 1980, Bern, Mills et al. 1983). In addition, early E2 exposure 
has also been designated a risk factor for breast cancer by the National Cancer 
Institute (NCI) (Feigelson and Henderson 1996, Persson 2000, Lippman, Krueger 
et al. 2001). However, no studies existed to examine if early E2 exposure resulted 
in changes in mammary epithelial cell populations during puberty; moreover, no 
previous studies have examined L-R differences in response to early E2 exposure. 
Here we show for the first time that early E2 exposure results in asymmetric ductal 
morphogenesis during puberty, asymmetrically down-regulates transcription 
factors that induce MaSC differentiation, and asymmetrically increases MaSC 
populations.  
Previous reports indicating that early E2 exposure increased mammary 
gland sensitivity to endogenous E2 (Warner, Yau et al. 1980, Wadia, Vandenberg 
et al. 2007), but decreased ERα expression (DiPaolo and Jones 2000) at first seem 
counter intuitive. However the data presented here give a possible explanation. 
Although ERα+ luminal progenitor cells are decreased at puberty, MaSCs, the cells 
shown to contribute the most to pubescent development (Rios, Fu et al. 2014) are 
increased. In addition, ERα+ luminal progenitor cells signal to MaSCs through 
138 
 
paracrine signaling, and with more MaSCs available, the response to that 
paracrine signaling may be intensified resulting in a larger ductal networks later in 
puberty  (Jean 1971, Jean 1971, Mori, Bern et al. 1976, Warner 1976, Bern, Mills 
et al. 1983). In addition to reconciling previous reports of ERα regulation and long 
term effects of early E2 exposure on development, the data presented here may 
also give insight into why early E2 exposure increases risk for mammary 
tumorigenesis. Increases in MaSCs are thought to increase risk for later 
tumorigenesis, because MaSCs are long-lived allowing these cells to accumulate 
mutations over time (Dontu, Al-Hajj et al. 2003, Dontu, El-Ashry et al. 2004, Spike, 
Engle et al. 2012, Makarem, Kannan et al. 2013).   
Lastly, this report is the first to show that the L and R TMGs are differentially 
susceptible to changes induced by E2. Clinically, this may be relevant to endocrine 
therapies used to treat ER+ breast cancers as well as hormone replacement 
therapy. It is conceivable that if TMGs are differentially susceptible to early 
estrogen exposure, the L and R breasts may also respond L-R differently to 
estrogen exposures post-menopause increasing breast cancer risks for one breast 
more than the other, or estrogen inhibition through the use of aromatase inhibitors 










 Left-right (L-R) asymmetry exists within many paired organs, such as lungs, 
kidneys, heart, and brain. L-R asymmetry is established during early 
embryogenesis and is essential to organ development and proper positioning of 
the visceral organs. Recently our lab has found that the mammary glands are also 
L-R asymmetric although bilaterally paired (Fuseler, Robichaux et al. 2014, 
Robichaux, Hallett et al. 2014). However, the origin of mammary gland laterality is 
unknown. For other bilaterally paired asymmetric organs, the origin of laterality is 
embryonic. In mice, L-R asymmetry is established at the node where unilateral 
expression of genes such as Nodal, Lefty and Pitx2 establish a feedback loop of 
L-side expression that elicits L-R differences in developing organs (Nakamura and 
Hamada 2012).  
 Although L-R asymmetry is essential in organogenesis, bilateral symmetry 
is also necessary during somite development (Kawakami, Raya et al. 2005, 
Vermot, Gallego Llamas et al. 2005, Brend and Holley 2009). Somites are 
segmented mesodermal structures that later give rise to important structures such 
as vertebrae, skeletal muscle, and ribs, but also signal to surrounding tissues to 
initiate growth and development (Gilbert 2000, Cho, Kwon et al. 2012).  Despite 
the bilateral symmetry of somites, somites are lateralized structures with L-R 
differences in gene expression (Golding, Partridge et al. 2004, Golding, Tsoni et 
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al. 2004). Bilateral symmetry of somites is conditional on proper spatiotemporal 
expression of retinoic acid (RA) to block the effects of L-R patterning during 
embryogenesis (Kawakami, Raya et al. 2005, Vermot, Gallego Llamas et al. 2005, 
Brend and Holley 2009, Vilhais-Neto, Maruhashi et al. 2010). Chemical inhibition 
of RA signaling ex vivo results in obliteration of Lef1, a Wnt responsive gene and 
an essential regulator of mammary gland induction demonstrating the necessity of 
RA signaling during mammary gland initiation (Chu, Hens et al. 2004, Veltmaat, 
Van Veelen et al. 2004, Cho, Kwon et al. 2012). Reduced RA signaling results in 
asymmetric somite formation for somites 9-16 at embryonic day 8-9.5 (E8.5-9) 
(Kawakami, Raya et al. 2005, Vermot, Gallego Llamas et al. 2005, Vilhais-Neto, 
Maruhashi et al. 2010). In addition, thoracic mammary gland (TMG) pairs 2 and 3 
require somitic FGF for initiation and reside over somites 11-16 (Veltmaat, Relaix 
et al. 2006).  However, reduced RA signaling does not affect somite symmetry after 
somite 16 development.  Inguinal mammary gland (IMG) pair 4 develops 
overlaying somites 22-24 and does not require somitic FGF for initiation (Veltmaat, 
Relaix et al. 2006), therefore should not be affected by altered somite formation 
due to reduced RA signaling. Therefore, if lateralized somitic signals regulate L-R 
patterning of the TMGs, altered RA signaling will result in L-R different alterations 
of the TMGs, but not IMGs. 
  To test this hypothesis, the Retinoic X Receptor alpha (RXRα) knockout 
mouse were used. Complete homozygous RXRα knockout (RXRα-/-) is embryonic 
lethal, therefore partial RXRα knockout, mice heterozygous for RXRα knockout 
(RXRα-/+) mice were used. RXR is one of two types of nuclear receptors for which 
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RA signals with the second being Retinoic Acid Receptor (RAR) family of receptors 
(di Masi, Leboffe et al. 2014). These receptors often act as heterodimers that act 
on retinoic acid response elements (RAREs) of target genes (di Masi, Leboffe et 
al. 2014). Previous studies examining the role of RARα1 on mammary gland 
development found that knockout of RARα1 resulted in hyperplastic ductal 
morphogenesis and increased luminal progenitors, but decreased mammary stem 
cells and protected against Wnt-1 driven tumorigenesis in IMGs (Cohn, Ossowski 
et al. 2010). Interestingly, although authors did not quantify changes in TMGs, 
representative images of RARα1 KO TMGs appear to have smaller ductal 
networks than representative images of WT TMGs suggesting that altered RA 
signaling effects TMGs and IMGs differently. The role of RXRα has been shown to 
be essential for normal heart development, and the primary isotype of RXR 
receptors embryonically expressed (Mark, Ghyselinck et al. 2009); however, no 
previous studies have examined the role of RXRα on mammary gland 
development.  In this study, we demonstrate that knockdown of RXRα via the 
RXRα+/- mouse results in two distinct phenotypes of TMG development as 
compared to WT. In addition, we show that LTMGs are more sensitive to 
perturbations in RXRα signaling compared to RTMGs, and lastly, that IMGs are 




MATERIALS AND METHODS 
 
Mice 
All experiments were performed in accordance with the regulations of the Medical 
University of South Carolina Institutional Animal Care and Use Committee. 
C57BL/6 wild-type mice were obtained from Harlan.  RXRα+/- mice were bred at 
MUSC and generously provided by Dr. Steven Kubalak. Mice were fed Harlan 
Teklad rodent diet 2918 and provided water ad libitum. Mice were euthanized at 
28 days of age and thoracic and inguinal mammary glands were harvested.  
 
Histology and image collection 
Carmine red stained whole mounts were prepared as previously described (de 
Assis, Warri et al. 2010)  from #3 and #8 thoracic mammary glands (TMGs) and 
#4 and #9 inguinal mammary glands (IMGs) of day-28 mice and were imaged on 
an Olympus SZX12 stereomicroscope equipped with a Spot camera. Overlapping 
images of each whole mount were processed into a single composite image with 
Adobe Photoshop®.  
 
Image analysis 
The color images of the mammary glands were converted to 8-bit monochrome 
images for image and fractal analysis. The mammary gland within an image was 
outlined and isolated from the background tissue and defined as a Region of 
Interest (ROI) (Figure 5). The isolated image of the mammary gland was 
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thresholded using the set threshold subroutine of MetaMorph Image analysis 
software (ver. 6.1). The area (A) and integrated optical density (IOD) of the ductal 
epithelial networks were measured using the integrated morphometry analysis 
sub-routine of MetaMorph. The fractal dimension (D), was determined by the box 
counting method using HarFA software (Nezadal, Zemeskal et al. 2001) 
[http://www.fch.vutbr.cz/lectures/imagesci]) applied to the isolated image of the 
mammary gland using the same threshold values. 
 
Integrated optical density (IOD).   
The IOD of the mammary gland ROI delineated by the thresholded boundaries is 
considered to be the “mass” of the ROI and a measurement of the total amount of 
labeled material in the region (Walter and Berns 1986, Fuseler, Merrill et al. 2006, 
Fuseler, Millette et al. 2007, Rogers and Fuseler 2007, Fuseler and Valarmathi 
2012). The IOD of a selected region can be expressed as the weighted sum of the 
image histogram in which each term in the histogram is multiplied by the gray value 
it represents. When applied to thresholded boundaries the IOD is defined by the 
following expression: 
                           T2 
IOD (T1, T2) =  ∑ H (GV) x GV 
                           GV = T1 
Where the upper and lower thresholds defining the ROI in the histogram are 
given by T1 and  T2.  GV is the gray value of each pixel and H (GV) is the gray 
level histogram.  
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Application of the fractal dimension (D) 
The thoracic mammary glands appear as irregular and complex objects composed 
of parts at different levels of resolution (ducts of different bore sizes) which are 
functionally and physiologically similar (self-similar) to the whole object. Under the 
conditions of these properties, the thoracic mammary glands can be considered 
fractal objects and their topological dimension, the fractal dimension (D), 
expressed by a non-integer number lying between two Euclidian integer 
topological dimensions (Grizzi, Russo et al. 2005). The values of D characterizing 
the thoracic mammary glands are therefore fractional. Since the thoracic mammary 
gland is essentially a 2-dimensional object, the D values will lie between 1 and 2. 
As the mammary gland becomes more complex and irregular, its D value becomes 
greater, approaching 2.  In applying fractal analysis, the D value of the mammary 
gland is determined by applying the box-counting method (Fernandez and Jelinek 
2001, Grizzi, Russo et al. 2005).  The box-counting method has been the most 
widely used and general model for applying fractal analysis to biological and non-
biological systems. The box-counting method consists of a grid of boxes of size e 
superimposed over the image of the structure, and the number of boxes containing 
any part of the structure recorded as N(e). A fractal object expresses a straight line 
when Log[N(e)] is plotted against Log(1/e). The box fractal dimension D can be 
determined from the slope of the regression line. That is: D= Log[N(e)] / Log(1/e). 
The D values of the thoracic mammary glands were determined using HarFA 
software (Nezadal, Zemeskal et al. 2001) 
[http://www.fch.vutbr.cz/lectures/imagesci]. The HarFA software assigned mesh 
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sizes of boxes with e values ranging from 2 to 207 pixels and 30 steps within this 
range were calculated to generate the Log[N(e)] versus Log(1/e) lines to 
determined.  
 
Branch points and terminal end buds (TEBs) 





RXRα+/- TMGs have two distinct phenotypes during pubescent ductal 
morphogenesis 
To test the hypothesis that mammary gland laterality originates 
embryonically, RXRα knockout mice were used. RXRα-/- mice are embryonic lethal 
and could not be used for this study (Sucov, Dyson et al. 1994); therefore RXRα+/- 
mice were used. Approximately half of the RXRα+/- mice had TMGs with 
pronounced hypoplastic development as compared to WT (Figure 22A, E). In 
addition to decreased ductal network development, these mice had observable L-
R differences in morphology (Figure 22A). In hypoplastic RXRα+/- mice, RTMGs 
had larger ductal network areas, more terminal end buds (TEBs), more branch 
points, and higher IOD (mass) as compared to LTMGs (Figure 22B). However, 
hypoplastic RXRα+/- mice had no L-R differences in fractal dimension (complexity) 
or relative density (Figure 22B). The other half of RXRα+/- mice were hyperplastic 
in development as compared to WT (Figure 22C, E) and had no L-R differences in 
morphology similar to WT (Figure 22D, F). Interestingly, C57/Bl6 WT TMGs are L-
R different in fractal dimension, a measure of ductal complexity (Figure 22F) a L-
R difference not observed in FVB/N WT TMGs (Robichaux, Hallett et al. 2014). 
Overall this data demonstrates that RXRα+/- TMGs have two distinct phenotypes 
as compared to WT during pubescent development, and that reduction of RA 
signaling results in aberrations in mammary gland development leading to L-R 




Figure 22. RXRα+/- TMGs have two distinct phenotypes during pubescent 
ductal morphogenesis. Hypoplastic TMGs from RXRα+/- mice (A) are L-R 
asymmetric in ductal network area, TEBs, Branch Points, and IOD, but not fractal 
dimension or relative density (N=7, B). Hyperplastic TMGs from RXRα+/- mice (C) 
are distinct from hyperplastic RXRα+/- TMGs, and are L-R symmetric in all 
morphometric parameters (N=5, D). TMGs from WT mice (E) are symmetric in all 
morphometric parameters except fractal dimension (N=12, F). Statistical 
differences were determined by students’ t-tests, *, p<0.05; **, p<0.01.  
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LTMGs are more vulnerable to RXRα+/- knockout than RTMGs 
 To determine if L and R TMGs are equally sensitive to RXRα+/- knockdown, 
L and R TMGs of both RXRα+/- hyperplastic TMGs and hypoplastic TMGs were 
compared to WT TMGs independently. LTMGs of hyperplastic RXRα+/- mice have 
increased ductal network areas, terminal end buds, IOD, and density compared to 
WT (Figure 23A). In addition, hyperplastic RXRα+/- LTMGs have increased ductal 
network areas, terminal end buds, branch points, and IOD compared to RXRα+/- 
hypoplastic LTMGs (Figure 23A). When RXRα+/- hypoplastic LTMGs were 
compared to WT LTMGs, RXRα+/-, hypoplastic LTMGs were found to have reduced 
ductal network areas, branch points, IOD, fractal dimension, but had elevated 
density compared to WT LTMGs (Figure 23A). However, RTMGs of hyperplastic 
RXRα+/- mice and hypoplastic RXRα+/- mice only vary slightly from WT mice (Figure 
23B). RTMGs of hyperplastic RXRα+/- mice and hypoplastic RXRα+/- mice have no 
differences from WT in ductal network area, terminal end buds, branch points, or 
fractal dimension (Figure 23B). Minor increases in IOD were detected for 
hyperplastic RXRα+/- mice, and WT mice have decreased density compared to 
both RTMGs of hyperplastic RXRα+/- mice and hypoplastic RXRα+/- mice. This data 
demonstrates that LTMGs are more sensitive to perturbations in RA signaling and 




Figure 23. LTMGs are more vulnerable to RXRα+/- knockout than RTMGs. 
Hyperplastic LTMGs RXRα+/- TMGs are have larger ductal network areas, more 
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TEBs, increased IOD and increased relative density compared to WT LTMGs; 
whereas hypoplastic RXRα+/- LTMGs have smaller ductal networks, fewer branch 
points, and decreased IOD and fractal dimension compared to WT LTMGs (A). 
Hyperplastic and hypoplastic RXRα+/- RTMGs have no differences ductal network 
area, TEBs, branch points, or fractal dimension compared to WT RTMGs (B). IOD 
and relative density are the only morphometric parameters increased with RXRα 
knockdown. Statistical differences were determined by ANOVA and Bonferroni's 
post-tests, *, p<0.05; **, p<0.01.  
152 
 
IMGs are unaffected by RXRα+/- knockout 
Asynchrony in somite formation with reduced RA signaling is limited to 
early, thoracic somites 9-14; whereas more posterior somites that develop past 
approximately 16 somites develop symmetrically (Vermot, Gallego Llamas et al. 
2005). The somites underlying the inguinal mammary glands (approximately 
somites 22-24) (Veltmaat, Relaix et al. 2006), are unaffected by reduced RA 
signaling; therefore IMGs of RXRα+/- mice should develop normally.  RXRα+/- IMGs 
(Figure 24A) appear L-R symmetric and similar to WT IMGs (Figure 24B). Neither 
RXRα+/- IMGs nor WT IMGs have L-R differences in any morphometric parameter 
(Figure 24C, D). Independent L and R analysis of RXRα+/- IMGs vs. WT IMGs show 
slight symmetric increases in ductal network area and branch points for both LIMG 
and RIMGs of RXRα+/- mice compared to WT mice, but no other changes (Figure 
24E, F). This data is consistent with a previous study showing increases in ductal 
network area and branch points in IMGs of RARα1 knockout mice (Cohn, 
Ossowski et al. 2010). This data demonstrates that IMGs are not sensitive to 
RXRα+/- knockout. The lack of response to RXRα+/- knockout in IMGs and presence 
of pronounced L-R differences in TMG response to RXRα+/- knockout demonstrate 
the importance of somitic signals to the TMGs and suggests that L-R differences 






Figure 24. IMGs are unaffected by RXRα+/- knockout. RXRα+/- IMGs (A) nor WT 
IMGs (B) have L-R differences in any morphometric parameter (C, D). LIMGs (E) 
and RIMGs (F) of RXRα+/- mice have increased ductal network areas and branch 
points as compared to WT IMGs, but no other morphometric parameter is different 
in the RXRα+/- model compared to WT. Statistical differences were determined by 







 Due to the differences in phenotypes of the TMGs in RXRα+/- mice, RT-PCR 
was not a viable approach to determine consistent molecular differences in 
RXRα+/- vs. WT mice. Gene expression patterns were not consistent, therefore 
reliably segregating the RT-PCR results into two groups that may correlate with 
each of the phenotypes was not possible with the above sample size; therefore, 
an experimental design allowing visualization of the morphology of the ductal 
networks before RNA isolation is necessary. Crossing RXRα+/- mice with MMTV-
GFP mice, which have a fluorescent ductal epithelium, would allow for segregation 
into the two phenotypic groups before RNA isolation allowing us to probe for a 
molecular reason in the two different phenotypes of TMGs in RXRα+/- mice. 
However, the reason for the two different phenotypes of TMGs in RXRα+/- mice 
was not attributable to parents’ genetics (i.e. mother vs. father being RXRα+/- or 
WT) or the mother’s milk as both phenotypes came from the same liter in some 
instances. 
In the L-R different TMG phenotype, L-R differences may be attributable to 
L-R differences in FGF and Notch signaling. When asynchronous somite 
development takes place in Raldh2 knockout model, the embryos have an 
increase in FGF8 on the right side and an increase of Hes7, a Notch target gene, 
on the left side.  Half of the RXRα+/- TMGs have larger networks on the right side 
and over-expression of FGF in TMGs is associated with hyperplastic growth and 
tumorigenesis (Ngan, Ma et al. 2002). In addition, RXRα+/- TMGs with hypoplastic 
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growth had severely stunted LTMGs. Studies have shown that Notch signaling in 
mammary glands induces MaSC differentiation and luminal cell lineage 
determination (Bouras, Pal et al. 2008, Chakrabarti, Wei et al. 2012, Park, Raafat 
et al. 2013, Sale, Lafkas et al. 2013).  As MaSCs proliferate symmetrically, up-
regulation of Notch signaling on the left side of the embryo could induce early 
differentiation of MaSCs resulting in decreased growth potential at puberty due to 
a limited number of remaining MaSCs. Further studies are needed to determine 
the effects of RXRα knockout on early placode initiation and later pubescent 
development. Tissue specific knockout would allow for later studies of complete 
RXRα knockout reducing variability due to heterozygous genetics.  
Here we show that RXRα+/- knockout results in two distinct phenotypes of 
TMG development: 1.) L-R asymmetric hypoplastic development, and 2.) L-R 
symmetric hyperplastic development. In addition, LTMGs were much more 
sensitive to RXRα+/- knockout than RTMGs. LTMGs of both phenotype were 
altered as compared to WT, but RTMGs of both phenotypes only had changes 
from WT in ductal density. Lastly, we show that IMGs of RXRα+/- do not develop 
differently from WT IMGs. These data taken together demonstrate that TMGs are 
more sensitive to changes in RA signaling than IMGs, and that alterations in L-R 
embryonic patterning effect the L and R TMGs differently. This data is the first to 
suggest that L-R patterning of mammary glands is embryonic in origin and that 











 When beginning this project, a standardized objective method of quantifying 
mammary gland ductal networks did not exist. The current methods, were 
subjective and ambiguous. Chapter 2 details a sensitive, quantitative, and 
objective method of analyzing mammary ductal networks: fractal dimension 
analysis. Using fractal dimension analysis in conjunction with conventional 
morphometrics we detected differences in wild-type (WT) and MMTV-NeuTg/+ 
murine thoracic ductal network morphogenesis during pubescent development. 
Furthermore, fractal dimension analysis allowed us to observe left (L) side MMTV-
NeuTg/+ thoracic mammary glands (TMGs) show increased signs of neoplasia as 
compared to right (R) side MMTV-NeuTg/+ TMGs. This L-R difference in fractal 
dimension analysis of MMTV-NeuTg/+ TMGs was the first documentation of L-R 
differences in pubescent mammary gland development. Not only does fractal 
dimension analysis serve as a quantitative and sensitive approach in mice, but this 
technique if followed up on in human patients, could develop a more sensitive 
method of early neoplasia detection before overt breast tumor formation. Previous 
retrospective studies have shown that fractal dimension analysis of mammograms 
detected changes in mammary architecture over a year before clinical diagnosis 
(Rangayyan, Banik et al. 2010, Daye, Keller et al. 2013, Rangayyan, Banik et al. 
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2013). This suggests a window of preventative medicine for women with early 
neoplastic changes.  
 In chapter 3 WT mice are characterized for L-R differences during normal 
development and L-R differences are then challenged by ErbB2/Neu 
overexpression by using the MMTV-NeuTg/Tg mouse model. In chapter 3.1, despite 
the morphological symmetry of WT TMGs, L and R TMGs are demonstrated to be 
molecularly different by microarray analysis which was validated by RT-PCR. In 
addition, L-R different gene expression pathway analysis converged on mammary 
epithelial cell differentiation (Smalley and Ashworth 2003, Cicalese, Bonizzi et al. 
2009, Carr, Kiefer et al. 2012, Robichaux, Hallett et al. 2014).  
When the ErbB2/Neu transgene is overexpressed by the Murine Mammary 
Tumor Virus (MMTV) promoter as in the MMTV-NeuTg/Tg mouse model, TMGs 
develop asymmetrically with right side TMGs forming larger ducts, but left side 
TMGs forming more complex ducts. In addition, overexpression MMTV-NeuTg/Tg 
resulted in discordant gene regulation of novel laterality genes, and down-
regulation of transcription factors regulating mammary stem cell (MaSC) 
differentiation.  
In addition, inguinal mammary glands (IMGs) were shown to be less 
sensitive to MMTV-NeuTg/Tg overexpression and delayed in L-R asymmetric gene 
expression, not showing molecular laterality until after pubescent development for 
both WT and MMTV-NeuTg/Tg IMGs. Lastly, comparative genomic analysis of novel 
laterality genes to patient tumor situs displayed decreased patient survival when 
tumors had “right-side” laterality gene expression. This decreases in survival with 
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“right-side” gene expression exists across various breast cancer subtypes 
exhibiting the clinical relevance of molecular L-R differences. Chapter 3.1 was the 
first report demonstrating molecular L-R differences in WT mammary glands and 
the ability of genes to be un-coupled in regulation by transgenic overexpression of 
an oncogene in mammary glands. In addition, discordant gene regulation between 
TMGs and IMGs L vs. R show that each mammary gland is regulated 
independently along the anterior and posterior axis as well as the L-R axis.  
 In chapter 3.2 MaSCs of WT mice were studied for L-R differences in the 
presence or absence Lapatinib, a small molecule inhibitor targeting both ErbB2 
and EGFR. In addition, to determine the effect of ErbB2 over-expression on L and 
R MaSCs, L-R differences of MaSCs in the MMTV-NeuTg/Tg mouse model were 
also examined in the presence or absence of Lapatinib. WT mice have 2.5 fold 
more MaSCs in LTMGs as compared to RTMGs. Moreover, WT MaSCs from 
LTMGs have drastically upregulated ErbB2 expression, whereas WT MaSCs from 
RTMGs have dramatically upregulated EGFR expression. In addition to molecular 
differences, L-sided MaSCs form more mammospheres that are sensitive to 
treatment with Lapatinib. Conversely, R-sided MaSCs form larger 
mammospheres, and increase in self-renewal with increasing concentrations of 
Lapatinib treatment.  
In addition to L-R differences of WT TMG derived MaSCs, MMTV-NeuTg/Tg 
TMG derived MaSCs also display L-R differences in MaSC number. Neu 
overexpression in the MMTV-NeuTg/Tg model resulted in a statically significant 
increase in L-sided MaSCs, but not R-sided MaSCs enhancing the already existing 
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MaSC laterality. MMTV-NeuTg/Tg TMG derived MaSCs also displayed a L-R 
difference in ErbB2 and EGFR expression however, the L-R pattern was inverted 
in MMTV-NeuTg/Tg TMG derived MaSCs. L-side MMTV-NeuTg/Tg TMG derived 
MaSCs had elevated EGFR and R-sided MMTV-NeuTg/Tg TMG derived MaSCs 
had elevated ErbB2. Accompanying inversion of EGFR and ErbB2 expression, 
mammosphere growth and response to Lapatinib was inverted in MMTV-NeuTg/Tg 
TMG derived MaSCs. R-sided MMTV-NeuTg/Tg TMG derived MaSCs formed more 
mammospheres and responded in a dose dependent manner to Lapatinib 
treatment; whereas L-sided MMTV-NeuTg/Tg TMG derived MaSCs showed little 
response to Lapatinib treatment and had no change in self-renewal. However, all 
MMTV-NeuTg/Tg TMG derived MaSCs had elevated sensitivity to Lapatinib 
treatment as compared to WT, which was expected. Previous studies show that in 
MMTV- NeuTg/Tg mice, in general mammary epithelial cells overexpress Neu/ErbB2 
(Guy, Webster et al. 1992), although in our study, R-sided MMTV-NeuTg/Tg TMG 
derived MaSCs were shown to express more ErbB2 as compared to L sided 
MMTV-NeuTg/Tg TMG derived MaSCs. This study not only demonstrates a 
correlation between ErbB2 expression and Lapatinib sensitivity, but also a novel 
correlation between EGFR and Lapatinib sensitivity. Moreover, EGFR expression 
correlated to either protection from Lapatinib treatment as well as a slight 
stimulation of MaSC self-renewal in WT and MMTV-NeuTg/Tg MaSCs.  Furthermore, 
this study is the first to show not only a L-R differential response to a clinically used 
breast cancer therapy, but a possible unilateral adverse effect that may promote 
future secondary reoccurrence of a more aggressive breast cancer subtype.  
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Future studies are needed to determine the long term effects of Lapatinib treatment 
on normal tissue and future breast cancer risks.  
Together, chapter 3 is the first to demonstrate that L and R TMGs are lateralized 
organs with differential response to molecular perturbations. Moreover, L and R 
MaSCs are non-identical and have L-R differential potential in response to 
inhibition of growth factors. Overall these studies demonstrate that increases in 
number of MaSCs, as well as a lack of inhibition to Lapatinib correlate with elevated 
EGFR expression and poor patient survival. In addition, responsiveness to 
Lapatinib, as well as patient survival correlate with elevated ErbB2/ErbB3 
expression. Moreover, increases in number of MaSCs correlates with smaller (less 
differentiated) ductal networks (Table 3). From a basic science point of view, these 
studies enforce the idea that L and R should not be combined for studies of 
mammary gland biology or breast cancer. From a clinical perspective, these 
studies demonstrate that tumor situs is an additional parameter of diagnosis that 
should be taken into account in deciding a method of therapy or prognosis.   
In chapter 4, the effect of neonatal exposure to 17β-estradiol (E2) on normal 
mammary glands is examined. Early E2 exposure is shown to asymmetrically 
effect pubescent development of TMGs, but not IMGs. TMGs undergo 
asymmetrical ductal morphogenesis with RTMGs being larger than LTMGs. In 
addition, early E2 exposure resulted in down-regulation of transcription factors that 
regulate ductal morphogenesis including transcription factors that regulate both 
luminal cell and basal cell lineage differentiation. FACS analysis revealed an 
overall decrease in luminal progenitors, but more so in LTMGs, correlating with 
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RT-PCR data. RT-PCR demonstrated a larger decrease in luminal progenitor 
markers as well as ERα in the LTMG. Additionally, FACS revealed an asymmetric 
increase in MaSCs, corresponding with an increase in MaSC markers by RT-PCR. 
Chapter 4 was the first report of TMGs capacity to respond L-R different to 
systemic hormone exposure and reconciled previous reports of down-regulation of 
ERα, but increased sensitivity to endogenous estrogens later in puberty via 
demonstration of up-regulation of MaSCs (Warner, Yau et al. 1980, DiPaolo and 
Jones 2000, Wadia, Vandenberg et al. 2007). Also increases in MaSC populations 
also may explain why neonatal estrogen exposure increases tumorigenesis with 
carcinogen exposure later in life (Warner and Warner 1975, Mori, Bern et al. 1976). 




Table 3: Summary of laterality findings in dissertation. Increases in number of 
MaSCs, as well as a lack of inhibition to Lapatinib correlate with elevated EGFR 
expression and poor patient survival. In addition, responsiveness to Lapatinib, as 
well as patient survival correlate with elevated ErbB2/ErbB3 expression. In 
addition, increases in number of MaSCs correlates with smaller (less 
differentiated) ductal networks. 
 
 WT MMTV-NeuTg/Tg E2 
Morphology L=R L<R L<R 
Number of MaSC L>R L>R L<R 
Increase in MaSC Right (10 weeks) 
Left only 
(compared to WT) 
L > R 
(compared to WT) 
Number of Mammospheres L>R L<R Unknown 
Size of Mammospheres L<R L=R Unknown 
Expression of EGFR Right Left Unknown 
Expression of ErbB2 Left Right Unknown 
Inhibition to Lapatinib Left Right Unknown 
Better Patient Survival Left Unknown Unknown 
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Lastly in chapter 5, using the RXRα+/- knockout mouse we find TMGs are 
more susceptible to changes in RA signaling than IMGs. RXRα+/- knockout TMGs 
have two distinct phenotypes: 1.) L-R asymmetric hypoplastic development, and 
2.) L-R symmetric hyperplastic development. LTMGs were much more sensitive to 
RXRα+/- knockout than RTMGs. LTMGs of both phenotype were altered as 
compared to WT, but RTMGs of both phenotypes only had changes from WT in 
ductal density. In L-R asymmetric hypoplastic TMGs, decreased LTMG 
development in response to RXRα+/- knockout may be due to decreased MaSCs 
in LTMGs due to an aberrant increases in Notch signaling as seen in the Raldh2 
knockout model (Vilhais-Neto, Maruhashi et al. 2010). Up-regulated Notch 
signaling is known to increase MaSC differentiation and luminal cell lineage 
determination reducing MaSC populations (Bouras, Pal et al. 2008, Chakrabarti, 
Wei et al. 2012, Park, Raafat et al. 2013). To determine if this truly is the 
mechanism of action, RXRα-/- knockout placodes could be harvested and analyzed 
by RT-PCR. In addition, increases in RTMG growth could be due to increased FGF 
signaling as seen in the Raldh2 knockout model (Vilhais-Neto, Maruhashi et al. 
2010), because increased FGF results in mammary hyperplasia (Ngan, Ma et al. 
2002).  Lastly, we show that IMGs of RXRα+/- do not develop differently from WT 
IMGs. IMG unreceptiveness was expected because IMGs have been shown to 
develop independently of somitic FGF and the somites underlying the IMGs are 
not altered by RA reduction (Vermot, Gallego Llamas et al. 2005, Veltmaat, Relaix 
et al. 2006, Vilhais-Neto, Maruhashi et al. 2010). These data taken together 
demonstrate that TMGs are more sensitive to changes in RA signaling than IMGs, 
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and that alterations in L-R embryonic patterning effect the L and R TMGs 
differently. This data suggests that L-R patterning of mammary glands is 
embryonic in origin, originates from somitic signals, and that perturbations in 
embryonic L-R patterning have long term effects on mammary gland development.  
The results of the studies within this dissertation form 3 major conclusions: 
1.) mammary glands and the cell populations within the mammary glands are 
lateralized with the potential to response L-R differently to both neoplastic insults 
as well as drugs used to treat breast cancers; 2.) L-R differences in TMGs originate 
embryonically like other bilaterally paired organs; and lastly, 3.) TMGs and IMGs 
are not identical and because TMGs have more similarities to human development, 
and are more sensitive to outside perturbations,  TMGs are more appropriate for 





The data presented here has opened up an entirely new area of mammary 
gland biology: L vs. R response to experimentation. These type of experiments 
can be dually informative. Underlying L-R differences under normal conditions 
have yet to be fully understood and can give insight into disease progression and 
perhaps disease prevention, but also L-R differences can be exploited to 
understand relationships between molecular differences and response to 
experimentation yielding better understanding of mechanism of action. The future 
directions for this project vary from early embryonic development and additional 
studies in pubescent development, to branching into later time-points of 
development not yet studied such as pregnancy, lactation, and involution. In 
addition to developmental questions, the data here can also continue into studies 
of cancer biology in attempts to understand how L-R differences in normal 
mammary gland biology result in L-R differences in tumor biology including 
response to clinical therapies and long term risks.  
Embryonically, a mechanism of how somites deliver a lateralized signal of 
placode initiation is unknown. Potential studies include mechanistic studies of hb-
EGF, a transient left-side dominate somitic ligand that binds to ErbB family 
members known to effect mammary gland development (Golding, Tsoni et al. 
2004). Increases in ErbB family signaling have been shown to increase MaSC 
populations (Olayioye, Neve et al. 2000, Troyer and Lee 2001, Korkaya, Paulson 
et al. 2008, Spike, Engle et al. 2012, Ithimakin, Day et al. 2013, Korkaya and Wicha 
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2013), and could be origin of L-side dominate MaSC numbers. Mouse models with 
inverted L-R asymmetry such as the situs inversus mouse could also give definitive 
proof if L-R differences in mammary gland biology originate embryonically 
(Yokoyama, Copeland et al. 1993). Although the FVB/N-Invsinv mouse model of 
situs inversus dies by 7 days of age (Yokoyama, Copeland et al. 1993), embryonic 
studies of placode formation and L-R differences of primary ducts would determine 
if mammary gland laterality is a product of embryonic L-R patterning.  
  To continue the current studies during pubescent development, more 
studies are needed to tease out the mechanism of ErbB2 and EGFR expression 
and MaSC response to Lapatinib. The L-R pattern of ErbB2 and EGFR expression 
correlating with Lapatinib treatment of both WT and MMTV-NeuTg/Tg MaSCs 
suggests that ErbB2 and EGFR expression regulates MaSC response to Lapatinib 
and self-renewal.  However, Lapatinib can bind both receptors (Wood, Truesdale 
et al. 2004, Burris, Hurwitz et al. 2005, Zhang, Pal et al. 2008, Scaltriti, Verma et 
al. 2009), and studies using a drug that can only bind one receptor or the other are 
necessary to further tease out the relationship between ErbB2 and EGFR gene 
expression and self-renewal. Additional studies are also needed to examine other 
cell populations within the mammary glands. E2 studies demonstrate that E2 can 
effect luminal populations L-R differently therefore MaSCs are not the only 
lateralized mammary epithelial population within the mammary glands. 
Characterizing L-R differences in other cell populations may determine how E2 is 
capable of asymmetric increases in MaSC populations and if asymmetric response 
to ErbB2/Neu overexpression effects other cell populations. 
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In addition to epithelial cell studies, characterization of microenvironmental 
differences are necessary. Ductal morphogenesis at puberty is not only driven by 
epithelial cell cross-talk but paracrine signaling from the surrounding stroma. L-R 
differences could not be supported long-term unless the microenvironment were 
L-R different. ECM components such as collagen and MMPs have been shown to 
regulate MaSC proliferation and self-renewal (Barcus, Keely et al. 2013, Chen, 
Bhat-Nakshatri et al. 2013, Kessenbrock, Dijkgraaf et al. 2013). However, no 
studies have examined if these ECM components are L-R different. Mammary 
gland transplantation experiments could determine if L-R different 
microenvironments play a role in maintaining L-R differences in mammary glands. 
Because MaSCs and possibly other cell populations have L-R differences in 
number as well as gene expression, the number and cell type will have to be 
controlled in these experiments. Therefore, injecting the same number of a single 
population of mammary epithelial cells from the L and R TMGs into ipsilateral 
(same) and contralateral (opposite) sides of cleared TMGs would determine if the 
microenvironment propagates molecular L-R differences in mammary epithelial 
cells (Figure 25). In addition, this experiment completed in limiting dilutions of 
MaSCs from the L and R TMGs would give functional in vivo data for L-R 
differences in MaSC self-renewal observed in pervious in vitro mammosphere 
experiments. If the L and R fat pads have different reconstitution potentials with 
cells from the same side of origin, then the L and R microenvironments are 
different. If the L (or R) fat pad has a different reconstitution potential depending 
on the side of origin the cells came from, then the L and R MaSCs are functionally 
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different in vivo.  If the L and R fat pads have the same reconstitution potential 
regardless of the side of origin of the donor cells, the MaSCs and the 




Figure 25. Mammary gland limited dilution repopulation experimental 
design. Ipsilateral (same side) and contralateral (opposite side) injections of 
limiting dilutions of MaSCs would determine if WT MaSCs and or 
microenvironments are functionally different in vivo.  If the L and R fat pads have 
different reconstitution potentials with cells from the same side of origin, then the 
L and R microenvironments are different. If the L (or R) fat pad has a different 
reconstitution potential depending on the side of origin the cells came from, then 
the L and R MaSCs are functionally different in vivo.  If the L and R fat pads have 
the same reconstitution potential regardless of the side of origin of the donor cells, 
the MaSCs and the microenvironment is functionally L-R equivalent in vivo. 
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Studies of L-R differences in other developmental time points have yet to 
be completed by our lab. L-R differences in pathways regulating luminal cell 
determination would suggest that lactation may also be L-R different. Baseline L-
R differences in β-casein (Figure 19D), a milk protein, of WT mice would suggest 
that milk production may in fact be lateralized; in addition, human studies show 
that the L and R breast produce milk at different rates (Engstrom, Meier et al. 
2007). Marsupials are capable of producing two different types of milk for 
developing offspring of different ages in contralateral glands (Sebastian, De Matteo 
et al. 1998), therefore it is conceivable that humans are also capable of producing 
milk with L-R differences. Studies of mouse milk composition over multiple 
pregnancies, both pre- and post-partum, would determine if the nutritional 
composition of milk is lateralized and/or changes over subsequent pregnancies. L-
R differences in involution also need examination. Studies show that pregnancy 
and subsequent involution change the morphology and cell biology of the 
mammary glands, resulting in decrease risks for breast cancer (D'Cruz, Moody et 
al. 2002, Albrektsen, Heuch et al. 2005, Meier-Abt, Milani et al. 2013). The effect 
of pregnancy and involution has not been examined L vs. R. Studies examining 
MaSC number and function post-partum and after involution would determine if 
protective changes have symmetrically.  
In addition to studies furthering knowledge of normal development, studies 
examining the role of L-R differences in tumor initiation, progression, and response 
to therapy are necessary. Results of the Lapatinib study in WT and MMTV-NeuTg/Tg 
mice suggest that MaSCs expressing higher levels of EGFR increase in self-
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renewal with Lapatinib treatment. This data suggest that Lapatinib treatment may 
increase MaSC potential and heighten risk for future aggressive breast cancer 
subtypes. To test this hypothesis, WT mice could be given Lapatinib (or DMSO 
control) treatment for several weeks then exposed to a carcinogen known to induce 
mammary tumors such as 7,12-Dimethylbenz[a]anthracene (DMBA). Tumor 
initiation and tumor histology L vs. R would determine if Lapatinib increases risks 
for breast cancer long term and if the change in breast cancer risk is lateralized.  
The L-R differential response to both Lapatinib and E2 exposure suggest 
that the mammary glands and MaSCs will respond L-R differently to multiple 
chemical compounds. Importantly, commonly used clinical therapies such as 
aromatase inhibitors, the taxol family of drugs, platinum based therapies, as well 
as radiation should be tested for efficacy and long term risks L vs R. Current 
studies have never taken L vs. R differences into account in determining 
effectiveness. Complementary to future studies with Lapatinib, drug screening 
common clinical therapies L vs. R for both normal MaSCs and tumor derived 
MaSCs may allow clinicians to also use L vs. R side of tumor origin as an additional 
parameter in determining the proper and most effective form of treatment while 
minimizing long-term risks.   
The role of tumor situs in metastasis should also be examined. 
Epidemiological studies show that although more tumors form on the left side, right 
side tumors appear to be more metastatic and aggressive (Fatima, Zaman et al. 
2013). L-R differences in tumor incidence via multiple mouse models such as the 
MMTV-NeuTg/Tg model, or the polyoma virus middle T antigen expressing mouse 
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(MMTV-PyMT), which develops more heterogeneous tumors, would determine L-
R differences in tumor laterality.  Injecting mice with labeled tumor cells (different 
colors for different sides) and allowing tumors to grow and metastasize would 
determine if the microenvironment of the tumor dictates tumor aggressiveness. In 
addition, injecting tumor derived cells from L and R tumors would determine if L 
and R tumors differ in metastatic properties such as location of metastasis (tail vain 
for lung, cardiac injection for brain), number of metastatic sites, or size of 
metastases. Lastly, tail vain or cardiac injections of L and R fluorescently labeled 
(different colors for different sides) tumor derived cells simultaneously would 
determine if L and R tumor cells differ in the aggressiveness of metastases 
competitively.  
Experiments to determine if distinct molecular L-R differences in MaSC 
populations contribute to differences in tumor biology (ie tumor incidence, 
progression), response to therapy, and overall survival are still needed. First a duel 
reporter mouse expressing green fluorescence protein (GFP) when Wnt3a is 
expressed and expressing red fluorescence protein (RFP) when Epb4 is 
expressed under the MMTV promoter (to make GFP and RFP expression 
mammary specific) would need to be created. Because left side MaSCs express 
higher levels of stem cell marker Wnt3a and low levels of stem cell marker Epb4, 
left side MaSCs should be predominately GFP expressing; whereas right-side 
MaSCs express high levels of Epb4 and low levels of Wnt3a, right side MaSCs 
should be predominately RFP expressing. Then, these duel reporter mice would 
be treated with the carcinogen 7,12-Dimethylbenz-[a]anthracene (DMBA) at 
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puberty to induce mammary tumors. Mammary tumors would be examined for GFP 
and RFP expression to determine if Wnt3a-MaSCs (left side predominate) or 
Epb4-MaSCs (right side predominate) contribute more often to tumorigenesis. In 
addition, tumor size, histology, and metastases would be quantified and compared 
L vs. R as well as GFP-predominate or RFP-predominate to determine if tumor 
biology differs depending side of tumor origin and/or on the type of MaSC 
contributing to tumorigenesis, thereby answering the question does MaSC subtype 
correlate with tumor biology and heterogeneity. In addition overall survival would 
be compared L vs. R as well as by tumor subtype (GFP-predominate vs. RFP-
predominate) to determine if sidedness and/or MaSC gene expression (Wnt3a vs. 
Epb4) plays a role in overall survival of mice. Also metastatic sites of involvement 
will be analyzed to determine if Wnt3a-MaSCs or Epb4-MaSCs expressing tumors 
have larger or more frequent metastases.  
Previous reports, as well as our studies in Chapter 3, demonstrate that Epb4 
expressing MaSCs are less sensitive to chemotherapeutic agents (Pfefferle, Spike 
et al. 2015). To determine if L-R differences in MaSCs also relate to therapeutic 
sensitivity, duel reporter mice with DMBA derived tumors will also be given 
Lapatinib, taxol, or a combination of both drugs at clinically relevant doses. L-R 
differences in response to therapy would be quantified by changes in tumor size, 
changes in metastatic frequency and size, as well as overall survival. In addition, 
remaining tumors would be dissected to determine if there decreases in GFP and 
RFP expressing cells occurred and if so if are GFP-Wnt3a and RFP-Epb4 cancer 
stem cells equally responsive to therapeutic agents.  In addition, EGF family of 
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receptor expression will be analyzed by RT-PCR to determine if receptor 
expression correlates with MaSC gene expression (Wnt3a vs Epb4), overall 
survival, and/or response to Lapatinib or taxol. Our studies suggest that MaSCs 
with higher EGFR expression will correlate with poor survival as well as decreased 
therapeutic sensitivity. EGFR/ErbB2 expression could not be used as the stem cell 
specific (L-R different) markers in the reporter mouse, because EGFR and ErbB2 
are not specific to MaSCs whereas Wnt3a and Epb4 are MaSC specific. Lastly, 
reporter mice could be crossed with MMTV-NeuTg/Tg mice and the experiments 
repeated to determine if, like MaSC growth properties, will L-R differences in tumor 
biology, survival, and response to therapy invert in laterality.  These experiments 
would demonstrate that not only are there two distinct subtypes of MaSCs, but 
these subsets of MaSCs are L-R different, and are the basis of L-R differences in 
breast cancer epidemiology. In addition, these studies could find novel bio-markers 
in predicting breast cancer responsiveness.  
The field of mammary and tumor laterality is wide open. Mammary gland 
laterality is another tool to understanding normal mammary gland biology as well 
as progression into disease and tumor biology. Thorough understanding of normal 
biology and disease progression leads to increased breast cancer prevention and 
treatment. Early intervention for breast cancer patients is lacking; current early 
intervention is often limited to double mastectomy, with little un-invasive 
pharmaceutical treatment. Using normal mammary gland laterality and tumor 
laterality as a tool to understand normal and neoplastic development, earlier 
windows of prevention may be found and exploited to prevent breast cancer in high 
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risk patients. Moreover, if L-R differences in gene expression regulate therapeutic 
sensitivity, previously described drug screens to identify drugs that preferentially 
target specific MaSC populations could be matched to patient tumor gene 






Albrektsen, G., I. Heuch, S. Hansen and G. Kvale (2005). "Breast cancer risk by 
age at birth, time since birth and time intervals between births: exploring 
interaction effects." Br J Cancer 92(1): 167-175. 
Alvi, A. J., H. Clayton, C. Joshi, T. Enver, A. Ashworth, M. Vivanco, T. C. Dale and 
M. J. Smalley (2003). "Functional and molecular characterisation of 
mammary side population cells." Breast Cancer Res 5(1): R1-8. 
Anderson, S. M., M. C. Rudolph, J. L. McManaman and M. C. Neville (2007). "Key 
stages in mammary gland development. Secretory activation in the 
mammary gland: it's not just about milk protein synthesis!" Breast Cancer 
Res 9(1): 204. 
Arkoob, K., M. Al-Nsour, O. Al-Nemry and B. Al-Hajawi (2010). "Epidemiology of 
breast cancer in women in Jordan: patient characteristics and survival 
analysis." East Mediterr Health J 16(10): 1032-1038. 
Asselin-Labat, M. L., K. D. Sutherland, H. Barker, R. Thomas, M. Shackleton, N. 
C. Forrest, L. Hartley, L. Robb, F. G. Grosveld, J. van der Wees, G. J. 
Lindeman and J. E. Visvader (2007). "Gata-3 is an essential regulator of 
mammary-gland morphogenesis and luminal-cell differentiation." Nat Cell 
Biol 9(2): 201-209. 
178 
 
Asselin-Labat, M. L., F. Vaillant, M. Shackleton, T. Bouras, G. J. Lindeman and J. 
E. Visvader (2008). "Delineating the epithelial hierarchy in the mouse 
mammary gland." Cold Spring Harb Symp Quant Biol 73: 469-478. 
Asselin-Labat, M. L., F. Vaillant, J. M. Sheridan, B. Pal, D. Wu, E. R. Simpson, H. 
Yasuda, G. K. Smyth, T. J. Martin, G. J. Lindeman and J. E. Visvader 
(2010). "Control of mammary stem cell function by steroid hormone 
signalling." Nature 465(7299): 798-802. 
Aupperlee, M. D., J. R. Leipprandt, J. M. Bennett, R. C. Schwartz and S. Z. Haslam 
(2013). "Amphiregulin mediates progesterone-induced mammary ductal 
development during puberty." Breast Cancer Res 15(3): R44. 
Balinsky, B. I. (1950). "On the prenatal growth of the mammary gland rudiment in 
the mouse." J Anat 84(3): 227-235. 
Bao, J., K. D. Yu, Y. Z. Jiang, Z. M. Shao and G. H. Di (2014). "The effect of 
laterality and primary tumor site on cancer-specific mortality in breast 
cancer: a SEER population-based study." PLoS One 9(4): e94815. 
Baquero, M. T., J. A. Hanna, V. Neumeister, H. Cheng, A. M. Molinaro, L. N. Harris 
and D. L. Rimm (2012). "Stathmin expression and its relationship to 
microtubule-associated protein tau and outcome in breast cancer." Cancer 
118(19): 4660-4669. 
Barcus, C. E., P. J. Keely, K. W. Eliceiri and L. A. Schuler (2013). "Stiff collagen 
matrices increase tumorigenic prolactin signaling in breast cancer cells." J 
Biol Chem 288(18): 12722-12732. 
179 
 
Baselga, J. (2006). "Targeting tyrosine kinases in cancer: the second wave." 
Science 312(5777): 1175-1178. 
Baselga, J., D. Rischin, M. Ranson, H. Calvert, E. Raymond, D. G. Kieback, S. B. 
Kaye, L. Gianni, A. Harris, T. Bjork, S. D. Averbuch, A. Feyereislova, H. 
Swaisland, F. Rojo and J. Albanell (2002). "Phase I safety, 
pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral 
epidermal growth factor receptor tyrosine kinase inhibitor, in patients with 
five selected solid tumor types." J Clin Oncol 20(21): 4292-4302. 
Bern, H. A., K. T. Mills and L. A. Jones (1983). "Critical period for neonatal estrogen 
exposure in occurrence of mammary gland abnormalities in adult mice." 
Proc Soc Exp Biol Med 172(2): 239-242. 
Biro, F. M. and J. Deardorff (2013). "Identifying opportunities for cancer prevention 
during preadolescence and adolescence: puberty as a window of 
susceptibility." J Adolesc Health 52(5 Suppl): S15-20. 
Bizzarri, M., A. Giuliani, A. Cucina, F. D'Anselmi, A. M. Soto and C. Sonnenschein 
(2011). "Fractal analysis in a systems biology approach to cancer." Semin 
Cancer Biol 21(3): 175-182. 
Bodicoat, D. H., M. J. Schoemaker, M. E. Jones, E. McFadden, J. Griffin, A. 
Ashworth and A. J. Swerdlow (2014). "Timing of pubertal stages and breast 




Bonnette, S. G. and D. L. Hadsell (2001). "Targeted disruption of the IGF-I receptor 
gene decreases cellular proliferation in mammary terminal end buds." 
Endocrinology 142(11): 4937-4945. 
Booth, B. W., C. A. Boulanger and G. H. Smith (2008). "Selective segregation of 
DNA strands persists in long-label-retaining mammary cells during 
pregnancy." Breast Cancer Res 10(5): R90. 
Boras-Granic, K., P. Dann and J. J. Wysolmerski (2014). "Embryonic cells 
contribute directly to the quiescent stem cell population in the adult mouse 
mammary gland." Breast Cancer Res 16(6): 487. 
Borisenkov, M. F., Bazhenov, S. M. (2001). "Survival in Human Breast Cancer: 
Effects of Tumor Laterality and the Time of the Year of Surgery." Human 
Physiology 27(5): 631-634. 
Bouras, T., B. Pal, F. Vaillant, G. Harburg, M. L. Asselin-Labat, S. R. Oakes, G. J. 
Lindeman and J. E. Visvader (2008). "Notch signaling regulates mammary 
stem cell function and luminal cell-fate commitment." Cell Stem Cell 3(4): 
429-441. 
Braverman, B. and M. Tambasco (2013). "Scale-specific multifractal medical 
image analysis." Comput Math Methods Med 2013: 262931. 
Brend, T. and S. A. Holley (2009). "Balancing segmentation and laterality during 
vertebrate development." Semin Cell Dev Biol 20(4): 472-478. 
Brill, B., N. Boecher, B. Groner and C. S. Shemanko (2008). "A sparing procedure 
to clear the mouse mammary fat pad of epithelial components for 
transplantation analysis." Lab Anim 42(1): 104-110. 
181 
 
Brisken, C. (2002). "Hormonal control of alveolar development and its implications 
for breast carcinogenesis." J Mammary Gland Biol Neoplasia 7(1): 39-48. 
Brisken, C., S. Park, T. Vass, J. P. Lydon, B. W. O'Malley and R. A. Weinberg 
(1998). "A paracrine role for the epithelial progesterone receptor in 
mammary gland development." Proc Natl Acad Sci U S A 95(9): 5076-5081. 
Burris, H. A., 3rd, H. I. Hurwitz, E. C. Dees, A. Dowlati, K. L. Blackwell, B. O'Neil, 
P. K. Marcom, M. J. Ellis, B. Overmoyer, S. F. Jones, J. L. Harris, D. A. 
Smith, K. M. Koch, A. Stead, S. Mangum and N. L. Spector (2005). "Phase 
I safety, pharmacokinetics, and clinical activity study of lapatinib 
(GW572016), a reversible dual inhibitor of epidermal growth factor receptor 
tyrosine kinases, in heavily pretreated patients with metastatic carcinomas." 
J Clin Oncol 23(23): 5305-5313. 
Cardiff, R. D. and S. R. Wellings (1999). "The comparative pathology of human 
and mouse mammary glands." J Mammary Gland Biol Neoplasia 4(1): 105-
122. 
Carey, L. A., C. M. Perou, C. A. Livasy, L. G. Dressler, D. Cowan, K. Conway, G. 
Karaca, M. A. Troester, C. K. Tse, S. Edmiston, S. L. Deming, J. Geradts, 
M. C. Cheang, T. O. Nielsen, P. G. Moorman, H. S. Earp and R. C. Millikan 
(2006). "Race, breast cancer subtypes, and survival in the Carolina Breast 
Cancer Study." JAMA 295(21): 2492-2502. 
Carr, J. R., M. M. Kiefer, H. J. Park, J. Li, Z. Wang, J. Fontanarosa, D. DeWaal, D. 
Kopanja, E. V. Benevolenskaya, G. Guzman and P. Raychaudhuri (2012). 
"FoxM1 regulates mammary luminal cell fate." Cell Rep 1(6): 715-729. 
182 
 
Carr, J. R., H. J. Park, Z. Wang, M. M. Kiefer and P. Raychaudhuri (2010). "FoxM1 
mediates resistance to herceptin and paclitaxel." Cancer Res 70(12): 5054-
5063. 
Chakrabarti, R., Y. Wei, R. A. Romano, C. DeCoste, Y. Kang and S. Sinha (2012). 
"Elf5 regulates mammary gland stem/progenitor cell fate by influencing 
notch signaling." Stem Cells 30(7): 1496-1508. 
Chatsiproios, D. (2010). "Safety Profile and Clinical Recommendations for the Use 
of Lapatinib." Breast Care (Basel) 5(s1): 16-21. 
Chen, D., P. Bhat-Nakshatri, C. Goswami, S. Badve and H. Nakshatri (2013). 
"ANTXR1, a stem cell-enriched functional biomarker, connects collagen 
signaling to cancer stem-like cells and metastasis in breast cancer." Cancer 
Res 73(18): 5821-5833. 
Chintapalli, V. R., S. Terhzaz, J. Wang, M. Al Bratty, D. G. Watson, P. Herzyk, S. 
A. Davies and J. A. Dow (2012). "Functional correlates of positional and 
gender-specific renal asymmetry in Drosophila." PLoS One 7(4): e32577. 
Chiquet-Ehrismann, R., E. J. Mackie, C. A. Pearson and T. Sakakura (1986). 
"Tenascin: an extracellular matrix protein involved in tissue interactions 
during fetal development and oncogenesis." Cell 47(1): 131-139. 
Cho, K. W., H. J. Kwon, J. O. Shin, J. M. Lee, S. W. Cho, C. Tickle and H. S. Jung 
(2012). "Retinoic acid signaling and the initiation of mammary gland 
development." Dev Biol 365(1): 259-266. 
Chou, J., S. Provot and Z. Werb (2010). "GATA3 in development and cancer 
differentiation: cells GATA have it!" J Cell Physiol 222(1): 42-49. 
183 
 
Chu, E. Y., J. Hens, T. Andl, A. Kairo, T. P. Yamaguchi, C. Brisken, A. Glick, J. J. 
Wysolmerski and S. E. Millar (2004). "Canonical WNT signaling promotes 
mammary placode development and is essential for initiation of mammary 
gland morphogenesis." Development 131(19): 4819-4829. 
Cicalese, A., G. Bonizzi, C. E. Pasi, M. Faretta, S. Ronzoni, B. Giulini, C. Brisken, 
S. Minucci, P. P. Di Fiore and P. G. Pelicci (2009). "The tumor suppressor 
p53 regulates polarity of self-renewing divisions in mammary stem cells." 
Cell 138(6): 1083-1095. 
Clarke, R. B., E. Anderson, A. Howell and C. S. Potten (2003). "Regulation of 
human breast epithelial stem cells." Cell Prolif 36 Suppl 1: 45-58. 
Cohn, E., L. Ossowski, S. Bertran, C. Marzan and E. F. Farias (2010). "RARalpha1 
control of mammary gland ductal morphogenesis and wnt1-tumorigenesis." 
Breast Cancer Res 12(5): R79. 
Colby, D. R. and J. G. Vandenberg (1974). "Regulatory effects of urinary 
pheromones on puberty in the mouse." Biol Reprod 11(3): 268-279. 
Cross, S. S. (1997). "Fractals in pathology." J Pathol 182(1): 1-8. 
Cross, S. S., J. P. Bury, T. J. Stephenson and R. F. Harrison (1997). "Image 
analysis of low magnification images of fine needle aspirates of the breast 
produces useful discrimination between benign and malignant cases." 
Cytopathology 8(4): 265-273. 
D'Cruz, C. M., S. E. Moody, S. R. Master, J. L. Hartman, E. A. Keiper, M. B. 
Imielinski, J. D. Cox, J. Y. Wang, S. I. Ha, B. A. Keister and L. A. Chodosh 
(2002). "Persistent parity-induced changes in growth factors, TGF-beta3, 
184 
 
and differentiation in the rodent mammary gland." Mol Endocrinol 16(9): 
2034-2051. 
Daniel, C. W., G. B. Silberstein and P. Strickland (1987). "Direct action of 17 beta-
estradiol on mouse mammary ducts analyzed by sustained release implants 
and steroid autoradiography." Cancer Res 47(22): 6052-6057. 
DasGupta, R. and E. Fuchs (1999). "Multiple roles for activated LEF/TCF 
transcription complexes during hair follicle development and differentiation." 
Development 126(20): 4557-4568. 
Davenport, T. G., L. A. Jerome-Majewska and V. E. Papaioannou (2003). 
"Mammary gland, limb and yolk sac defects in mice lacking Tbx3, the gene 
mutated in human ulnar mammary syndrome." Development 130(10): 2263-
2273. 
Daye, D., B. Keller, E. F. Conant, J. Chen, M. D. Schnall, A. D. Maidment and D. 
Kontos (2013). "Mammographic parenchymal patterns as an imaging 
marker of endogenous hormonal exposure: a preliminary study in a high-
risk population." Acad Radiol 20(5): 635-646. 
de Assis, S., A. Warri, M. I. Cruz and L. Hilakivi-Clarke (2010). "Changes in 
mammary gland morphology and breast cancer risk in rats." J Vis Exp(44). 
Delahunt, B., P. Bethwaite and J. N. Nacey (1994). "Renal cell carcinoma in New 
Zealand: a national survival study." Urology 43(3): 300-309. 
Desmedt, C., F. Piette, S. Loi, Y. Wang, F. Lallemand, B. Haibe-Kains, G. Viale, 
M. Delorenzi, Y. Zhang, M. S. d'Assignies, J. Bergh, R. Lidereau, P. Ellis, 
A. L. Harris, J. G. Klijn, J. A. Foekens, F. Cardoso, M. J. Piccart, M. Buyse 
185 
 
and C. Sotiriou (2007). "Strong time dependence of the 76-gene prognostic 
signature for node-negative breast cancer patients in the TRANSBIG 
multicenter independent validation series." Clin Cancer Res 13(11): 3207-
3214. 
Dey, P. and S. K. Mohanty (2003). "Fractal dimensions of breast lesions on 
cytology smears." Diagn Cytopathol 29(2): 85-86. 
Di Giovanni, P., T. S. Ahearn, S. I. Semple, L. M. Lovell, I. Miller, F. J. Gilbert, T. 
W. Redpath, S. D. Heys and R. T. Staff (2012). "The biological correlates of 
macroscopic breast tumour structure measured using fractal analysis in 
patients undergoing neoadjuvant chemotherapy." Breast Cancer Res Treat 
133(3): 1199-1206. 
di Masi, A., L. Leboffe, E. De Marinis, F. Pagano, L. Cicconi, C. Rochette-Egly, F. 
Lo Coco, P. Ascenzi and C. Nervi (2014). "Retinoic acid receptors and 
cancer: From molecular mechanisms to therapy." Mol Aspects Med. 
Diaz-Guerra, E., M. A. Lillo, S. Santamaria and J. A. Garcia-Sanz (2012). "Intrinsic 
cues and hormones control mouse mammary epithelial tree size." FASEB 
J 26(9): 3844-3853. 
DiPaolo, D. and L. A. Jones (2000). "Neonatal estradiol exposure alters mouse 
mammary estrogen receptor alpha expression." Int J Oncol 16(5): 935-941. 
Dontu, G., M. Al-Hajj, W. M. Abdallah, M. F. Clarke and M. S. Wicha (2003). "Stem 




Dontu, G., D. El-Ashry and M. S. Wicha (2004). "Breast cancer, stem/progenitor 
cells and the estrogen receptor." Trends Endocrinol Metab 15(5): 193-197. 
dos Santos, C. O., C. Rebbeck, E. Rozhkova, A. Valentine, A. Samuels, L. R. 
Kadiri, P. Osten, E. Y. Harris, P. J. Uren, A. D. Smith and G. J. Hannon 
(2013). "Molecular hierarchy of mammary differentiation yields refined 
markers of mammary stem cells." Proc Natl Acad Sci U S A 110(18): 7123-
7130. 
Durnberger, H. and K. Kratochwil (1980). "Specificity of tissue interaction and 
origin of mesenchymal cells in the androgen response of the embryonic 
mammary gland." Cell 19(2): 465-471. 
Eblaghie, M. C., S. J. Song, J. Y. Kim, K. Akita, C. Tickle and H. S. Jung (2004). 
"Interactions between FGF and Wnt signals and Tbx3 gene expression in 
mammary gland initiation in mouse embryos." J Anat 205(1): 1-13. 
Eccles, S. A. (2011). "The epidermal growth factor receptor/Erb-B/HER family in 
normal and malignant breast biology." Int J Dev Biol 55(7-9): 685-696. 
Engstrom, J. L., P. P. Meier, B. Jegier, J. E. Motykowski and J. L. Zuleger (2007). 
"Comparison of milk output from the right and left breasts during 
simultaneous pumping in mothers of very low birthweight infants." 
Breastfeed Med 2(2): 83-91. 
Eroles, P., A. Bosch, J. A. Perez-Fidalgo and A. Lluch (2012). "Molecular biology 
in breast cancer: intrinsic subtypes and signaling pathways." Cancer Treat 
Rev 38(6): 698-707. 
187 
 
Farnie, G. and R. B. Clarke (2007). "Mammary stem cells and breast cancer--role 
of Notch signalling." Stem Cell Rev 3(2): 169-175. 
Fata, J. E., Z. Werb and M. J. Bissell (2004). "Regulation of mammary gland 
branching morphogenesis by the extracellular matrix and its remodeling 
enzymes." Breast Cancer Res 6(1): 1-11. 
Fatima, N., M. U. Zaman, A. Maqbool, S. H. Khan and N. Riaz (2013). "Lower 
incidence but more aggressive behavior of right sided breast cancer in 
Pakistani women: does right deserve more respect?" Asian Pac J Cancer 
Prev 14(1): 43-45. 
Feigelson, H. S. and B. E. Henderson (1996). "Estrogens and breast cancer." 
Carcinogenesis 17(11): 2279-2284. 
Feng, Y., D. Manka, K. U. Wagner and S. A. Khan (2007). "Estrogen receptor-
alpha expression in the mammary epithelium is required for ductal and 
alveolar morphogenesis in mice." Proc Natl Acad Sci U S A 104(37): 14718-
14723. 
Fenton, S. E. (2006). "Endocrine-disrupting compounds and mammary gland 
development: early exposure and later life consequences." Endocrinology 
147(6 Suppl): S18-24. 
Fenton, S. E. (2006). "Endocrine-Disrupting Compounds and Mammary Gland 
Development: Early Exposure and Later Life Consequences." 
Endocrinology 147(6): s18-24. 
188 
 
Fenton, S. E., C. Reed and R. R. Newbold (2012). "Perinatal environmental 
exposures affect mammary development, function, and cancer risk in 
adulthood." Annu Rev Pharmacol Toxicol 52: 455-479. 
Fernandez, E. and H. F. Jelinek (2001). "Use of fractal theory in neuroscience: 
methods, advantages, and potential problems." Methods 24(4): 309-321. 
Fillmore, C. M., P. B. Gupta, J. A. Rudnick, S. Caballero, P. J. Keller, E. S. Lander 
and C. Kuperwasser (2010). "Estrogen expands breast cancer stem-like 
cells through paracrine FGF/Tbx3 signaling." Proc Natl Acad Sci U S A 
107(50): 21737-21742. 
Fisher, B., J. P. Costantino, D. L. Wickerham, C. K. Redmond, M. Kavanah, W. M. 
Cronin, V. Vogel, A. Robidoux, N. Dimitrov, J. Atkins, M. Daly, S. Wieand, 
E. Tan-Chiu, L. Ford and N. Wolmark (1998). "Tamoxifen for prevention of 
breast cancer: report of the National Surgical Adjuvant Breast and Bowel 
Project P-1 Study." J Natl Cancer Inst 90(18): 1371-1388. 
Fuseler, J. W., D. M. Merrill, J. A. Rogers, M. B. Grisham and R. E. Wolf (2006). 
"Analysis and quantitation of NF-kappaB nuclear translocation in tumor 
necrosis factor alpha (TNF-alpha) activated vascular endothelial cells." 
Microsc Microanal 12(3): 269-276. 
Fuseler, J. W., C. F. Millette, J. M. Davis and W. Carver (2007). "Fractal and image 
analysis of morphological changes in the actin cytoskeleton of neonatal 




Fuseler, J. W., J. P. Robichaux, H. I. Atiyah and A. F. Ramsdell (2014). 
"Morphometric and fractal dimension analysis identifies early neoplastic 
changes in mammary epithelium of MMTV-cNeu mice." Anticancer Res 
34(3): 1171-1177. 
Fuseler, J. W., J. P. Robichaux, H. I. Atiyah and A. F. Ramsdell (2014). 
"Morphometric and fractal dimension analysis identifies early neoplastic 
changes in mammary epithelium of MMTV-cNeu mice." Anticancer Res. 
34(3): 1171-1177. 
Fuseler, J. W. and M. T. Valarmathi (2012). "Modulation of the migration and 
differentiation potential of adult bone marrow stromal stem cells by nitric 
oxide." Biomaterials 33(4): 1032-1043. 
Gilbert, S. (2000). Paraxial Mesoderm: The somites and their derivatives. 
Sunderland, MA, Sinauer Associates. 
Golding, J. P., T. A. Partridge, J. R. Beauchamp, T. King, N. A. Brown, M. 
Gassmann and P. S. Zammit (2004). "Mouse myotomes pairs exhibit left-
right asymmetric expression of MLC3F and alpha-skeletal actin." Dev Dyn 
231(4): 795-800. 
Golding, J. P., S. Tsoni, M. Dixon, K. T. Yee, T. A. Partridge, J. R. Beauchamp, M. 
Gassmann and P. S. Zammit (2004). "Heparin-binding EGF-like growth 
factor shows transient left-right asymmetrical expression in mouse 
myotome pairs." Gene Expr Patterns 5(1): 3-9. 
Greene RR, B. M., Ivy AC (1940). "The effects of estrogens on the antenatal 
development of the rat." American Journal of Anatomy 67: 305-345. 
190 
 
Grizzi, F., C. Russo, P. Colombo, B. Franceschini, E. E. Frezza, E. Cobos and M. 
Chiriva-Internati (2005). "Quantitative evaluation and modeling of two-
dimensional neovascular network complexity: the surface fractal 
dimension." BMC Cancer 5: 14. 
Group, U. S. C. S. W. (2013). "United States Cancer Statistics: 199-2009 Incidence 
and Mortality Web-based Report." from Available at: www.cdc.gov/uscs. 
Guo, W., Z. Keckesova, J. L. Donaher, T. Shibue, V. Tischler, F. Reinhardt, S. 
Itzkovitz, A. Noske, U. Zurrer-Hardi, G. Bell, W. L. Tam, S. A. Mani, A. van 
Oudenaarden and R. A. Weinberg (2012). "Slug and Sox9 cooperatively 
determine the mammary stem cell state." Cell 148(5): 1015-1028. 
Guy, C. T., M. A. Webster, M. Schaller, T. J. Parsons, R. D. Cardiff and W. J. Muller 
(1992). "Expression of the neu protooncogene in the mammary epithelium 
of transgenic mice induces metastatic disease." Proc Natl Acad Sci U S A 
89(22): 10578-10582. 
Hallett, R. M., A. Dvorkin-Gheva, A. Bane and J. A. Hassell (2012). "A gene 
signature for predicting outcome in patients with basal-like breast cancer." 
Sci Rep 2: 227. 
Hallett, R. M., G. Pond and J. A. Hassell (2012). "A target based approach 
identifies genomic predictors of breast cancer patient response to 
chemotherapy." BMC Med Genomics 5: 16. 
Han, Z. X., H. M. Wang, G. Jiang, X. P. Du, X. Y. Gao and D. S. Pei (2013). 
"Overcoming Paclitaxel Resistance in Lung Cancer Cells Via Dual Inhibition 
of Stathmin and Bcl-2." Cancer Biother Radiopharm. 
191 
 
Hartveit, F., M. Tangen and E. Hartveit (1984). "Side and survival in breast cancer." 
Oncology 41(3): 149-154. 
Hatzis, C., L. Pusztai, V. Valero, D. J. Booser, L. Esserman, A. Lluch, T. Vidaurre, 
F. Holmes, E. Souchon, H. Wang, M. Martin, J. Cotrina, H. Gomez, R. 
Hubbard, J. I. Chacon, J. Ferrer-Lozano, R. Dyer, M. Buxton, Y. Gong, Y. 
Wu, N. Ibrahim, E. Andreopoulou, N. T. Ueno, K. Hunt, W. Yang, A. Nazario, 
A. DeMichele, J. O'Shaughnessy, G. N. Hortobagyi and W. F. Symmans "A 
genomic predictor of response and survival following taxane-anthracycline 
chemotherapy for invasive breast cancer." JAMA 305(18): 1873-1881. 
Hens, J. R. and J. J. Wysolmerski (2005). "Key stages of mammary gland 
development: molecular mechanisms involved in the formation of the 
embryonic mammary gland." Breast Cancer Res 7(5): 220-224. 
Heuberger, B., I. Fitzka, G. Wasner and K. Kratochwil (1982). "Induction of 
androgen receptor formation by epithelium-mesenchyme interaction in 
embryonic mouse mammary gland." Proc Natl Acad Sci U S A 79(9): 2957-
2961. 
Hilakivi-Clarke, L., E. Cho, M. Raygada and N. Kenney (1997). "Alterations in 
mammary gland development following neonatal exposure to estradiol, 
transforming growth factor alpha, and estrogen receptor antagonist ICI 
182,780." J Cell Physiol 170(3): 279-289. 
Hilakivi-Clarke, L., I. Onojafe, M. Raygada, E. Cho, R. Clarke and M. E. Lippman 
(1996). "Breast cancer risk in rats fed a diet high in n-6 polyunsaturated fatty 
acids during pregnancy." J Natl Cancer Inst 88(24): 1821-1827. 
192 
 
Howard, B. A. (2012). "In the beginning: the establishment of the mammary lineage 
during embryogenesis." Semin Cell Dev Biol 23(5): 574-582. 
Howard, B. A. and B. A. Gusterson (2000). "Human breast development." J 
Mammary Gland Biol Neoplasia 5(2): 119-137. 
Hutchinson, J. N. and W. J. Muller (2000). "Transgenic mouse models of human 
breast cancer." Oncogene 19(53): 6130-6137. 
Inaguma, Y., M. Kusakabe, E. J. Mackie, C. A. Pearson, R. Chiquet-Ehrismann 
and T. Sakakura (1988). "Epithelial induction of stromal tenascin in the 
mouse mammary gland: from embryogenesis to carcinogenesis." Dev Biol 
128(2): 245-255. 
Incassati, A., A. Chandramouli, R. Eelkema and P. Cowin (2010). "Key signaling 
nodes in mammary gland development and cancer: beta-catenin." Breast 
Cancer Res 12(6): 213. 
Irizarry, R. A., B. Hobbs, F. Collin, Y. D. Beazer-Barclay, K. J. Antonellis, U. Scherf 
and T. P. Speed (2003). "Exploration, normalization, and summaries of high 
density oligonucleotide array probe level data." Biostatistics 4(2): 249-264. 
Ishimaru, Y., T. Komatsu, M. Kasahara, Y. Katoh-Fukui, H. Ogawa, Y. Toyama, M. 
Maekawa, K. Toshimori, R. A. Chandraratna, K. Morohashi and H. Yoshioka 
(2008). "Mechanism of asymmetric ovarian development in chick embryos." 
Development 135(4): 677-685. 
Ithimakin, S., K. C. Day, F. Malik, Q. Zen, S. J. Dawsey, T. F. Bersano-Begey, A. 
A. Quraishi, K. W. Ignatoski, S. Daignault, A. Davis, C. L. Hall, N. 
Palanisamy, A. N. Heath, N. Tawakkol, T. K. Luther, S. G. Clouthier, W. A. 
193 
 
Chadwick, M. L. Day, C. G. Kleer, D. G. Thomas, D. F. Hayes, H. Korkaya 
and M. S. Wicha (2013). "HER2 drives luminal breast cancer stem cells in 
the absence of HER2 amplification: implications for efficacy of adjuvant 
trastuzumab." Cancer Res 73(5): 1635-1646. 
Ivshina, A. V., J. George, O. Senko, B. Mow, T. C. Putti, J. Smeds, T. Lindahl, Y. 
Pawitan, P. Hall, H. Nordgren, J. E. Wong, E. T. Liu, J. Bergh, V. A. 
Kuznetsov and L. D. Miller (2006). "Genetic reclassification of histologic 
grade delineates new clinical subtypes of breast cancer." Cancer Res 
66(21): 10292-10301. 
Jean, C. (1971). "[Analysis of mammary deformities in the newborn induced by the 
injection of estrogens into the pregnant mother, in the rat and mouse]." Arch 
Anat Microsc Morphol Exp 60(2): 147-168. 
Jean, C. (1971). "[Postnatal mammary development of mice born of mothers 
treated with estradiol during pregnancy. Study at puberty and adult age 
under various experimental and physiological conditions]." Arch Sci Physiol 
(Paris) 25(2): 145-185. 
Joshi, P. A., H. W. Jackson, A. G. Beristain, M. A. Di Grappa, P. A. Mote, C. L. 
Clarke, J. Stingl, P. D. Waterhouse and R. Khokha (2010). "Progesterone 
induces adult mammary stem cell expansion." Nature 465(7299): 803-807. 
Kawakami, Y., A. Raya, R. M. Raya, C. Rodriguez-Esteban and J. C. Izpisua 
Belmonte (2005). "Retinoic acid signalling links left-right asymmetric 
patterning and bilaterally symmetric somitogenesis in the zebrafish 
embryo." Nature 435(7039): 165-171. 
194 
 
Kenney, N. J., G. H. Smith, E. Lawrence, J. C. Barrett and D. S. Salomon (2001). 
"Identification of Stem Cell Units in the Terminal End Bud and Duct of the 
Mouse Mammary Gland." J Biomed Biotechnol 1(3): 133-143. 
Kessenbrock, K., G. J. Dijkgraaf, D. A. Lawson, L. E. Littlepage, P. Shahi, U. Pieper 
and Z. Werb (2013). "A role for matrix metalloproteinases in regulating 
mammary stem cell function via the Wnt signaling pathway." Cell Stem Cell 
13(3): 300-313. 
Kontos, D., L. C. Ikejimba, P. R. Bakic, A. B. Troxel, E. F. Conant and A. D. 
Maidment (2011). "Analysis of parenchymal texture with digital breast 
tomosynthesis: comparison with digital mammography and implications for 
cancer risk assessment." Radiology 261(1): 80-91. 
Korkaya, H., A. Paulson, F. Iovino and M. S. Wicha (2008). "HER2 regulates the 
mammary stem/progenitor cell population driving tumorigenesis and 
invasion." Oncogene 27(47): 6120-6130. 
Korkaya, H. and M. S. Wicha (2013). "HER2 and breast cancer stem cells: more 
than meets the eye." Cancer Res 73(12): 3489-3493. 
Kouros-Mehr, H., E. M. Slorach, M. D. Sternlicht and Z. Werb (2006). "GATA-3 
maintains the differentiation of the luminal cell fate in the mammary gland." 
Cell 127(5): 1041-1055. 
Kratochwil, K. (1969). "Organ specificity in mesenchymal induction demonstrated 
in the embryonic development of the mammary gland of the mouse." Dev 
Biol 20(1): 46-71. 
195 
 
Kratochwil, K. (1977). "Development and loss of androgen responsiveness in the 
embryonic rudiment of the mouse mammary gland." Dev Biol 61(2): 358-
365. 
Kwok, J. M., B. Peck, L. J. Monteiro, H. D. Schwenen, J. Millour, R. C. Coombes, 
S. S. Myatt and E. W. Lam (2010). "FOXM1 confers acquired cisplatin 
resistance in breast cancer cells." Mol Cancer Res 8(1): 24-34. 
Laughney, A. M., V. Krishnaswamy, E. J. Rizzo, M. C. Schwab, R. J. Barth, B. W. 
Pogue, K. D. Paulsen and W. A. Wells (2012). "Scatter spectroscopic 
imaging distinguishes between breast pathologies in tissues relevant to 
surgical margin assessment." Clin Cancer Res 18(22): 6315-6325. 
Lee, A. V., P. Zhang, M. Ivanova, S. Bonnette, S. Oesterreich, J. M. Rosen, S. 
Grimm, R. C. Hovey, B. K. Vonderhaar, C. R. Kahn, D. Torres, J. George, 
S. Mohsin, D. C. Allred and D. L. Hadsell (2003). "Developmental and 
hormonal signals dramatically alter the localization and abundance of 
insulin receptor substrate proteins in the mammary gland." Endocrinology 
144(6): 2683-2694. 
Lee, H. J., D. Gallego-Ortega, A. Ledger, D. Schramek, P. Joshi, M. M. Szwarc, 
C. Cho, J. P. Lydon, R. Khokha, J. M. Penninger and C. J. Ormandy (2013). 
"Progesterone drives mammary secretory differentiation via RankL-
mediated induction of Elf5 in luminal progenitor cells." Development 140(7): 
1397-1401. 
Levin, M. (2005). "Left-right asymmetry in embryonic development: a 
comprehensive review." Mech Dev 122(1): 3-25. 
196 
 
Li, M., X. Liu, G. Robinson, U. Bar-Peled, K. U. Wagner, W. S. Young, L. 
Hennighausen and P. A. Furth (1997). "Mammary-derived signals activate 
programmed cell death during the first stage of mammary gland involution." 
Proc Natl Acad Sci U S A 94(7): 3425-3430. 
Lim, E., F. Vaillant, D. Wu, N. C. Forrest, B. Pal, A. H. Hart, M. L. Asselin-Labat, 
D. E. Gyorki, T. Ward, A. Partanen, F. Feleppa, L. I. Huschtscha, H. J. 
Thorne, kConFab, S. B. Fox, M. Yan, J. D. French, M. A. Brown, G. K. 
Smyth, J. E. Visvader and G. J. Lindeman (2009). "Aberrant luminal 
progenitors as the candidate target population for basal tumor development 
in BRCA1 mutation carriers." Nat Med 15(8): 907-913. 
Lindsay, J., X. Jiao, T. Sakamaki, M. C. Casimiro, L. A. Shirley, T. H. Tran, X. Ju, 
M. Liu, Z. Li, C. Wang, S. Katiyar, M. Rao, K. G. Allen, R. I. Glazer, C. Ge, 
P. Stanley, M. P. Lisanti, H. Rui and R. G. Pestell (2008). "ErbB2 induces 
Notch1 activity and function in breast cancer cells." Clin Transl Sci 1(2): 
107-115. 
Lippman, M. E., K. A. Krueger, S. Eckert, A. Sashegyi, E. L. Walls, S. Jamal, J. A. 
Cauley and S. R. Cummings (2001). "Indicators of lifetime estrogen 
exposure: effect on breast cancer incidence and interaction with raloxifene 
therapy in the multiple outcomes of raloxifene evaluation study 
participants." J Clin Oncol 19(12): 3111-3116. 
Liu, X., G. W. Robinson, K. U. Wagner, L. Garrett, A. Wynshaw-Boris and L. 
Hennighausen (1997). "Stat5a is mandatory for adult mammary gland 
development and lactogenesis." Genes Dev 11(2): 179-186. 
197 
 
Lonning, P. E. (2007). "Breast cancer prognostication and prediction: are we 
making progress?" Ann Oncol 18 Suppl 8: viii3-7. 
Lopez, J., L. Ogren, R. Verjan and F. Talamantes (1988). "Effects of perinatal 
exposure to a synthetic estrogen and progestin on mammary tumorigenesis 
in mice." Teratology 38(2): 129-134. 
Losa, G. A. and T. F. Nonnenmacher (1996). "Self-similarity and fractal irregularity 
in pathologic tissues." Mod Pathol 9(3): 174-182. 
Lu, P., M. D. Sternlicht and Z. Werb (2006). "Comparative mechanisms of 
branching morphogenesis in diverse systems." J Mammary Gland Biol 
Neoplasia 11(3-4): 213-228. 
Lu, P. and Z. Werb (2008). "Patterning mechanisms of branched organs." Science 
322(5907): 1506-1509. 
Lydon, J. P. (2010). "Stem cells: Cues from steroid hormones." Nature 465(7299): 
695-696. 
Lydon, J. P., F. J. DeMayo, C. R. Funk, S. K. Mani, A. R. Hughes, C. A. 
Montgomery, Jr., G. Shyamala, O. M. Conneely and B. W. O'Malley (1995). 
"Mice lacking progesterone receptor exhibit pleiotropic reproductive 
abnormalities." Genes Dev 9(18): 2266-2278. 
Mailleux, A. A., B. Spencer-Dene, C. Dillon, D. Ndiaye, C. Savona-Baron, N. Itoh, 
S. Kato, C. Dickson, J. P. Thiery and S. Bellusci (2002). "Role of 
FGF10/FGFR2b signaling during mammary gland development in the 
mouse embryo." Development 129(1): 53-60. 
198 
 
Makarem, M., N. Kannan, L. V. Nguyen, D. J. Knapp, S. Balani, M. D. Prater, J. 
Stingl, A. Raouf, O. Nemirovsky, P. Eirew and C. J. Eaves (2013). 
"Developmental changes in the in vitro activated regenerative activity of 
primitive mammary epithelial cells." PLoS Biol 11(8): e1001630. 
Makarem, M., B. T. Spike, C. Dravis, N. Kannan, G. M. Wahl and C. J. Eaves 
(2013). "Stem cells and the developing mammary gland." J Mammary Gland 
Biol Neoplasia 18(2): 209-219. 
Mark, M., N. B. Ghyselinck and P. Chambon (2009). "Function of retinoic acid 
receptors during embryonic development." Nucl Recept Signal 7: e002. 
Markey, C. M., E. H. Luque, M. Munoz De Toro, C. Sonnenschein and A. M. Soto 
(2001). "In utero exposure to bisphenol A alters the development and tissue 
organization of the mouse mammary gland." Biol Reprod 65(4): 1215-1223. 
Marti, A., Z. Feng, H. J. Altermatt and R. Jaggi (1997). "Milk accumulation triggers 
apoptosis of mammary epithelial cells." Eur J Cell Biol 73(2): 158-165. 
McDermott, S. P. and M. S. Wicha (2010). "Breast tumors: of mice and women." 
Breast Cancer Res 12(3): 108. 
Meier-Abt, F., E. Milani, T. Roloff, H. Brinkhaus, S. Duss, D. S. Meyer, I. Klebba, 
P. J. Balwierz, E. van Nimwegen and M. Bentires-Alj (2013). "Parity induces 
differentiation and reduces Wnt/Notch signaling ratio and proliferation 
potential of basal stem/progenitor cells isolated from mouse mammary 
epithelium." Breast Cancer Res 15(2): R36. 
Mendes-Pereira, A. M., D. Sims, T. Dexter, K. Fenwick, I. Assiotis, I. Kozarewa, C. 
Mitsopoulos, J. Hakas, M. Zvelebil, C. J. Lord and A. Ashworth (2012). 
199 
 
"Genome-wide functional screen identifies a compendium of genes 
affecting sensitivity to tamoxifen." Proc Natl Acad Sci U S A 109(8): 2730-
2735. 
Meng, X. L., D. Su, L. Wang, Y. Gao, Y. J. Hu, H. J. Yang and S. N. Xie (2012). 
"Low expression of stathmin in tumor predicts high response to neoadjuvant 
chemotherapy with docetaxel-containing regimens in locally advanced 
breast cancer." Genet Test Mol Biomarkers 16(7): 689-694. 
Miceli, C., A. Tejada, A. Castaneda and S. J. Mistry (2013). "Cell cycle inhibition 
therapy that targets stathmin in in vitro and in vivo models of breast cancer." 
Cancer Gene Ther. 
Miller, L. D., J. Smeds, J. George, V. B. Vega, L. Vergara, A. Ploner, Y. Pawitan, 
P. Hall, S. Klaar, E. T. Liu and J. Bergh (2005). "An expression signature 
for p53 status in human breast cancer predicts mutation status, 
transcriptional effects, and patient survival." Proc Natl Acad Sci U S A 
102(38): 13550-13555. 
Millour, J., D. Constantinidou, A. V. Stavropoulou, M. S. Wilson, S. S. Myatt, J. M. 
Kwok, K. Sivanandan, R. C. Coombes, R. H. Medema, J. Hartman, A. E. 
Lykkesfeldt and E. W. Lam (2010). "FOXM1 is a transcriptional target of 
ERalpha and has a critical role in breast cancer endocrine sensitivity and 
resistance." Oncogene 29(20): 2983-2995. 
Molyneux, G., F. C. Geyer, F. A. Magnay, A. McCarthy, H. Kendrick, R. Natrajan, 
A. Mackay, A. Grigoriadis, A. Tutt, A. Ashworth, J. S. Reis-Filho and M. J. 
Smalley (2010). "BRCA1 basal-like breast cancers originate from luminal 
200 
 
epithelial progenitors and not from basal stem cells." Cell Stem Cell 7(3): 
403-417. 
Monks, J., D. Rosner, F. J. Geske, L. Lehman, L. Hanson, M. C. Neville and V. A. 
Fadok (2005). "Epithelial cells as phagocytes: apoptotic epithelial cells are 
engulfed by mammary alveolar epithelial cells and repress inflammatory 
mediator release." Cell Death Differ 12(2): 107-114. 
Mori, T., H. A. Bern, K. T. Mills and P. N. Young (1976). "Long-term effects of 
neonatal steroid exposure on mammary gland development and 
tumorigenesis in mice." J Natl Cancer Inst 57(5): 1057-1062. 
Mukherjee, S., S. G. Louie, M. Campbell, L. Esserman and G. Shyamala (2000). 
"Ductal growth is impeded in mammary glands of C-neu transgenic mice." 
Oncogene 19(52): 5982-5987. 
Muller, W. J., C. L. Arteaga, S. K. Muthuswamy, P. M. Siegel, M. A. Webster, R. 
D. Cardiff, K. S. Meise, F. Li, S. A. Halter and R. J. Coffey (1996). 
"Synergistic interaction of the Neu proto-oncogene product and 
transforming growth factor alpha in the mammary epithelium of transgenic 
mice." Mol Cell Biol 16(10): 5726-5736. 
Nakamura, T. and H. Hamada (2012). "Left-right patterning: conserved and 
divergent mechanisms." Development 139(18): 3257-3262. 
National Institutes of Health. (2002, April 28, 2002). "Stem Cell Basics: 




Nautiyal, J., J. H. Steel, M. R. Mane, O. Oduwole, A. Poliandri, X. Alexi, N. Wood, 
M. Poutanen, W. Zwart, J. Stingl and M. G. Parker (2013). "The 
transcriptional co-factor RIP140 regulates mammary gland development by 
promoting the generation of key mitogenic signals." Development 140(5): 
1079-1089. 
Nezadal, M., O. Zemeskal and M. Buchnicek (2001). The box-counting: critical 
study, 4th conference on prediction, synergetic and more…. The Faculty of 
Management, Institute of Information Technologies, Faculty of Technology, 
Tomas Bata University in Zlin. 
Ngan, E. S., Z. Q. Ma, S. S. Chua, F. J. DeMayo and S. Y. Tsai (2002). "Inducible 
expression of FGF-3 in mouse mammary gland." Proc Natl Acad Sci U S A 
99(17): 11187-11192. 
Nyirenda, N., D. L. Farkas and V. K. Ramanujan (2011). "Preclinical evaluation of 
nuclear morphometry and tissue topology for breast carcinoma detection 
and margin assessment." Breast Cancer Res Treat 126(2): 345-354. 
Oakes, S. R., H. N. Hilton and C. J. Ormandy (2006). "The alveolar switch: 
coordinating the proliferative cues and cell fate decisions that drive the 
formation of lobuloalveoli from ductal epithelium." Breast Cancer Res 8(2): 
207. 
Oakes, S. R., M. J. Naylor, M. L. Asselin-Labat, K. D. Blazek, M. Gardiner-Garden, 
H. N. Hilton, M. Kazlauskas, M. A. Pritchard, L. A. Chodosh, P. L. Pfeffer, 
G. J. Lindeman, J. E. Visvader and C. J. Ormandy (2008). "The Ets 
202 
 
transcription factor Elf5 specifies mammary alveolar cell fate." Genes Dev 
22(5): 581-586. 
Okasha, M., P. McCarron, D. Gunnell and G. D. Smith (2003). "Exposures in 
childhood, adolescence and early adulthood and breast cancer risk: a 
systematic review of the literature." Breast Cancer Res Treat 78(2): 223-
276. 
Olayioye, M. A., R. M. Neve, H. A. Lane and N. E. Hynes (2000). "The ErbB 
signaling network: receptor heterodimerization in development and cancer." 
EMBO J 19(13): 3159-3167. 
Park, J. P., A. Raafat, J. A. Feltracco, W. M. Blanding and B. W. Booth (2013). 
"Differential gene expression in nuclear label-retaining cells in the 
developing mouse mammary gland." Stem Cells Dev 22(8): 1297-1306. 
Patterson, K. D., T. A. Drysdale and P. A. Krieg (2000). "Embryonic origins of 
spleen asymmetry." Development 127(1): 167-175. 
Perkins, C. I., J. Hotes, B. A. Kohler and H. L. Howe (2004). "Association between 
breast cancer laterality and tumor location, United States, 1994-1998." 
Cancer Causes Control 15(7): 637-645. 
Persson, I. (2000). "Estrogens in the causation of breast, endometrial and ovarian 
cancers - evidence and hypotheses from epidemiological findings." J 
Steroid Biochem Mol Biol 74(5): 357-364. 
Pfefferle, A. D., B. T. Spike, G. M. Wahl and C. M. Perou (2015). "Luminal 
progenitor and fetal mammary stem cell expression features predict breast 
203 
 
tumor response to neoadjuvant chemotherapy." Breast Cancer Res Treat 
149(2): 425-437. 
Polyak, K. and R. Kalluri (2010). "The role of the microenvironment in mammary 
gland development and cancer." Cold Spring Harb Perspect Biol 2(11): 
a003244. 
Prat, A. and C. M. Perou (2009). "Mammary development meets cancer 
genomics." Nat Med 15(8): 842-844. 
Propper, A. and L. Gomot (1967). "[Tissue interactions during organogenesis of 
the mammary gland in the rabbit embryo]." C R Acad Sci Hebd Seances 
Acad Sci D 264(22): 2573-2575. 
Propper, A. Y. (1978). "Wandering epithelial cells in the rabbit embryo milk line. A 
preliminary scanning electron microscope study." Dev Biol 67(1): 225-231. 
Raguso, G., A. Ancona, L. Chieppa, S. L'Abbate, M. L. Pepe, F. Mangieri, M. De 
Palo and R. M. Rangayyan (2010). "Application of fractal analysis to 
mammography." Conf Proc IEEE Eng Med Biol Soc 2010: 3182-3185. 
Rangayyan, R. M., S. Banik and J. E. Desautels (2010). "Computer-aided 
detection of architectural distortion in prior mammograms of interval 
cancer." J Digit Imaging 23(5): 611-631. 
Rangayyan, R. M., S. Banik and J. E. Desautels (2013). "Detection of architectural 




Rashidnasab, A., P. Elangovan, M. Yip, O. Diaz, D. R. Dance, K. C. Young and K. 
Wells (2013). "Simulation and assessment of realistic breast lesions using 
fractal growth models." Phys Med Biol 58(16): 5613-5627. 
Raya, A. and J. C. Izpisua Belmonte (2006). "Left-right asymmetry in the vertebrate 
embryo: from early information to higher-level integration." Nat Rev Genet 
7(4): 283-293. 
Regan, J. L., H. Kendrick, F. A. Magnay, V. Vafaizadeh, B. Groner and M. J. 
Smalley (2012). "c-Kit is required for growth and survival of the cells of origin 
of Brca1-mutation-associated breast cancer." Oncogene 31(7): 869-883. 
Reichman, M. E., S. Altekruse, C. I. Li, V. W. Chen, D. Deapen, M. Potts, X. C. 
Wu, D. Morrell, J. Hafterson, A. I. Phipps, L. C. Harlan, L. G. Ries and B. K. 
Edwards (2010). "Feasibility study for collection of HER2 data by National 
Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) 
Program central cancer registries." Cancer Epidemiol Biomarkers Prev 
19(1): 144-147. 
Richert, M. M., K. L. Schwertfeger, J. W. Ryder and S. M. Anderson (2000). "An 
atlas of mouse mammary gland development." J Mammary Gland Biol 
Neoplasia 5(2): 227-241. 
Rios, A. C., N. Y. Fu, G. J. Lindeman and J. E. Visvader (2014). "In situ 




Robichaux, J. P., R. M. Hallett, J. W. Fuseler, J. A. Hassell and A. F. Ramsdell 
(2014). "Mammary glands exhibit molecular laterality and undergo left-right 
asymmetric ductal epithelial growth in MMTV-cNeu mice*." Oncogene. 
Rogers, J. A. and J. W. Fuseler (2007). "Regulation of NF-kappaB activation and 
nuclear translocation by exogenous nitric oxide (NO) donors in TNF-alpha 
activated vascular endothelial cells." Nitric Oxide 16(3): 379-391. 
Roychoudhuri, R., V. Putcha and H. Moller (2006). "Cancer and laterality: a study 
of the five major paired organs (UK)." Cancer Causes Control 17(5): 655-
662. 
Roychoudhuri, R., V. Putcha and H. Møller (2006). "Cancer and Laterality: A Study 
of The Five Major Paired Organs (UK)." Cancer Causes and Control 17(5): 
655-662. 
Ruan, W., C. B. Newman and D. L. Kleinberg (1992). "Intact and amino-terminally 
shortened forms of insulin-like growth factor I induce mammary gland 
differentiation and development." Proc Natl Acad Sci U S A 89(22): 10872-
10876. 
Saez, R. A., W. L. McGuire and G. M. Clark (1989). "Prognostic factors in breast 
cancer." Semin Surg Oncol 5(2): 102-110. 
Sakakura, T. (1991). "New aspects of stroma-parenchyma relations in mammary 
gland differentiation." Int Rev Cytol 125: 165-202. 
Sakakura, T., I. Kusano, M. Kusakabe, Y. Inaguma and Y. Nishizuka (1987). 
"Biology of mammary fat pad in fetal mouse: capacity to support 
206 
 
development of various fetal epithelia in vivo." Development 100(3): 421-
430. 
Sakakura, T., Y. Nishizuka and C. J. Dawe (1976). "Mesenchyme-dependent 
morphogenesis and epithelium-specific cytodifferentiation in mouse 
mammary gland." Science 194(4272): 1439-1441. 
Sakakura, T., Y. Sakagami and Y. Nishizuka (1979). "Persistence of 
responsiveness of adult mouse mammary gland to induction by embryonic 
mesenchyme." Dev Biol 72(2): 201-210. 
Sakakura, T., Y. Sakagami and Y. Nishizuka (1982). "Dual origin of mesenchymal 
tissues participating in mouse mammary gland embryogenesis." Dev Biol 
91(1): 202-207. 
Sale, S., D. Lafkas and S. Artavanis-Tsakonas (2013). "Notch2 genetic fate 
mapping reveals two previously unrecognized mammary epithelial 
lineages." Nat Cell Biol 15(5): 451-460. 
Saleh, F. and S. Abdeen (2007). "Pathobiological features of breast tumours in the 
State of Kuwait: a comprehensive analysis." J Carcinog 6: 12. 
Scaltriti, M., C. Verma, M. Guzman, J. Jimenez, J. L. Parra, K. Pedersen, D. J. 
Smith, S. Landolfi, S. Ramon y Cajal, J. Arribas and J. Baselga (2009). 
"Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and 
accumulation of HER2 and potentiates trastuzumab-dependent cell 
cytotoxicity." Oncogene 28(6): 803-814. 
207 
 
Schaefer, C. F., K. Anthony, S. Krupa, J. Buchoff, M. Day, T. Hannay and K. H. 
Buetow (2009). "PID: the Pathway Interaction Database." Nucleic Acids Res 
37(Database issue): D674-679. 
Sebastian, L. T., L. De Matteo, G. Shaw and M. B. Renfree (1998). "Mesotocin 
receptors during pregnancy, parturition and lactation in the tammar 
wallaby." Anim Reprod Sci 51(1): 57-74. 
Sell, S. (2010). "On the stem cell origin of cancer." Am J Pathol 176(6): 2584-2494. 
Shackleton, M., F. Vaillant, K. J. Simpson, J. Stingl, G. K. Smyth, M. L. Asselin-
Labat, L. Wu, G. J. Lindeman and J. E. Visvader (2006). "Generation of a 
functional mammary gland from a single stem cell." Nature 439(7072): 84-
88. 
Shaw, F. L., H. Harrison, K. Spence, M. P. Ablett, B. M. Simoes, G. Farnie and R. 
B. Clarke (2012). "A detailed mammosphere assay protocol for the 
quantification of breast stem cell activity." J Mammary Gland Biol Neoplasia 
17(2): 111-117. 
Shehata, M., A. Teschendorff, G. Sharp, N. Novcic, A. Russell, S. Avril, M. Prater, 
P. Eirew, C. Caldas, C. J. Watson and J. Stingl (2012). "Phenotypic and 
functional characterization of the luminal cell hierarchy of the mammary 
gland." Breast Cancer Res 14(5): R134. 
Shiratori, H. and H. Hamada (2006). "The left-right axis in the mouse: from origin 
to morphology." Development 133(11): 2095-2104. 
Silberstein, G. B. (2001). "Postnatal mammary gland morphogenesis." Microsc 
Res Tech 52(2): 155-162. 
208 
 
Simoes, B. M., M. Piva, O. Iriondo, V. Comaills, J. A. Lopez-Ruiz, I. Zabalza, J. A. 
Mieza, O. Acinas and M. D. Vivanco (2011). "Effects of estrogen on the 
proportion of stem cells in the breast." Breast Cancer Res Treat 129(1): 23-
35. 
Smalley, M. and A. Ashworth (2003). "Stem cells and breast cancer: A field in 
transit." Nat Rev Cancer 3(11): 832-844. 
Smalley, M. J. (2010). "Isolation, culture and analysis of mouse mammary 
epithelial cells." Methods Mol Biol 633: 139-170. 
Smalley, M. J., H. Kendrick, J. M. Sheridan, J. L. Regan, M. D. Prater, G. J. 
Lindeman, C. J. Watson, J. E. Visvader and J. Stingl (2012). "Isolation of 
mouse mammary epithelial subpopulations: a comparison of leading 
methods." J Mammary Gland Biol Neoplasia 17(2): 91-97. 
Smalley, M. J., I. Titley and A. Ashworth (2005). "An improved definition of mouse 
mammary epithelial side population cells." Cytotherapy 7(6): 497-508. 
Smith, T. G., Jr., G. D. Lange and W. B. Marks (1996). "Fractal methods and results 
in cellular morphology--dimensions, lacunarity and multifractals." J Neurosci 
Methods 69(2): 123-136. 
Sopel, M. (2010). "The myoepithelial cell: its role in normal mammary glands and 
breast cancer." Folia Morphol (Warsz) 69(1): 1-14. 
Sotiriou, C. and L. Pusztai (2009). "Gene-expression signatures in breast cancer." 
N Engl J Med 360(8): 790-800. 
Spike, B. T., D. D. Engle, J. C. Lin, S. K. Cheung, J. La and G. M. Wahl (2012). "A 
mammary stem cell population identified and characterized in late 
209 
 
embryogenesis reveals similarities to human breast cancer." Cell Stem Cell 
10(2): 183-197. 
Stalsberg, H. (1969). "The origin of heart asymmetry: right and left contributions to 
the early chick embryo heart." Dev Biol 19(2): 109-127. 
Sternlicht, M. D. (2006). "Key stages in mammary gland development: the cues 
that regulate ductal branching morphogenesis." Breast Cancer Res 8(1): 
201. 
Sternlicht, M. D., H. Kouros-Mehr, P. Lu and Z. Werb (2006). "Hormonal and local 
control of mammary branching morphogenesis." Differentiation 74(7): 365-
381. 
Stingl, J., P. Eirew, I. Ricketson, M. Shackleton, F. Vaillant, D. Choi, H. I. Li and C. 
J. Eaves (2006). "Purification and unique properties of mammary epithelial 
stem cells." Nature 439(7079): 993-997. 
Stull, M. A., M. M. Richert, A. V. Loladze and T. L. Wood (2002). "Requirement for 
IGF-I in epidermal growth factor-mediated cell cycle progression of 
mammary epithelial cells." Endocrinology 143(5): 1872-1879. 
Stull, M. A., A. M. Rowzee, A. V. Loladze and T. L. Wood (2004). "Growth factor 
regulation of cell cycle progression in mammary epithelial cells." J 
Mammary Gland Biol Neoplasia 9(1): 15-26. 
Su, D., S. M. Smith, M. Preti, P. Schwartz, T. J. Rutherford, G. Menato, S. Danese, 
S. Ma, H. Yu and D. Katsaros (2009). "Stathmin and tubulin expression and 
survival of ovarian cancer patients receiving platinum treatment with and 
without paclitaxel." Cancer 115(11): 2453-2463. 
210 
 
Sucov, H. M., E. Dyson, C. L. Gumeringer, J. Price, K. R. Chien and R. M. Evans 
(1994). "RXR alpha mutant mice establish a genetic basis for vitamin A 
signaling in heart morphogenesis." Genes Dev 8(9): 1007-1018. 
Sullivan, A. C., J. P. Hunt and A. L. Oldenburg (2011). "Fractal analysis for 
classification of breast carcinoma in optical coherence tomography." J 
Biomed Opt 16(6): 066010. 
Tambasco, M., M. Eliasziw and A. M. Magliocco (2010). "Morphologic complexity 
of epithelial architecture for predicting invasive breast cancer survival." J 
Transl Med 8: 140. 
Tambasco, M. and A. M. Magliocco (2008). "Relationship between tumor grade 
and computed architectural complexity in breast cancer specimens." Hum 
Pathol 39(5): 740-746. 
Teh, M. T. (2012). "FOXM1 coming of age: time for translation into clinical 
benefits?" Front Oncol 2: 146. 
Troyer, K. L. and D. C. Lee (2001). "Regulation of mouse mammary gland 
development and tumorigenesis by the ERBB signaling network." J 
Mammary Gland Biol Neoplasia 6(1): 7-21. 
U.S. Food and Drug Administration (2012). "Tykerb (lapatinib) Prescribing 
Information February 2012." 
Veltmaat, J. M., A. A. Mailleux, J. P. Thiery and S. Bellusci (2003). "Mouse 
embryonic mammogenesis as a model for the molecular regulation of 
pattern formation." Differentiation 71(1): 1-17. 
211 
 
Veltmaat, J. M., A. F. Ramsdell and E. Sterneck (2013). "Positional variations in 
mammary gland development and cancer." J Mammary Gland Biol 
Neoplasia 18(2): 179-188. 
Veltmaat, J. M., F. Relaix, L. T. Le, K. Kratochwil, F. G. Sala, W. van Veelen, R. 
Rice, B. Spencer-Dene, A. A. Mailleux, D. P. Rice, J. P. Thiery and S. 
Bellusci (2006). "Gli3-mediated somitic Fgf10 expression gradients are 
required for the induction and patterning of mammary epithelium along the 
embryonic axes." Development 133(12): 2325-2335. 
Veltmaat, J. M., W. Van Veelen, J. P. Thiery and S. Bellusci (2004). "Identification 
of the mammary line in mouse by Wnt10b expression." Dev Dyn 229(2): 
349-356. 
Vermot, J., J. Gallego Llamas, V. Fraulob, K. Niederreither, P. Chambon and P. 
Dolle (2005). "Retinoic acid controls the bilateral symmetry of somite 
formation in the mouse embryo." Science 308(5721): 563-566. 
Vilhais-Neto, G. C., M. Maruhashi, K. T. Smith, M. Vasseur-Cognet, A. S. 
Peterson, J. L. Workman and O. Pourquie (2010). "Rere controls retinoic 
acid signalling and somite bilateral symmetry." Nature 463(7283): 953-957. 
Visvader, J. E. (2009). "Keeping abreast of the mammary epithelial hierarchy and 
breast tumorigenesis." Genes Dev 23(22): 2563-2577. 
Visvader, J. E. (2011). "Cells of origin in cancer." Nature 469(7330): 314-322. 
Visvader, J. E. and G. H. Smith (2011). "Murine mammary epithelial stem cells: 




Visvader, J. E. and J. Stingl (2014). "Mammary stem cells and the differentiation 
hierarchy: current status and perspectives." Genes Dev 28(11): 1143-1158. 
Wadia, P. R., L. N. Vandenberg, C. M. Schaeberle, B. S. Rubin, C. Sonnenschein 
and A. M. Soto (2007). "Perinatal bisphenol A exposure increases estrogen 
sensitivity of the mammary gland in diverse mouse strains." Environ Health 
Perspect 115(4): 592-598. 
Walker, B. E. (1984). "Tumors of female offspring of mice exposed prenatally to 
diethylstilbestrol." J Natl Cancer Inst 73(1): 133-140. 
Walker, B. E. (1990). "Tumors in female offspring of control and diethylstilbestrol-
exposed mice fed high-fat diets." J Natl Cancer Inst 82(1): 50-54. 
Walter, J., R. J.  and M. W. Berns (1986). Digital Image Processing and Analysis. 
Video Microscopy. S. Inoue. New York and London, Plenum Press: 327-
392. 
Wang, Y., J. G. Klijn, Y. Zhang, A. M. Sieuwerts, M. P. Look, F. Yang, D. Talantov, 
M. Timmermans, M. E. Meijer-van Gelder, J. Yu, T. Jatkoe, E. M. Berns, D. 
Atkins and J. A. Foekens (2005). "Gene-expression profiles to predict 
distant metastasis of lymph-node-negative primary breast cancer." Lancet 
365(9460): 671-679. 
Wang, Y. A., K. Shen, Y. Wang and S. C. Brooks (2005). "Retinoic acid signaling 




Wang, Z., Y. Li, A. Ahmad, A. S. Azmi, S. Banerjee, D. Kong and F. H. Sarkar 
(2010). "Targeting Notch signaling pathway to overcome drug resistance for 
cancer therapy." Biochim Biophys Acta 1806(2): 258-267. 
Warner, M. R. (1976). "Effect of various doses of estrogen to BALB/cCrgl neonatal 
female mice on mammary growth and branching at 5 weeks of age." Cell 
Tissue Kinet 9(5): 429-438. 
Warner, M. R. and R. L. Warner (1975). "Effects of age at carcinogen 
administration and exposure as neonates to 17beta-estradiol on 
subsequent gland-pair distribution of murine mammary dysplasias." J Natl 
Cancer Inst 54(6): 1369-1372. 
Warner, M. R., L. Yau and J. M. Rosen (1980). "Long term effects of perinatal 
injection of estrogen and progesterone on the morphological and 
biochemical development of the mammary gland." Endocrinology 106(3): 
823-832. 
Watson, C. J. (2006). "Involution: apoptosis and tissue remodelling that convert 
the mammary gland from milk factory to a quiescent organ." Breast Cancer 
Res 8(2): 203. 
Watson, C. J. and W. T. Khaled (2008). "Mammary development in the embryo 
and adult: a journey of morphogenesis and commitment." Development 
135(6): 995-1003. 
Weiss, H. A., S. S. Devesa and L. A. Brinton (1996). "Laterality of breast cancer in 
the United States." Cancer Causes Control 7(5): 539-543. 
214 
 
Wilting, J. and M. Hagedorn (2011). "Left-right asymmetry in embryonic 
development and breast cancer: common molecular determinants?" Curr 
Med Chem 18(36): 5519-5527. 
Wood, E. R., A. T. Truesdale, O. B. McDonald, D. Yuan, A. Hassell, S. H. 
Dickerson, B. Ellis, C. Pennisi, E. Horne, K. Lackey, K. J. Alligood, D. W. 
Rusnak, T. M. Gilmer and L. Shewchuk (2004). "A unique structure for 
epidermal growth factor receptor bound to GW572016 (Lapatinib): 
relationships among protein conformation, inhibitor off-rate, and receptor 
activity in tumor cells." Cancer Res 64(18): 6652-6659. 
Yokoyama, T., N. G. Copeland, N. A. Jenkins, C. A. Montgomery, F. F. Elder and 
P. A. Overbeek (1993). "Reversal of left-right asymmetry: a situs inversus 
mutation." Science 260(5108): 679-682. 
Yoruk, O., M. Karasen, H. Timur, T. Erdem, S. Dane and U. Tan (2009). 
"Lateralizations of head-neck cancers are not associated with peripheral 
asymmetry of cell-mediated immunity." Int J Neurosci 119(6): 815-820. 
Zeeneldin, A. A., M. Ramadan, N. Elmashad, I. Fakhr, A. Diaa and E. Mosaad 
(2013). "Breast cancer laterality among Egyptian patients and its 
association with treatments and survival." J Egypt Natl Canc Inst 25(4): 199-
207. 
Zeps, N., J. M. Bentel, J. M. Papadimitriou and H. J. Dawkins (1999). "Murine 
progesterone receptor expression in proliferating mammary epithelial cells 
during normal pubertal development and adult estrous cycle. Association 
with eralpha and erbeta status." J Histochem Cytochem 47(10): 1323-1330. 
215 
 
Zeps, N., H. J. Dawkins, J. M. Papadimitriou, S. L. Redmond and M. I. Walters 
(1996). "Detection of a population of long-lived cells in mammary epithelium 
of the mouse." Cell Tissue Res 286(3): 525-536. 
Zhang, D., A. Pal, W. G. Bornmann, F. Yamasaki, F. J. Esteva, G. N. Hortobagyi, 
C. Bartholomeusz and N. T. Ueno (2008). "Activity of lapatinib is 
independent of EGFR expression level in HER2-overexpressing breast 
cancer cells." Mol Cancer Ther 7(7): 1846-1850. 
Zhao, S. and R. D. Fernald (2005). "Comprehensive algorithm for quantitative real-
time polymerase chain reaction." J Comput Biol 12(8): 1047-1064. 
Zhao, X., G. K. Malhotra, H. Band and V. Band (2012). "Derivation of myoepithelial 
progenitor cells from bipotent mammary stem/progenitor cells." PLoS One 
7(4): e35338. 
Zvelebil, M., E. Oliemuller, Q. Gao, O. Wansbury, A. Mackay, H. Kendrick, M. J. 
Smalley, J. S. Reis-Filho and B. A. Howard (2013). "Embryonic mammary 
signature subsets are activated in Brca1-/- and basal-like breast cancers." 






Jacqulyne Robichaux earned her Bachelor of Science degree in Chemistry with a 
minor in mathematics from Nicholls State University in Thibodaux, Louisiana in 
2010. She joined the doctoral program in biomedical science at the Medical 
University of South Carolina in 2010. Jacqulyne was a recipient of the dissertation 
scholarship award from the Southern Regional Education Board in 2014 and 
placed second at Perry Haluska Student research day for an oral PhD presentation 
in 2013. In addition, Jacqulyne has presented at a national Gordon Conference on 
mammary gland biology and published in Oncogene as well as AntiCancer 
Research. Jacqulyne’s dissertation was supervised by Dr. Ann Ramsdell.  
217 
 
